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In chapter 4 the high incidence of delayed graft function that occurs after kidney 
donation after circulatory death is discussed. We investigated if combining T cell 
depletion (with ATGFresenius) with a regular, unadjusted dose of tacrolimus would lead 
to a reduced incidence and duration of delayed graft function after transplantation with 
a DCD donor kidney. 
In chapter 5 the issue of steroidresistant allograft rejection is addressed. The current 
standard treatment for steroidresistant allograft rejection is the polyclonal antiT cell 
preparation ATGThymoglobulin. An alternative agent that can be used for the 
treatment of these rejections is alemtuzumab, a monoclonal antibody that depletes T and 
B cells. In a retrospective analysis we compared the effectiveness and safety of ATG
Thymoglobulin and alemtuzumab for the treatment of steroidresistant allograft 
rejection.  
While immunosuppressive therapy traditionally focuses on T cells, the role of B cells and 
antibodies in acute allograft rejection has received more attention over the recent years 
for several reasons. First because of the negative prognostic impact of donorspecific 
antiHLA antibodies. Secondly because of the presence of B cell clusters in biopsies of 
patients with severe rejection, and thirdly because of the frequent finding of capillary 
deposition of C4d, a split product of C4 of the classical complement pathway, in patients 
with acute rejection [2, 3]. B cells are the progenitors of plasma cells, they function as 
effective antigen presenting cells, and they can secrete different cytokines to stimulate 
the immune system. Moreover, interfering specifically with B cells by rituximab 
treatment has shown to be effective in diseases that were considered to be mainly T cell 
driven, like rheumatoid arthritis [4, 5]. 
For these reasons, B cell depletion at the time of transplantation might be beneficial to 
prevent acute allograft rejection. In chapter 6 the results are reported of a randomized, 
placebocontrolled clinical trial in 280 renal transplant patients treated with either a 
single dose of rituximab or placebo at the moment of transplantation, added to a 
standard immunosuppressive regimen. We tested the hypothesis that this would safely 
and effectively reduce the incidence of biopsyproven acute renal allograft rejection 
during the first six months posttransplant. 
Chapter 7 focuses on the histopathology of acute allograft rejection in patients 
participating in the abovementioned clinical trial. Several researchers have reported an 
association between the presence of intragraft B cells during allograft rejection and a 
worse graft outcome. In this chapter we analyzed whether B cell depletion with 
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In most transplant centers immunosuppressive therapy after renal transplantation 
consists of the combination of a calcineurin inhibitor, mycophenolic acid and steroids, 
combined with induction therapy. With this treatment the incidence of allograft rejection 
during the first six months after transplantation has dropped to 1020% in the last 
decades. This has greatly improved allograft and patient survival in the first year after 
transplantation [1]. Prevention of allograft rejection does also reduce the risk of chronic 
allograft dysfunction, which is the cause of late graft loss in about half of the patients. 
By further reducing the incidence of acute allograft rejection, longterm graft survival 
could therefore improve. Although strong immunosuppressive therapy can result in 
lower rates of acute allograft rejection, this benefit is almost always counterbalanced by 
an increased risk of infections and cancer. The optimal therapy to prevent rejection 
should therefore effectively intervene with the immune response against the allograft, 
while leaving the rest of the immune system as competent as possible to fight micro
organisms and malignant cells. 
Another strategy to optimize results after transplantation is the safe and effective 
treatment of severe allograft rejection. If allograft rejection persists despite steroid
therapy, additional therapy is required to prevent graft loss. The current treatment with 
polyclonal antiT cell immunoglobulins is effective but associated with severe side 
effects, which limits its use. The challenge is to find a treatment that is at least as 
effective to revert the rejection process, but is better tolerated. 
A third important issue after transplantation is the occurrence of delayed graft function. 
This results in the prolonged need for dialysis, with increased morbidity, mortality, and 
prolonged hospital stay. Moreover, the lack of early graft function requires performing 
graft biopsies at regular intervals to exclude acute allograft rejection. The incidence of 
delayed graft function is especially high after transplantation of kidneys donated after 
circulatory death (DCD), since in these cases there is an additional warm ischemia time 
which is lacking in donation after brain death (DBD). 
This thesis is based on studies concerning the safety and efficacy of novel approaches to 
address these three issues (prevention of rejection, treatment of steroidresistant 
rejection and prevention of delayed graft function). As an introduction for the clinical 
trials presented in this thesis, chapter 2 describes the general aspects of allograft 
rejection and its treatment with antiT cell antibodies. In chapter 3 the place of 
monoclonal antibodies in renal transplantation is described.  
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10 
rituximab had an effect on the type of rejection (T cell mediated versus antibody 
mediated), and on the intragraft presence of B cells. We also examined whether the 
presence of B cells was associated with more steroidresistance and a worse graft 
function 
Since the immune system is a complex interplay between cells, tissues and molecules we 
explored whether rituximab had other effects in addition to B cell depletion. Chapter 8 
assesses the potential problem of the release of cytokines after infusion of rituximab, as 
is seen in lymphoma patients with high B cell counts. We studied this phenomenon in 
our transplant patients and tried to identify the cell type responsible for the cytokine 
release. 
In chapter 9 the effect of rituximab on IL17 production is analyzed. Th17 cells are 
characterized by the ability to produce several cytokines (especially IL17 and IL21). 
Th17 cells are not only involved in the immune response against extracellular 
pathogens, but recent studies show that they might also play a role in allograft rejection 
and that B cells could contribute to a Th17 response. Based on these findings, we tested 
the effect of rituximab on the ability of T cells to produce cytokines (including IL17) 
after ex vivo stimulation.  
Finally, in chapter 10, the findings from the abovementioned studies are summarized 
and put into perspective of the current and future practice of renal transplantation. 
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The immunology of rejection 
Next to the surgical challenges of transplantation, the manipulation of the alloimmune 
response is crucial for a successful renal transplantation. The alloimmune response 
consists of a recognition phase and an effector phase, in which different cells and 
molecules are involved [6]. After reperfusion, the immune system of the recipient comes 
into contact with alloantigens of the donor. Incompatibility between donor and recipient 
leads to an immune response. The nonselfHLA (human leukocyte antigen) molecules of 
the donor are the major alloantigens, although disparities in minor alloantigens (e.g., the 
aldosterone receptor or HY antigen) also play a role in the alloimmune response [7]. The 
alloantigens are processed by antigenpresenting cells expressing MHC (major 
histocompatibility complex) class II molecules, such as dendritic cells, macrophages and 
B cells. Hereby, they stimulate naive or memory T cells either in secondary lymphoid 
organs or in the graft itself. The T cells recognize a specific part or peptide of the 
processed alloantigen in the context of the MHC molecule via their T cell receptor (TCR). 
Like T cells, B cells can be activated when they recognize complete, unprocessed 
alloantigens with their B cell receptor. 
After binding of the alloantigen to the TCR, a second, costimulatory signal has to be 
provided by the antigenpresenting cell for optimal T cell stimulation. This provides the 
initiation of a cascade of different molecular pathways which results in increased 
transcription of many proteins, including IL2. Binding of IL2 to its receptor activates a 
pathway in which the molecular target of rapamycin is stimulated. This finally leads to 
progression of the cell cycle and cell proliferation and differentiation, hereby starting the 
effector phase. 
In the effector phase, naive CD4+ T cells can differentiate into specific T cell subsets. 
Initially, there were thought to be only two major subsets; Thelper 1 (Th1) cells, that 
are mainly involved in cellmediated responses, and Thelper 2 (Th2) cells, especially 
providing help in humoral immunity. Afterwards, new subsets have been described, such 
as regulatory T cells (Treg) which preserve peripheral tolerance, and T cells that secrete 
IL17 (Th17).  
Most B cells need T cell help for full activation, affinity maturation and immunoglobulin 
class switching. After differentiation into plasma cells, alloantibodies are produced, of 
which IgM or immunecomplexed IgGs in particular can lead to classical pathway 
activation of the complement system. This activation will result in cleavage and 
activation of a cascade of proteins, finally resulting in the formation of the membrane 
12 
Abstract 
Introduction Given the central role of T cells in the alloimmune response, antiT cell 
antibodies retain a prominent place in the treatment of renal allograft rejection. During 
the past decades, many antiT cell antibodies have emerged and subsequently left the 
field of solid organ transplantation, but rabbit antithymocyte globulin (ATG) and the 
antiCD52 humanized rat monoclonal antibody alemtuzumab have remained. 
Areas covered This article reviews the literature about the use of ATG and alemtuzumab 
for the treatment of acute rejection after renal transplantation. Furthermore, it 
discusses possible side effects, including infusion reactions. A literature search using 
PubMed and Embase databases was undertaken using search words alemtuzumab, 
antithymocyte globulin, rejection, kidney and renal transplantation.  
Conclusion Treatment of severe or steroidresistant renal allograft rejections with ATG 
is very effective, but is also associated with frequent infusion reactions and an increased 
incidence of infections and posttransplant lymphoproliferative disease. Alemtuzumab 
may prove to be an attractive alternative. It can be administered easily, is relatively 
cheap and nearly devoid of acute side effects, but the longterm efficacy and safety as 
antirejection treatment are currently difficult to judge. 
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rejections are seldom exclusively cellular or humoral, but in most cases components of 
both can be found on histopathological examination. 
 
AntiT cell antibody products 
Given the central role of T cells in the alloimmune response, most efforts to control this 
response with antibodies have been directed toward the development of various kinds of 
depleting antiT cell antibodies. Most experience has been gained with the use of 
polyclonal antibodies. These antibodies are derived from unfractionated serum after 
immunization of different animals, mainly rabbits and horses, with human lymphoid 
cells or tissue. Experience with monoclonal antiT cell antibodies is more limited. During 
the past decades, many depleting antiT cell antibodies have emerged and subsequently 
left the field of solid organ transplantation, like the monoclonal antiCD3 antibody 
MuromonabCD3 (Orthoclone OKT3) and horse antithymocyte/antilymphocyte globulin 
(ATG/ALG; ATGAM and ALGMerieux). For the treatment of acute rejection, OKT3 and 
ATGAM/ALGMerieux are both outperformed by ATG, which is at least as effective and 
has a somewhat more favorable side effect profile [1113]. The declining usage of OKT3 
and ATGAM/ALGMerieux has led to their removal from the market.  
To date, only three antiT cell antibody products remain for use in clinical organ 
transplantation; rabbitATG from Genzyme (Cambridge, MA, USA), rabbitATG from 
Fresenius (Bad Homburg, Germany) and the antiCD52 humanized rat monoclonal 
antibody alemtuzumab from Genzyme. The mechanism of action of these antibodies is 
not completely known, although induction of apoptosis, complementmediated cell death 
and antibodydependent cell cytotoxicity are the proposed mechanism of action [14]. 
Both ATG products are polyclonal antibodies and target a broad range of molecules and 
cells. ATG targets mainly T cell derived antigens, including CD2, CD3, CD4, CD8, CD25, 
CD28, CD45 and CD40L, but also CD16 (NK cell marker), CD11a, CD18 (leukocyte 
adhesion molecules) and even markers on B cells and plasma cells [1517]. The broad 
immunomodulatory activity of ATG preparations is a consequence of the manufacturing 
process, during which unfractionated human thymocytes, and not only CD3+ T cells, are 
administered as immunogens. 
ATG should be administered intravenously using a central venous catheter, high flow 
vein or arteriovenous fistula. Extravasation can lead to local inflammatory reactions. As 
rapid administration is associated with more acute infusion reactions (mainly pulmonary 
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attack complex which leads to endothelial cell damage. Cytotoxicity via this mechanism 
is known as complementdependent cytotoxicity. The Fc part of an antibody can also 
bind to Fc receptors on natural killer (NK) cells and myeloid cells. Once the Fc receptor 
binds to the Fc part of the antibody, the effector cell releases cytokines and the contents 
of cytotoxic granules (perforin and granzymes) resulting in cell death by triggering 
apoptosis (antibodydependent cellmediated cytotoxicity). The extent to which 
complementdependent cytotoxicity and antibodydependent cellmediated cytotoxicity 
take place depends on the density of bound antibodies, and the class and subclass of the 
antibodies [8]. 
 
Histopathological changes during acute rejection 
The histopathological hallmark of acute renal allograft rejection is massive influx of 
mononuclear cells (mainly T cells, but influx of B cells, monocytes, macrophages and 
mast cells can also be seen) in the kidney parenchyma. This leads to tubulointerstitial 
damage (especially tubulitis) and intimal arteritis. When this inflammation is not halted 
or the antigen is not eradicated (which is the case in renal transplantation), chronic 
inflammation can occur, which eventually will lead to chronic rejection and graft loss. In 
the chronically inflamed renal allograft, the immune cells can sometimes organize 
themselves into structures that resemble lymphoid organs, socalled lymphoid 
neogenesis. The infiltrate is not only composed of proliferating T cells, but also of B cells 
which contribute to a local humoral alloimmune response [9]. To ensure standardized 
reporting on the examination of renal allograft biopsies, the Banff 97 working 
classification of renal allograft pathology is used. This classification is based on 
semiquantitative lesion scoring focusing on tubulitis and arteritis, and is universally 
accepted in the transplant society [10]. 
A humoral or antibodymediated rejection in renal allografts is characterized by the 
demonstration of donorspecific antiHLA antibodies in combination with certain 
histological features. AntiHLA antibodies can bind to the renal vascular endothelium 
and lead to activation of the classical pathway of the complement system, causing 
deposition of complement split products such as C4d and C3d on the vascular 
endothelium. Activation of the complement system leads to the distinct pathological 
changes of humoral rejection, consisting of endothelial injury with fibrinoid changes in 
the vessel walls, thrombosis, glomerulitis and especially accumulation of 
polymorphonuclear leucocytes in peritubular capillaries [10]. In fact, renal allograft 
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rejections are seldom exclusively cellular or humoral, but in most cases components of 
both can be found on histopathological examination. 
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attack complex which leads to endothelial cell damage. Cytotoxicity via this mechanism 
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rejection (56 vs. 71% in steroid group), but showed improved patient (98 vs. 84% in 
steroid group, p = 0.02) and graft survival (78 vs. 50% in steroid group, p = 0.002) after a 
followup period of 1 year [26]. The other two trials did not show superiority of ATG with 
regard to either recurrent rejection or patient and graft survival. 
In a recent metaanalysis, the abovementioned trials were combined and pooled with 
data from additional studies that used accessory treatment (e.g., irradiation) or other 
antibodies (OKT3 or ALG). These pooled data show a lower failure rate to reverse 
rejection (relative risk of 0.57, with 95% confidence interval (CI) 0.38 – 0.67) and reduced 
graft loss (censored for death with functioning graft; relative risk 0.74 with 95% CI 0.58
0.95) in patients treated with antiT cell antibodies as compared with steroids, 
irrespective of the antibody preparation used [13]. However, the higher efficacy of antiT 
cell antibodies is counterbalanced by an impressive side effect profile and high costs. 
Therefore, highdose steroids remain the current firstline treatment of first rejection 
episodes, reserving antiT cell antibodies for steroidresistant rejections. It remains 
unclear however, whether more severe rejections (Banff IIA or IIB) should be treated 
initially with antiT cell antibodies [29]. 
Only two trials have been published with the offlabel use of alemtuzumab for treatment 
of first episodes of acute rejection after renal transplantation. The first trial described 
longterm results of a cohort of 15 patients who received intravenous alemtuzumab as 
firstline treatment of biopsyproven acute rejection [30]. These patients were compared 
with a historical control group, which received steroids as initial therapy, followed by 
ATG if rejection persisted. All rejection episodes were successfully treated with 
alemtuzumab and only one recurrent rejection occurred. After treatment with 
alemtuzumab, 10year patient survival was significantly lower than observed in the 
control group (60 vs. 88%, p = 0.02) due to an excess of early infectionassociated death. 
Tenyear graft survival was not different in both groups (40% in alemtuzumab group vs. 
52% in control group), although there was a trend to better graft function in the 
alemtuzumab group (serum creatinine 143 vs. 183 mol/l, p = 0.06). In another trial, a 
subgroup of 11 patients was also treated with alemtuzumab as firstline antirejection 
therapy [31]. However, data were analyzed for all of the 40 included patients, hampering 
the interpretation of these data. 
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edema, fever and hypotension), infusing the initial dose over 4 – 6 h helps to prevent or 
ameliorate these reactions. The duration of therapy is mainly dependent on center
specific preference, but is generally accepted to be 10 – 14 days. Close monitoring of the 
level of T cell numbers or total lymphocyte number in peripheral blood can be used to 
determine the dosage required to achieve T cell depletion and to limit (infectious) 
complications of excessive immunosuppression [1820]. In ATGtreated patients, T cell 
depletion generally lasts for about a year, with a slower reconstitution of naive cells as 
compared with memory T cells [15]. 
Alemtuzumab is a humanized monoclonal antibody, directed specifically to the CD52 
molecule which is expressed on T, B, and NK cells, monocytes, macrophages and 
dendritic cells [21]. In general, the depletion of T cells caused by alemtuzumab is more 
prolonged compared with that induced by ATG, with T cell recovery to about only 50% of 
baseline levels at 36 months after administration [22]. Detailed studies of lymphocyte 
subsets have shown a longlasting reduction in thymic output of CD4+ T cells [23, 24]. 
For a further description of alemtuzumab, we refer to chapter 3 of this thesis. 
 
Treatment of first acute rejection episodes 
The firstline treatment of established acute cellular allograft rejection is highdose 
steroids. Rather surprisingly, the dose and duration of highdose steroid therapy have 
not been studied in randomized trials. Several prospective, randomized trials with antiT 
cell antibodies have been performed, but only four of them directly compared ATG with 
highdose intravenous or oral steroids (Table 1) [2528]. These trials were relatively 
small (20 – 100 patients) and had a variable period of followup, ranging from 12 – 48 
months. Direct comparison of the outcome of these trials is complicated by significant 
differences in treatment regimen, maintenance immunosuppression, and treatment in 
the control group. Only one study showed superiority of ATG in the prevention of 
recurrent rejection (16 vs. 72% in steroid group, p < 0.01), although this trial might have 
been biased by using a relatively low dose of steroids in the control group and a 
subsequent high risk of recurrent rejection in that group [27]. This trial did not show a 
significant difference in 4year graft survival (80 vs. 88% in steroid group). However, 
since recurrent rejection is a predictor for chronic transplant failure, the effect might be 
visible after longer followup. Another trial compared administration of ATG with high
dose oral steroids (standard antirejection therapy for that time; 200 mg/day with rapid 
tapering to 25 mg in 2 weeks). This trial did not show a significant effect on recurrent 
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Treatment of recurrent or steroidresistant rejection episodes 
When treatment with steroids fails or a rejection quickly recurs, treatment with antiT 
cell antibodies is a logical next step. In this setting, various studies have been performed, 
comparing one antibody with another (OKT3 with ATG or ALG), comparing different 
preparations (rabbit ATG vs. horse ATG), or different doses (lowdose OKT3 vs. high
dose OKT3). After the removal of ALG and OKT3 from the market, the results of these 
studies have become less relevant. Nonetheless, three small trials (21 – 60 patients) 
comparing OKT3 with ATG did not show any superiority of OKT3 with respect to rate of 
rejection reversal, and graft or patient survival (Table 2) [17, 32, 33]. In the same meta
analysis as mentioned above, pooling of the data from these three trials did not change 
this conclusion [13]. Experience with the use of alemtuzumab for treatment of steroid
resistant rejection is scarce and no randomized trials have been published on this 
subject. Most papers report on a few patients, merely demonstrating that recurrent or 
steroidresistant rejection can be reversed with alemtuzumab [3436]. Interpretation is 
difficult however, since treatment of alemtuzumab was combined with other 
immunosuppressive therapies like plasmapheresis. 
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Treatment of recurrent or steroidresistant rejection episodes 
When treatment with steroids fails or a rejection quickly recurs, treatment with antiT 
cell antibodies is a logical next step. In this setting, various studies have been performed, 
comparing one antibody with another (OKT3 with ATG or ALG), comparing different 
preparations (rabbit ATG vs. horse ATG), or different doses (lowdose OKT3 vs. high
dose OKT3). After the removal of ALG and OKT3 from the market, the results of these 
studies have become less relevant. Nonetheless, three small trials (21 – 60 patients) 
comparing OKT3 with ATG did not show any superiority of OKT3 with respect to rate of 
rejection reversal, and graft or patient survival (Table 2) [17, 32, 33]. In the same meta
analysis as mentioned above, pooling of the data from these three trials did not change 
this conclusion [13]. Experience with the use of alemtuzumab for treatment of steroid
resistant rejection is scarce and no randomized trials have been published on this 
subject. Most papers report on a few patients, merely demonstrating that recurrent or 
steroidresistant rejection can be reversed with alemtuzumab [3436]. Interpretation is 
difficult however, since treatment of alemtuzumab was combined with other 
immunosuppressive therapies like plasmapheresis. 
21 
There is one larger observational trial describing 40 patients (mentioned above), in 
whom alemtuzumab was given because of steroidresistant rejections, or rejections equal 
to or more severe than Banff 1B. Graft survival was 74% after 1 year, with a patient 
survival of 95% [31]. The incidence of recurrent rejection episodes was not reported. Due 
to the noncomparative nature of this study, it is difficult to draw conclusions regarding 
the efficacy as compared with that of other treatment modalities. 
 
Side effects of antiT cell antibodies 
Although highly effective, the use of antiT cell antibodies is associated with several 
problems. Especially the first administration of these antibodies can be followed by a 
release of various cytokines, mainly IL6 and TNFa. Most studies investigating the 
possible source of these cytokines are performed in OKT3treated patients. In this 
setting, these cytokines are thought to be released by a transient activation of T cells, 
before they undergo cell lysis, although it is also possible that monocytes or macrophages 
are the source of the cytokines [13, 15, 37]. The clinical manifestations of a cytokine 
release syndrome are fever, chills, headache, dyspnea, myalgia and hypotension. The 
release of cytokines probably contributes to diarrhea, pulmonary edema and intra
allograft thrombosis. Leukocytopenia and thrombocytopenia are also commonly 
encountered side effects. Patients receiving OKT3 were approximately three times more 
likely than patients receiving other antibodies to experience these side effects [13]. Data 
on the safety of alemtuzumab are mainly based on its use as induction agent. In earlier 
trials, intravenous administration of alemtuzumab was associated with infusion 
reactions in about 50% of patients, but most were generally mild [31]. In more recent 
trials, in which alemtuzumab was given subcutaneously, infusion reactions were rare or 
not reported [38]. Taken together, the amount of data concerning the severity and extent 
of infusion reactions in patients with acute rejection treated with alemtuzumab remains 
very limited. 
Owing to the broad number of cellular targets of polyclonal antibodies, undesired cross
reactivities can lead to additional toxicity. In the past, the production of polyclonal 
antibodies was technically challenging, leading to differences in biological activity 
between different batches. However, a recent study evaluating the capacity of different 
antiT cell preparations to bind to leukocyte antigens and the successive functional 
effects showed little batchtobatch variation [39]. Since the polyclonal antiT cell 
antibodies are nonhuman, treatment can be followed by the formation of xenogeneic Ta
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There is one larger observational trial describing 40 patients (mentioned above), in 
whom alemtuzumab was given because of steroidresistant rejections, or rejections equal 
to or more severe than Banff 1B. Graft survival was 74% after 1 year, with a patient 
survival of 95% [31]. The incidence of recurrent rejection episodes was not reported. Due 
to the noncomparative nature of this study, it is difficult to draw conclusions regarding 
the efficacy as compared with that of other treatment modalities. 
 
Side effects of antiT cell antibodies 
Although highly effective, the use of antiT cell antibodies is associated with several 
problems. Especially the first administration of these antibodies can be followed by a 
release of various cytokines, mainly IL6 and TNFa. Most studies investigating the 
possible source of these cytokines are performed in OKT3treated patients. In this 
setting, these cytokines are thought to be released by a transient activation of T cells, 
before they undergo cell lysis, although it is also possible that monocytes or macrophages 
are the source of the cytokines [13, 15, 37]. The clinical manifestations of a cytokine 
release syndrome are fever, chills, headache, dyspnea, myalgia and hypotension. The 
release of cytokines probably contributes to diarrhea, pulmonary edema and intra
allograft thrombosis. Leukocytopenia and thrombocytopenia are also commonly 
encountered side effects. Patients receiving OKT3 were approximately three times more 
likely than patients receiving other antibodies to experience these side effects [13]. Data 
on the safety of alemtuzumab are mainly based on its use as induction agent. In earlier 
trials, intravenous administration of alemtuzumab was associated with infusion 
reactions in about 50% of patients, but most were generally mild [31]. In more recent 
trials, in which alemtuzumab was given subcutaneously, infusion reactions were rare or 
not reported [38]. Taken together, the amount of data concerning the severity and extent 
of infusion reactions in patients with acute rejection treated with alemtuzumab remains 
very limited. 
Owing to the broad number of cellular targets of polyclonal antibodies, undesired cross
reactivities can lead to additional toxicity. In the past, the production of polyclonal 
antibodies was technically challenging, leading to differences in biological activity 
between different batches. However, a recent study evaluating the capacity of different 
antiT cell preparations to bind to leukocyte antigens and the successive functional 
effects showed little batchtobatch variation [39]. Since the polyclonal antiT cell 
antibodies are nonhuman, treatment can be followed by the formation of xenogeneic Ta
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rejections but an increased incidence of CMV disease [50]. This could not be confirmed in 
a larger cohort of 547 patients [51]. However, the latter study showed that the risk of 
developing opportunistic infections was increased when patients received alemtuzumab 
for the treatment of allograft rejection compared with those who received alemtuzumab 
as induction therapy (21 vs. 4.5%; p < 0.001). In a recent, noncomparative study with 40 
patients treated with alemtuzumab for steroidresistant or severe rejection, a total of 14 
patients (35%) had infectious complications, of whom two (5%) died [31].  
 
Malignant complications of antiT cell antibodies 
Another feared side effect of antiT cell antibodies is the development of posttransplant 
lymphoproliferative disease (PTLD). The incidence of PTLD is probably higher after 
treatment with antiT cell antibodies as compared with highdose steroids [13, 52]. 
Because PTLD can occur after completion of the followup of clinical trials, most data are 
derived from registry databases. These databases have their specific drawbacks and 
cannot prove causality, but most of them show a slightly increased risk of PTLD when 
antiT cell antibodies are used for induction. The Scientific Registry of Transplant 
Recipients performed an analysis of 41,686 patients who underwent transplantation 
[53]. A total of 181 patients (0.43%) developed PTLD and patients receiving antiT cell 
antibodies as induction treatment had a relative risk of 1.8 (95% CI 1.3 – 2.4). This risk 
appeared to be especially high in ATGtreated patients, with a relative risk of 3.0 (95% 
CI 1.5 – 5.9). In the US Renal Data System, using a population of 38,519 patients, the 
relative risk of developing PTLD was only increased in patients receiving monoclonal 
antibodies for induction, with a relative risk of 1.7 (95% CI 1.0 – 2.8) [52]. A study based 
on 25,127 Medicare patients could not find any increment in any subcategory [54]. The 
risk of PTLD seems to decrease over time, with an actual incidence of below 0.5 – 1% at 
several years after transplantation. In a recent metaanalysis, no increase of the risk of 
PTLD or any other malignancy could be found in patients treated with antiT cell 
antibodies for rejection, compared with steroids [13]. 
In clinical trials, only a few cases of PLTD have been reported after the use of 
alemtuzumab [55, 56]. This is possibly related to the potent depletion of both T and B 
cells. The largest survey has been performed using the Organ Procurement and 
Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database [57]. 
In this analysis, 59,560 kidney recipients were studied, of which 1691 were treated with 
alemtuzumab as induction therapy. The incidence of PTLD within 2 years after 
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(antihorse or antirabbit) antibodies. These xenogeneic antibodies can diminish the 
efficacy after extended or repeated use and can also lead to anaphylaxis and serum 
sickness [40, 41]. This can be a reason to avoid repeated use of polyclonal antibodies, for 
example, for treatment of acute rejection episodes after subsequent transplantations. 
Another approach is epidermal testing of all patients, or measurement of preformed 
xenogeneic antibodies in serum [42, 43]. To measure the presence of antibodies against 
rabbit IgG, a rheumatoid factor test that is based on agglutination of rabbit IgGcoated 
particles can be used. Data on the formation of xenogeneic antibodies after treatment 
with alemtuzumab are conflicting. Since it is a humanized antibody, a low formation rate 
of xenogeneic antibodies would be expected. In 62 leukemia patients who were treated 
with alemtuzumab, only 2 patients (3%) produced significant levels of antialemtuzumab 
antibodies [44]. However, in patients with rheumatoid arthritis, antialemtuzumab 
antibodies could be found in the majority of alemtuzumabtreated patients (54% to even 
100%) [45, 46]. Especially repeated, subcutaneous administration seemed to favor the 
formation of xenogeneic antibodies. 
Treatment of multiple sclerosis patients with alemtuzumab is associated with an 
increased incidence of secondary autoimmune disease, especially of the thyroid gland 
[47]. Autoimmune thyroid disease after treatment with alemtuzumab has also been 
reported in renal transplant patients [48]. The mechanism of (thyroid) autoimmunity 
after alemtuzumab treatment is likely related to loss of selftolerance in the immune 
reconstitution that occurs following profound lymphopenia, and in multiple sclerosis 
patients the risk is higher in patients with increased levels of IL21 [49]. 
 
Infectious complications of antiT cell antibodies 
Patients who received antiT cell antibodies appear more likely to develop serious and 
sometime fatal infections, especially if they have received a significant 
immunosuppressant load before treatment (either before or after transplantation) [30, 
31]. Most experience stems from the use of antiT cell antibodies as induction therapy. Of 
special interest is the reported increased incidence of cytomegalovirus (CMV) disease in 
early trials. In later trials, using adequate antiviral prophylaxis, an increased incidence 
after induction was not reported [15]. After rejection therapy with antiT cell antibodies, 
no increased risk of CMV infection has been reported, either in individual trials or in 
pooled data, but this may have been accomplished by the use of antiviral prophylaxis 
[13]. In one induction trial, patients treated with alemtuzumab showed less acute 
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Table 3. Comparison between ATG and alemtuzumab 
 ATG Alemtuzumab 
   
Type of antibody Polyclonal Monoclonal 
Targeted antigens Multiple, including CD3, CD4, 
CD8, and CD40L  
CD52 
Targeted cells Mainly T cells, to a lesser extent 
B cells and NK cells 
T cells, B cells, NK cells, 
monocytes, macrophages, 
dendritic cells, eosinophils, 
mast cells 
Route of 
administration 
Intravenous, mostly via central 
venous catheter 
Subcutaneous and 
intravenous  
Dosing regimen Based on bodyweight and 
lymphocyte / thrombocyte 
counts 
Fixed dose 
Treatment duration Usually daily dosing for 10 – 14 
days 
Single dose, or two doses on 
two consecutive days 
Side effects during or 
shortly after infusion 
Fever, chills, dyspnea, nausea, 
diarrhea, headache, general 
pain, and pulmonary edema 
Generally none when given 
subcutaneously 
Costs of treatment 
(drugs only) 
Variable, ranging from  
€850  €3800 
Fixed, €1000 
 
 
Conclusion 
Given the central role of T cells in the alloimmune response, antiT cell antibodies like 
ATG and alemtuzumab are rational tools in the treatment of renal allograft rejection. 
Due to a more favorable side effect profile and lower costs, highdose steroids remain the 
primary therapy for a first rejection episode. Severe or steroidresistant renal allograft 
rejections are commonly treated with a 10 to 14day course of ATG. This treatment is 
very effective, but is also associated with frequent infusion reactions and an increased 
incidence of infections and PTLD. Moreover, repeated use of ATG can be hampered by 
the development of antibodies against rabbit immunoglobulins. Alemtuzumab is 
commonly administered as an induction agent in the prophylaxis of rejection, but data 
on its use for treatment of acute rejection are limited. Administration is easy and nearly 
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transplantation was 0.37%, which was not significantly different compared with either 
no induction therapy (0.43%), or induction with basiliximab (0.38%) or daclizumab 
(0.33%). In the same analysis, ATG was associated with a significantly increased risk of 
PTLD (0.67%).  
 
Differences between ATG and alemtuzumab 
The main differences between ATG and alemtuzumab are summarized in Table 3. ATG 
targets a broad range of T cell surface antigens, but it also contains antibodies against 
NK and B cells. Alemtuzumab targets a single antigen, which is found on different cells: 
T, NK, and B cells. Alemtuzumab induces a more profound depletion of B cells than ATG 
[58]. Moreover, CD52 expression has also been described for monocytes, macrophages, 
dendritic cells, eosinophils and mast cells [5961]. Whether these differences affect the 
efficacy of the antibodies to combat graft rejection is currently unknown. 
Both ATG and alemtuzumab can induce longlasting depletion of T cells. In general, the 
depletion of T cells caused by alemtuzumab is more prolonged, with T cell recovery 
(especially CD4+ T cells) to only 50% of baseline levels at 36 months after administration 
[2224]. Depletion of other cell types is variable; NK cells return within 1 month, 
monocytes within 2 months, and B cells usually return within 6 months [62]. In ATG
treated patients CD4+ T cell depletion generally lasts for about a year [15]. 
As stated above, the reported incidence of infusion reactions is lower in patients 
receiving alemtuzumab, compared with those who receive ATG. Alemtuzumab can be 
administered by subcutaneous injection with potential advantages regarding safety, 
flexibility and convenience [63]. The need for a central venous catheter, which is usually 
required for administration of ATG and is known to be a potential site of infection, is 
absent in case of treatment with alemtuzumab. In most cases, treatment with 
alemtuzumab is cheaper than treatment with ATG. If patients are hospitalized during 
the treatment period (usually 10 – 14 days with ATG as compared with 2 – 4 days with 
alemtuzumab), the difference in costs could even be larger. 
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devoid of side effects, but the longterm efficacy and safety as antirejection treatment are 
currently difficult to judge. There is a demand for other highly effective antiT cell 
antibodies that lack the side effects of ATG and alemtuzumab. 
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Introduction 
For patients with endstage renal disease, renal transplantation is the treatment of 
choice to improve quality of life and increase life expectancy. Next to the surgical 
challenges of this procedure, the manipulation of the alloimmune response is crucial for 
a successful renal transplantation. The alloimmune response consists of a recognition 
phase and an effector phase, in which different cells and molecules are involved, as 
described in chapter 2. While alloantibodies can be detrimental for the renal allograft, 
the general efficacy of antibodies to bind their target has fuelled the interest in the use of 
antibodies for therapeutic purposes. Because immunoglobulins cannot pass the cell 
membrane, all targets are either found on the cell surface or are noncellular targets (e.g., 
complement factors). Given the central role that T cells play in the alloimmune response, 
it is not surprising that most efforts to control this response with antibodies have been 
directed toward the development of various kinds of antiT cell antibodies. More 
recently, antibodies against B cells and soluble molecules have gained interest for use in 
transplantation.  
In the next paragraph, we will start with a brief overview of the use of antibodies in 
renal transplantation. Subsequently, the various monoclonal antibodies that are used in 
renal transplantation are described in more detail (see Table 1 for an overview of 
currently used monoclonal antibodies). 
 
Intervention in the alloimmune response with antibodies 
In 1899, Metchnikoff was the first to use rabbit immune serum to remove leukocytes 
from human blood. More than 60 years later, the first use of rabbit antiserum to prevent 
allograft rejection in renal transplant recipients was reported. Nowadays, polyclonal 
rabbit antithymocyte globulin (ATG; Genzyme, Cambridge, MA, USA) is still commonly 
used to prevent and treat allograft rejection.  
Where polyclonal antibodies target a broad range of molecules, monoclonal antibodies 
have a single molecular target. Monoclonal antibody production starts with fusing B cells 
from immunized hosts with immortalized myeloma cells, thereby creating socalled 
hybridomas. After selecting the hybridomas that produce the desired antibody, these 
hybridomas are cloned and the monoclonal antibody is harvested from the supernatant. 
Usage of monoclonal antibodies provides the ability to specifically target cells or 
28 
Abstract 
Monoclonal antibodies are applied in various settings in renal transplantation. Depleting 
T cell antibodies are used for treatment of steroidresistant acute rejection and as 
induction therapy to reduce the intensity of concomitant immunosuppressive drug 
therapy. Induction therapy with the nondepleting IL2 receptor antagonists basiliximab 
and daclizumab, added to cyclosporinebased regimens, reduces the incidence of acute 
rejection without side effects. However, an increase in longterm graft and patient 
survival has not been demonstrated yet. The B celltargeting antibody rituximab is used 
in blood group ABOincompatible transplantation, in desensitization protocols, and for 
treatment of antibodymediated rejection. Eculizumab interrupts the complement 
pathway and is a promising tool for the treatment of antibodymediated rejection and 
posttransplant hemolytic–uremic syndrome. 
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MuromonabCD3 (OKT3): mouse antiCD3 
The first monoclonal antibody approved for use in human renal transplantation was 
muromonabCD3 (Orthoclone OKT3, Janssen Cilag, Beerse, Belgium). It targets the 
CD3 protein on the surface of T cells, which is part of the T cell receptor complex. 
Immediately after administration, CD3+ T cells are cleared from the circulation. In a 
prospective, randomized, multicenter trial, the efficacy in reversing acute rejection of 
renal transplants from deceased donors was clearly established. Not only did fullcourse 
treatment with OKT3 lead to superior reversal rates of acute rejection compared with 
highdose steroids (94 vs. 75%), it also showed efficacy in treating steroidresistant 
rejections [65]. OKT3 has also been used as induction therapy, although this is not based 
on randomized trials, and the drug has never been formally approved for this indication.  
Unfortunately, OKT3 has numerous adverse effects. Especially the first administration 
can be followed by a cytokine release syndrome, which is caused by a transient activation 
of T cells, before they undergo cell lysis [37]. The clinical manifestations of this syndrome 
are fever, chills, headache, dyspnea, myalgia and hypotension. The release of cytokines 
probably also contributes to diarrhea, pulmonary edema, intraallograft thrombosis, 
aseptic meningitis and temporary hearing loss. Furthermore, patients given OKT3 are 
more likely to develop serious infections (e.g., cytomegalovirus, Epstein–Barr virus, 
Listeria and Mycobacterium), and posttransplant lymphoproliferative disease [52]. For 
the treatment of acute rejection, OKT3 is outperformed by ATG, which is at least as 
effective and has a somewhat more favorable side effect profile [11]. The declining usage 
of OKT3 has recently led to its removal from the market. 
 
Alemtuzumab: humanized (rat) antiCD52 
CD52 is expressed on T cells, B cells, NK cells, monocytes, macrophages and dendritic 
cells. Early clinical trials with rat depleting antiCD52 antibodies (Campath1G and 
Campath1M) as induction therapy in renal transplantation showed effective lymphocyte 
depletion with reduced incidence of acute rejection, but with immunogenicity and also an 
increased incidence of infections [66]. The immunogenicity was reduced, but not 
completely eliminated, by humanizing the antibody (alemtuzumab; Campath1H, 
Genzyme). The depletion of T cells caused by alemtuzumab is long lasting; T cell levels 
recover to only 50% of baseline at 36 months after administration [22]. 
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molecules involved in the alloimmune response. A rational strategy to achieve selective 
immunosuppression would be to target antigens that are expressed on lymphocytes that 
respond to alloantigens, but are absent on resting lymphocytes. The classical example of 
such a target is the αchain of the receptor for IL2 (CD25) [64]. As outlined later, anti
CD25 antibodies have an important place in current treatment regimens after renal 
transplantation. While the prototypes of monoclonal antibodies were mostly of mouse 
origin and elicited human antimouse immunoglobulin antibodies, the currently used 
chimeric and humanized antibodies are far less immunogenic (Box 1). 
 
 AntiT cell monoclonal antibodies are especially used for treatment of acute rejection 
and as induction therapy during the first days or weeks after transplantation. Induction 
therapy can have several goals that are not mutually exclusive: to prevent acute 
rejection, to induce tolerance, to minimize steroid use, or to postpone or reduce the 
treatment with calcineurin inhibitors, especially in cases where the risk of acute tubular 
necrosis is high. The antiB cell monoclonal antibody rituximab is used in ABO
incompatible transplantation, in desensitization protocols, and for treatment of antibody
mediated rejection. Moreover, it has an important place in the treatment of 
posttransplant lymphoproliferative disease. Currently, no monoclonal antibody is used 
or registered for maintenance immunosuppression. 
Box 1. Naming of monoclonal antibodies.  
The naming of (new) monoclonal antibodies follows a strict pattern that has been 
described by the WHO in the International Nonproprietary Names (INN) Working 
Group Meeting on Nomenclature for Monoclonal Antibodies. The names of monoclonal 
antibodies are composed of a prefix, a substem A, a substem B and a suffix. The 
common suffix for monoclonal antibodies is ÂmabÊ. Substem B indicates the species on 
which the immunoglobulin sequence of the monoclonal antibody is based. For example, 
ÂaÊ for rat, ÂxiÊ for chimeric, ÂzuÊ for humanized and ÂuÊ for human. Substem A indicates 
the target class (molecule, cell or organ), for example, Âc(i)Ê for cardiovascular, Ât(u)Ê for 
tumor, and Âl(i)Ê for immunomodulating. Finally, the prefix can be random to contribute 
to a distinctive name. Therefore, basiliximab, is a monoclonal antibody of chimeric 
origin, with an immunomodulating target. The only monoclonal antibody that does not 
comply with this naming is muromonabCD3, which is short for murine monoclonal 
antibody against CD3. 
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completely eliminated, by humanizing the antibody (alemtuzumab; Campath1H, 
Genzyme). The depletion of T cells caused by alemtuzumab is long lasting; T cell levels 
recover to only 50% of baseline at 36 months after administration [22]. 
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molecules involved in the alloimmune response. A rational strategy to achieve selective 
immunosuppression would be to target antigens that are expressed on lymphocytes that 
respond to alloantigens, but are absent on resting lymphocytes. The classical example of 
such a target is the αchain of the receptor for IL2 (CD25) [64]. As outlined later, anti
CD25 antibodies have an important place in current treatment regimens after renal 
transplantation. While the prototypes of monoclonal antibodies were mostly of mouse 
origin and elicited human antimouse immunoglobulin antibodies, the currently used 
chimeric and humanized antibodies are far less immunogenic (Box 1). 
 
 AntiT cell monoclonal antibodies are especially used for treatment of acute rejection 
and as induction therapy during the first days or weeks after transplantation. Induction 
therapy can have several goals that are not mutually exclusive: to prevent acute 
rejection, to induce tolerance, to minimize steroid use, or to postpone or reduce the 
treatment with calcineurin inhibitors, especially in cases where the risk of acute tubular 
necrosis is high. The antiB cell monoclonal antibody rituximab is used in ABO
incompatible transplantation, in desensitization protocols, and for treatment of antibody
mediated rejection. Moreover, it has an important place in the treatment of 
posttransplant lymphoproliferative disease. Currently, no monoclonal antibody is used 
or registered for maintenance immunosuppression. 
Box 1. Naming of monoclonal antibodies.  
The naming of (new) monoclonal antibodies follows a strict pattern that has been 
described by the WHO in the International Nonproprietary Names (INN) Working 
Group Meeting on Nomenclature for Monoclonal Antibodies. The names of monoclonal 
antibodies are composed of a prefix, a substem A, a substem B and a suffix. The 
common suffix for monoclonal antibodies is ÂmabÊ. Substem B indicates the species on 
which the immunoglobulin sequence of the monoclonal antibody is based. For example, 
ÂaÊ for rat, ÂxiÊ for chimeric, ÂzuÊ for humanized and ÂuÊ for human. Substem A indicates 
the target class (molecule, cell or organ), for example, Âc(i)Ê for cardiovascular, Ât(u)Ê for 
tumor, and Âl(i)Ê for immunomodulating. Finally, the prefix can be random to contribute 
to a distinctive name. Therefore, basiliximab, is a monoclonal antibody of chimeric 
origin, with an immunomodulating target. The only monoclonal antibody that does not 
comply with this naming is muromonabCD3, which is short for murine monoclonal 
antibody against CD3. 
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Alemtuzumab is indicated for the treatment of chronic lymphatic leukemia. Experience 
with the offlabel use of alemtuzumab for treatment of acute rejection after renal 
transplantation is scarce and no randomized trials have been published on this subject. 
Most articles report on a few patients, merely demonstrating that allograft rejection can 
be reversed with alemtuzumab [34, 35]. There is one larger trial describing 40 patients, 
in whom alemtuzumab was given because of steroidresistant rejections, or rejections 
equal to or more severe than Banff 1B. Allograft survival was 74% after 1 year, with a 
patient survival of 95%. A total of 14 patients (35%) had infectious complications, of 
whom two patients (5%) died [31]. In another trial, 15 patients were treated with 
alemtuzumab for acute biopsyproven rejection and compared with a historical control 
group of patients treated with methylprednisolone. All rejection episodes were reversed 
by alemtuzumab and 10year allograft function was similar in both groups [30]. The use 
of alemtuzumab for the treatment of acute rejection may expand after the removal of 
OKT3 from the market. 
Most experience with alemtuzumab stems from the use as induction therapy, especially 
in the setting of a reduced intensity of maintenance immunosuppression. In such a 
scenario, alemtuzumab might contribute to the induction of antigenspecific tolerance 
[67]. The use of alemtuzumab as addon to standard triple or dual immunosuppression is 
considered to result in overimmunosuppression. In an initial trial with alemtuzumab 
induction therapy in 31 renal transplant recipients, a single dose of 30 mg was combined 
with lowdose cyclosporine maintenance immunosuppression. The incidence of early 
acute rejection episodes was approximately 20% and after 5 years of followup, there was 
no difference in incidence of rejection episodes, allograft function or allograft and patient 
survival, compared with patients who received cyclosporine, azathioprin and predniso
lone [68]. Importantly, there were no differences in the incidence of malignancies or 
infections. Rejections in the alemtuzumab group tended to occur beyond the first year 
after transplantation. Likewise, alemtuzumab induction followed by tacrolimus 
monotherapy resulted in similar graft and patient survival as tacrolimus in combination 
with mycophenolate mofetil and steroids [50]. In this trial, alemtuzumabtreated 
patients showed less acute rejections but an increased incidence of CMV infections. 
Multiple studies, mostly retrospective or observational in nature, have confirmed these 
results and underline the ability of induction therapy with alemtuzumab to reduce the 
intensity of maintenance immunosuppression [55, 69]. However, in a pilot trial of 29 
patients, the use of alemtuzumab with sirolimus monotherapy was associated with an 
increased risk of acute (humoral) rejection [70]. 
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Alemtuzumab is indicated for the treatment of chronic lymphatic leukemia. Experience 
with the offlabel use of alemtuzumab for treatment of acute rejection after renal 
transplantation is scarce and no randomized trials have been published on this subject. 
Most articles report on a few patients, merely demonstrating that allograft rejection can 
be reversed with alemtuzumab [34, 35]. There is one larger trial describing 40 patients, 
in whom alemtuzumab was given because of steroidresistant rejections, or rejections 
equal to or more severe than Banff 1B. Allograft survival was 74% after 1 year, with a 
patient survival of 95%. A total of 14 patients (35%) had infectious complications, of 
whom two patients (5%) died [31]. In another trial, 15 patients were treated with 
alemtuzumab for acute biopsyproven rejection and compared with a historical control 
group of patients treated with methylprednisolone. All rejection episodes were reversed 
by alemtuzumab and 10year allograft function was similar in both groups [30]. The use 
of alemtuzumab for the treatment of acute rejection may expand after the removal of 
OKT3 from the market. 
Most experience with alemtuzumab stems from the use as induction therapy, especially 
in the setting of a reduced intensity of maintenance immunosuppression. In such a 
scenario, alemtuzumab might contribute to the induction of antigenspecific tolerance 
[67]. The use of alemtuzumab as addon to standard triple or dual immunosuppression is 
considered to result in overimmunosuppression. In an initial trial with alemtuzumab 
induction therapy in 31 renal transplant recipients, a single dose of 30 mg was combined 
with lowdose cyclosporine maintenance immunosuppression. The incidence of early 
acute rejection episodes was approximately 20% and after 5 years of followup, there was 
no difference in incidence of rejection episodes, allograft function or allograft and patient 
survival, compared with patients who received cyclosporine, azathioprin and predniso
lone [68]. Importantly, there were no differences in the incidence of malignancies or 
infections. Rejections in the alemtuzumab group tended to occur beyond the first year 
after transplantation. Likewise, alemtuzumab induction followed by tacrolimus 
monotherapy resulted in similar graft and patient survival as tacrolimus in combination 
with mycophenolate mofetil and steroids [50]. In this trial, alemtuzumabtreated 
patients showed less acute rejections but an increased incidence of CMV infections. 
Multiple studies, mostly retrospective or observational in nature, have confirmed these 
results and underline the ability of induction therapy with alemtuzumab to reduce the 
intensity of maintenance immunosuppression [55, 69]. However, in a pilot trial of 29 
patients, the use of alemtuzumab with sirolimus monotherapy was associated with an 
increased risk of acute (humoral) rejection [70]. 
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Daclizumab: humanized (mouse) antiCD25 
Daclizumab (Roche, Basel, Switzerland) is a humanized antiIL2 receptor antibody. The 
efficacy of daclizumab in preventing acute rejection after renal transplantation was 
analyzed in two multicenter, randomized, placebocontrolled trials, in which 
maintenance immunosuppression consisted of triple and dual therapy, respectively. In 
both studies, a significant decrease in the incidence of biopsy confirmed acute rejection 
was observed, without an increase in side effects [79, 80]. 
 
Similarities & differences between basiliximab & daclizumab 
In 2003, a metaanalysis of trials comparing basiliximab or daclizumab with placebo as 
induction therapy confirmed that the incidence of biopsyproven acute rejection at 6 
months is reduced by approximately 50% (95% CI: 37–58%) with a similar effect size for 
basiliximab and daclizumab [81]. All studies included in this metaanalysis used a 
cyclosporinebased maintenance regimen. By now, most immunosuppressive regimens 
are based on tacrolimus, which appears to be a somewhat stronger immunosuppressant 
than cyclosporine [82]. The number of clinical trials studying the effects of IL2 receptor 
antagonists when added to a tacrolimusbased regimen is very limited and results from 
these studies are conflicting. In one trial, the addition of a single dose of daclizumab to 
tacrolimus, mycophenolate mofetil and steroids, seemed to reduce the incidence of acute 
biopsyproven rejection during the first 6 months after transplantation compared with 
placebo (6 vs. 16%) [83]. In pediatric recipients, the addition of basiliximab to a 
tacrolimusbased regimen had no benefits [84]. In a recent metaanalysis of the effects of 
IL2 receptor antagonists by the Cochrane Renal Group, three tacrolimusbased and 26 
cyclosporinebased regimens were included. Although combined analysis still confirmed 
the reduction of the incidence of acute rejection within 1 year after transplantation 
compared with placebo (relative risk: 0.72; 95% CI: 0.64–0.81), the effect was not 
significant in the subanalysis of the three tacrolimusbased studies (relative risk: 0.66; 
95% CI: 0.28–1.57) [85].  
Next to the reduced incidence of acute rejection within 1 year after transplantation, this 
metaanalysis showed significant reductions in graft loss, CMV disease, early 
malignancies and transplant dysfunction, although these differences were not sustained 
more than 1 year after transplantation.  
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In several trials, alemtuzumab has been directly compared with other agents used for 
induction therapy, such as ATG or antiCD25 antibodies. In general, the use of 
alemtuzumab was as least as effective as other induction agents in the prevention of 
acute rejection, while the number of drugs for maintenance immunosuppression could be 
reduced [7174]. Although alemtuzumab causes profound depletion of T and B cells, the 
incidence of acute side effects is comparable with placebo. Commonly reported is an 
increased incidence of infections, although this is mainly observed in patients with a 
high overall burden of immunosuppression, either after transplantation or 
pretransplantation for the underlying renal disease. 
 
Basiliximab: chimeric human–mouse antiCD25 
The first monoclonal antibodies targeting CD25 in humans were of mouse origin. 
Although effective in preventing acute rejection, the clinical applicability was limited by 
the development of antimouse immunoglobulin antibodies [75]. Basiliximab (Novartis 
Pharma, Basel, Switzerland) is a chimeric (human and mouse) nondepleting antiIL2 
receptor antibody. In the first randomized, doubleblind trial reported, 193 patients who 
received basiliximab were compared with 187 patients who received placebo [76]. Both 
groups received dual immunosuppressive therapy with cyclosporine and steroids. The 
incidence of biopsy confirmed acute rejection within 6 months after transplantation was 
30% in the basiliximab group, compared with 44% in the placebo group. The incidence of 
steroidresistant first rejection episodes that required antiT cell antibody therapy was 
significantly lower in the basiliximab group (10 vs. 23%). However, the incidence of graft 
loss at 12 months posttransplantation was similar in both groups (12 vs. 13%). 
Comparable results were found in another randomized, controlled trial 2 years later [77]. 
Patients treated with a triple immunosuppressive regimen, either azathioprin or 
mycophenolate mofetil added to cyclosporine and steroids, also benefit from induction 
therapy with basiliximab [78]. Basiliximab is generally associated with a tolerability 
profile that is similar to that reported with placebo. 
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In renal transplantation, the offlabel use of rituximab is part of the recipient treatment 
when an ABOincompatible living donor donates a kidney. These transplantations were 
previously only performed with intensive immunosuppression, plasmapheresis to remove 
antiA and/or antiB antibodies, and splenectomy. In 2001, the group of Tydén in Sweden 
replaced plasmapheresis with specific immune absorption of antiA and/or antiB 
antibodies, and splenectomy with a single dose of rituximab [96]. The initial experience 
with this regimen in 15 patients showed an incidence of acute rejection after 2 years of 
only 6.7%. Patient and graft survival were 100 and 86%, respectively. Moreover, cytokine 
release syndrome was not described and the incidence of infections or malignancies was 
not increased [97]. The favorable results of similar protocols have been confirmed by 
others, and have led to a substantial rise in the number of ABOincompatible living 
donor renal transplantations [98].  
Patients with a high level of antiHLA antibodies or with a positive crossmatch wait 
long, and sometimes in vain, for a kidney. To reduce the level of antiHLA antibodies, 76 
selected patients received rituximab and intravenous immunoglobulin before 
transplantation [99, 100]. Although the incidence of acute rejection after transplantation 
was relatively high (37%), the biggest potential gain of this approach is the possibility to 
transplant patients, who otherwise would have continued dialysis treatment.  
In steroidresistant rejections, clusters of B cells can be found in the renal interstitium, 
which are possibly associated with worse graft survival [3, 101]. Although most reports 
involve selected patient groups, acute or chronic antibodymediated rejection or steroid
resistant rejection episodes can respond to rituximab (even when there was no response 
to ATG and/or plasmapheresis) with clusters of B cells successfully being removed from 
the interstitium [102105].  
The data on the use of rituximab as induction therapy are limited. Based on their 
favorable experience with rituximab in ABOincompatible transplantations, Tydén et al. 
evaluated the effectiveness and safety of singledose rituximab induction therapy 
compared with placebo, added to tacrolimusbased triple therapy. The incidence of acute 
rejections after 6 months was 12% in the rituximab group and 18% in the placebo group, 
which was not significantly different [106]. Another trial, using two doses of rituximab 
with steroidfree maintenance immunosuppression, was halted early due to an excess 
rate of acute cellular rejection. This raises the possibility that regulatory B cells may be 
depleted by rituximab [107]. 
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Studies with IL2 receptor antibodies have mostly been performed in lowimmunological
risk patients, and some studies report that in highrisks patients, ATG might be superior 
to IL2 receptor antibodies for the prophylaxis of acute rejection [8688], although the 
Cochrane metaanalysis does not support this conclusion. In immunologically lowrisk 
patients, the use of IL2 receptor antagonists enables the avoidance of steroids in 
patients treated with tacrolimus and mycophenolate mofetil [89, 90].  
In theory, targeting of the IL2 receptor could also affect regulatory T cells with a 
CD4+CD25+FOXP3+ phenotype, which might impede graft acceptance. Although a shift 
of regulatory T cells from the CD25+ to the CD25 compartment during treatment with 
IL2 receptor antagonists has been observed, several studies have demonstrated that the 
suppressive function of the regulatory T cells was maintained [9193].  
Based on the data summarized above, induction therapy with IL2 receptor antagonists 
is recommended in the 2009 Kidney Disease: Improving Global Outcome (KDIGO) 
clinical practice guideline for the care of kidney transplant recipients [29]. The last 
published survey of the Organ Procurement and Transplantation Network (OPTN) in 
the USA reported that in 2006 approximately 28% of renal transplantations were 
performed with IL2 receptor antagonist induction therapy [94]. It is likely that the 
KDIGO recommendations will cause an increase in this percentage in the future.  
The only differences between basiliximab and daclizumab are in dosing and length of 
therapy. In clinical trials, up to 20% of patients did not receive the scheduled five doses 
of daclizumab, but it has been shown that two doses of daclizumab can provide prolonged 
blockade of the IL2 receptor [95]. The similar efficacy of basiliximab and daclizumab, 
combined with the lack of approval for a limited dosing regimen of daclizumab, probably 
contributed to the voluntary withdrawal of daclizumab from the market in 2009. 
 
Rituximab: chimeric human–mouse antiCD20 
Rituximab (MabThera, HoffmannLa Roche, Basel, Switzerland) is a chimeric human–
mouse antibody against the CD20 molecule on B cells. After binding, it leads to clearance 
of B cells from the circulation. Rituximab is approved for the treatment of B cell non
HodgkinÊs lymphomas and severe rheumatoid arthritis.  
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Rituximab has also successfully been used in the treatment of recurrent focal segmental 
glomerulosclerosis and membranous nephropathy after renal transplantation. However, 
controlled studies for these indications are lacking and in many of the reported cases the 
efficacy of rituximab is difficult to assess since it was combined with other 
immunosuppressive drugs or with plasmapheresis [108]. Finally, rituximab has an 
important place in the treatment of posttransplant lymphoproliferative disorder [109].  
Administration of rituximab can be followed by a mild cytokine release syndrome. 
Although rituximab induces longlasting B cell depletion, the risk of infections appears 
to be limited [97, 110, 111]. Several cases of lateonset neutropenia have been described 
[112]. 
 
Eculizumab: humanized (mouse) antiC5 
Eculizumab (Alexion, Cheshire, CT, USA) is a humanized (human–mouse) monoclonal 
antibody directed against the complement protein C5. It blocks the cleavage of C5 and 
halts the formation of the membrane attack complex. It is successfully used in 
paroxysmal nocturnal hemoglobinuria [113]. Eculizumab could potentially be beneficial 
in renal transplantation for treatment or prevention of antibodymediated rejection, 
which is accompanied by activation of the complement system. The first case reports 
show that eculizumab can be safely and effectively used in selected patients to prevent 
injury from CDC [114]. This creates a window of opportunity for other therapies to clear 
the donorspecific antibodies. After renal transplantation, hemolytic uremic syndrome 
(HUS) may occur either as a recurrent or de novo form. During recent years, it has 
become clear that dysregulation of the complement alternative pathway leading to 
continuous complement activation is involved in the pathogenesis of HUS [115]. Several 
case reports have now demonstrated that treatment with eculizumab can improve 
outcome in patients with HUS after renal transplantation [116, 117]. Since eculizumab 
diminishes the defense against encapsulated bacteria, especially meningococci, patients 
should ideally undergo meningococcal vaccination prior to receiving the first eculizumab 
treatment. The response to this vaccination could however be suboptimal, especially 
during (intensified) immunosuppressive therapy. 
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Introduction 
The increased waiting list for renal transplant has prompted the use of socalled 
„expanded criteria donors‰ to increase the number of renal allografts available for 
transplant. Donation after circulatory death (DCD) has emerged as a satisfactory option 
to provide renal allografts with patient and graft survival rates similar to those obtained 
with renal allografts from donation after brain death donors [118]. A major problem with 
transplant of renal allografts from DCD donors is the high incidence of delayed graft 
function (around 40% to 50%, but might be as high as 80%) [119]. This frequently results 
in the continued need for dialysis for some time after the transplant, with associated 
increases in morbidity and mortality, and prolonged hospital stay [120]. Moreover, the 
lack of graft function requires performing graft biopsies at regular intervals to exclude 
acute rejection. Finally, delayed graft function is a risk factor for acute rejection and 
graft loss, although the detrimental effect of delayed graft function on graft survival 
appears to be much weaker in transplants with DCD donor renal allograft than in 
transplants with donation after brain death donor renal allografts [121, 122]. 
Consequently, reducing the incidence of delayed graft function after transplant with 
DCD donor renal allografts would facilitate managing recipients during the first weeks 
after a transplant and potentially improve longterm outcomes. 
Renal allografts from a DCD donor have prolonged warm ischemia periods and therefore, 
have more severe ischemiareperfusion–associated tissue damage. Ischemiareperfusion 
injury involves a cascade of deleterious steps, including increased cytokine synthesis and 
leukocytemediated tissue damage. Next to neutrophils, T cells have been identified as 
important cellular mediators in ischemiareperfusion injury [123]. T cell depletion at the 
time of transplant may reduce the extent of tissue damage after ischemiareperfusion 
injury [120]. 
Various depleting antiTlymphocyte antibodies are available for use in transplant. They 
include rabbit antihuman thymocyte immunoglobulin (Thymoglobulin, Genzyme), 
equine antithymocyte immunoglobulin (Atgam, Pfizer), and rabbit antihuman 
activated Tlymphocyte immunoglobulin (ATGF; ATGFresenius, Fresenius Biotech 
GmbH). Rabbit antihuman activated Tlymphocyte immunoglobulin consists of highly 
purified immunoglobulins, derived from rabbits after immunization with a T
lymphoblast cell line (i.e., Jurkat cell line). Administering the polyclonal antiT
lymphocyte antibody ATGF results in rapid T cell depletion. Rabbit antihuman 
activated Tlymphocyte immunoglobulin also has some effects on other cells of the 
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Abstract 
Objectives: Reducing the incidence of delayed graft function after transplant with 
donation after circulatory death donor renal allografts would facilitate managing 
recipients during their first weeks after a transplant. To reduce this incidence, in most 
studies, induction therapy with depleting antiTlymphocyte antibodies is coupled with a 
reduction of the dosage of the calcineurin inhibitor. The separate effect of antiT cell 
therapy on the incidence and duration of delayed graft function is therefore difficult to 
assess. 
Patients and Methods: We performed a randomized study to evaluate the effect of a 
single intraoperative highdose of antiTlymphocyte immunoglobulin (ATG)Fresenius 
(9 mg/kg body weight) on the incidence of delayed graft function. Eligible adult recipients 
of a first donation after circulatory death donor renal allograft were randomly assigned 
to ATGFresenius or no induction therapy. Maintenance immunosuppression consisted of 
tacrolimus, in an unadjusted dose, mycophenolate mofetil, and steroids. 
Results: The study was prematurely terminated because of a lowerthananticipated 
inclusion rate. Baseline characteristics were comparable in the ATGFresenius group    
(n = 28) and the control group (n = 24). Twentytwo patients in the ATGFresenius group 
(79%) had delayed graft function, compared with 13 in the control group (54%; p = 0.06). 
Allograft and patient survival were comparable in both groups. Serious adverse events 
occurred more frequently in the ATGFresenius group than they did in the control group 
(57% vs. 29%; p < 0.05). 
Conclusions: Intraoperative administration of a single highdose of ATGFresenius in 
donation after circulatory death donor renal allograft recipients, followed by triple 
immunosuppression with an unadjusted tacrolimus dose, seems ineffective to reduce the 
incidence of delayed graft function. Moreover, this was associated with a higher rate of 
serious adverse events (EudraCTnumber, 200700021036.) 
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lymphocyte antibody ATGF results in rapid T cell depletion. Rabbit antihuman 
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Abstract 
Objectives: Reducing the incidence of delayed graft function after transplant with 
donation after circulatory death donor renal allografts would facilitate managing 
recipients during their first weeks after a transplant. To reduce this incidence, in most 
studies, induction therapy with depleting antiTlymphocyte antibodies is coupled with a 
reduction of the dosage of the calcineurin inhibitor. The separate effect of antiT cell 
therapy on the incidence and duration of delayed graft function is therefore difficult to 
assess. 
Patients and Methods: We performed a randomized study to evaluate the effect of a 
single intraoperative highdose of antiTlymphocyte immunoglobulin (ATG)Fresenius 
(9 mg/kg body weight) on the incidence of delayed graft function. Eligible adult recipients 
of a first donation after circulatory death donor renal allograft were randomly assigned 
to ATGFresenius or no induction therapy. Maintenance immunosuppression consisted of 
tacrolimus, in an unadjusted dose, mycophenolate mofetil, and steroids. 
Results: The study was prematurely terminated because of a lowerthananticipated 
inclusion rate. Baseline characteristics were comparable in the ATGFresenius group    
(n = 28) and the control group (n = 24). Twentytwo patients in the ATGFresenius group 
(79%) had delayed graft function, compared with 13 in the control group (54%; p = 0.06). 
Allograft and patient survival were comparable in both groups. Serious adverse events 
occurred more frequently in the ATGFresenius group than they did in the control group 
(57% vs. 29%; p < 0.05). 
Conclusions: Intraoperative administration of a single highdose of ATGFresenius in 
donation after circulatory death donor renal allograft recipients, followed by triple 
immunosuppression with an unadjusted tacrolimus dose, seems ineffective to reduce the 
incidence of delayed graft function. Moreover, this was associated with a higher rate of 
serious adverse events (EudraCTnumber, 200700021036.) 
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randomized at the coordinating center using a computerderived algorithm. Treatment 
assignments were printed on paper and put in concealed, numbered envelopes. 
Participants were stratified for the age of the recipient (< 50 and º 50 years) and the 
length of the first warm ischemia time (< 30 and º 30 minutes). Patients were assigned a 
consecutive number by the participating center, in the order in which they entered the 
study. The consecutive number corresponded with the envelope containing the assigned 
treatment, which was opened after eligibility of the patient was finally established and 
the patient was ready for treatment. 
Patients in the ATGF group received a single highdose of ATGF IV (9 mg/kg body 
weight, diluted in 500 mL saline) intraoperatively. Before the infusion of ATGF, 
patients received 250 mg of methylprednisolone IV. The infusion of ATGF was given in 
4 hours and did not need to be completed before reperfusion of the graft. Afterward, 
patients received triple immunosuppression with tacrolimus, mycophenolate mofetil, and 
steroids. In the control group, patients received only 250 mg of methylprednisolone 
intraoperatively and equal triple immunosuppression after transplant. 
In both groups, patients were treated with a regular, unadjusted dose of tacrolimus, to 
enable evaluation of the separate effect of adding ATGF. The initial dosage of 
tacrolimus was 0.2 mg/kg/day orally, starting within 24 hours posttransplant. The 
tacrolimus dosage was adjusted to a target trough level of 15 to 20 mg/L in the first 2 
weeks posttransplant, 10 to 15 mg/L during the 3 to 6 weeks after transplant, and 5 to 
10 mg/L thereafter. Mycophenolate mofetil was started at a dosage of 2000 mg/day. After 
2 weeks, the dosage was decreased to 1500 mg/day, unless the body weight was more 
than 90 kg. In patients with delayed graft function, the starting dosage was 1500 mg/day 
to reduce adverse events caused by an accumulation of metabolites. Prednisone was 
given in a dosage of 100 mg IV for the first 3 days after the operation. Afterward, the 
dosage of prednisone was tapered according to local practices. For prophylaxis of 
Pneumocystis jiroveci pneumonia, trimethoprim/sulfamethoxazole was given in a dosage 
of 480 mg daily. For prophylaxis of cytomegalovirus disease, valganciclovir was given in 
case of a seropositive donor and seronegative recipient in a dosage adjusted to allograft 
function.  
The primary endpoint of this study was the incidence of delayed graft function, defined 
as the need for dialysis following transplant. Secondary endpoints were the duration of 
initial delayed graft function (defined as the interval between the day of transplant and 
the last day of dialysis), and incidence of primary nonfunction of the allograft. Moreover, 
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immune system, namely proliferating Blymphocytes and other antigen presenting cells 
[16, 124]. 
In previous clinical studies on induction therapy with depleting antiTlymphocyte 
antibodies, this treatment was usually coupled to a reduction of the dosage of the 
calcineurin inhibitor (either tacrolimus or cyclosporine). Because calcineurin inhibitors 
can retard the recovery of graft function after renal transplant, the separate effect of 
antiT cell therapy on the incidence and duration of delayed graft function is difficult to 
judge in these studies [125]. Therefore, in our study, a different study protocol was 
chosen. A regular, unadjusted dose of tacrolimus was used in both the ATGF group and 
control group to evaluate the effect of ATGF on ischemiareperfusion injury. 
In this study, we evaluate whether a single, intraoperative highdose of ATGF added to 
a triple immunosuppressive drug regimen with an unadjusted dose of tacrolimus, could 
reduce the incidence and duration of delayed graft function after transplant with a DCD 
donor renal allograft. 
 
Patients and Methods 
This multicenter, randomized, open label study was conducted in 4 university centers in 
The Netherlands. The study was conducted in compliance with the applicable regulatory 
requirements and the Declaration of Helsinki. Written, informed consent was obtained 
from all patients. During the study, no changes were made to the design of the study. 
The conduct of the study was continually monitored by independent study nurses. 
All patients (aged º 18 years) who were candidates to receive a renal allograft from a 
DCD donor were eligible for this study. Acceptability criteria for donor age, and warm 
and cold ischemia times were according to local protocols. Exclusion criteria were a 
previous transplant or proposed transplant with multiple organs (e.g., kidneypancreas 
transplant); blood group incompatibility; current pregnancy or history of more than 3 
pregnancies; lack of consistent data on a panel reactive antibody; known presence of 
antibodies against rabbit immunoglobulin or previous treatment with rabbit 
immunoglobulin; known intolerance to any component of basal immunosuppression; 
HIVpositivity; leukocytes < 3.0 × 109/L and/or platelets < 50 × 109/L before transplant; 
(cured) malignancy (with the exception of basocellular or spinocellular skin cancer); and 
pulmonary edema or other signs of overhydration. Patients were randomly assigned (1:1) 
to either the ATGF group or the control group. Treatment assignments were 
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Results 
The study was prematurely terminated in June 2010 because of a much lowerthan
anticipated inclusion rate, without the prospect of improvement. Between January 2008 
and June 2010, all adult patients (n = 151) who were candidates to undergo transplant 
with a DCD donor renal allograft were assessed for eligibility. In total, 54 patients could 
be randomized (Figure 1). Most patients were ineligible because they met exclusion 
criteria, for example, a previous transplant. In addition, many patients could not be 
included because the preparation time for the transplant was too short to obtain proper 
informed consent. The 54 patients who were included for randomization did not differ 
from the 97 patients not included with respect to recipient age, sex, cause of endstage 
renal disease, and ischemia times (data not shown).  
Of the 54 included patients, 30 were randomized for treatment with ATGF. The data of 
two patients in the ATGF group were not analyzed because the transplant was 
cancelled because of the bad quality of the allograft and a positive crossmatch, 
respectively. Although one patient in the ATGF group did inadvertently not receive 
ATGF, this patient was included in the analysis. If this patient were excluded in a per
protocol analysis, the outcome on all endpoints did not change. All randomized patients 
finished the 3month followup. Patients within strata were equally randomized between 
ATGF and control treatment. The groups also showed no significant differences with 
respect to donor and recipient characteristics (Table 1).  
The incidence of delayed graft function did not significantly differ between both groups 
(79% in the ATGF group vs. 54% in the control group; p = 0.06; Table 2). Four patients 
in the ATGF group and two in the control group required only one dialysis session after 
transplant. The duration of delayed graft function, the incidence of primary non
function, and the incidence of biopsyproven rejection did not differ between the ATGF 
and the control group. At 3 months after transplant, patient and graft survival were 
100% and 96% in the ATGF group versus 96% and 83% in the control group. Serum 
creatinine was not different between groups at any moment after transplant. 
One day after transplant, the absolute lymphocyte count was lower in the ATGF group 
as compared to the control group (0.18 × 109/L, range, 0.00.48 × 109/L vs. 0.59 × 109/L, 
range 0.01.6 × 109/L; p < 0.01). Two weeks after transplant, this difference between the 
ATGF and control group disappeared. The thrombocyte count one day after transplant 
also was lower in the ATGF group (115 × 109/L, range 56256 × 109/L) as compared to the 
control group (191 × 109/L, range, 81336 × 109/L; p < 0.01). This difference was no longer 
44 
at 3 months after transplant, the incidence of acute rejection (clinically treated and 
biopsyproven), allograft function and proteinuria, patient and graft survival, incidence 
of arterial hypertension, use of antihypertensive drugs, incidence of hyperlipidemia, and 
incidence of posttransplant diabetes mellitus were recorded. As safety parameters, the 
incidence of infections, especially cytomegalovirus, the incidence of malignancies during 
the first 3 months after transplant, and the incidence of serious adverse events were 
recorded. Serious adverse events were defined as any untoward medical occurrence that 
at any dose resulted in death, was lifethreatening, required inpatient hospitalization or 
prolongation of existing hospitalization, or was otherwise medically significant to 
prevent or reduce permanent impairment or damage. Primary and secondary endpoints 
were not changed during the study. 
At any time during the application of ATGF or shortly after the infusion, there is a risk 
of anaphylactic reactions including a drop in blood pressure, chest pain, fever, or 
urticaria. Because the study used a single dose of ATGF, the only reason for 
discontinuation of the treatment was clinically significant symptoms during infusion. 
Therapy was not discontinued if the symptoms remained mild and reversible. 
Sample size determination was made under the assumption that the rate of delayed 
graft function would be 80% in the control group, with a reduction to 60% or less with 
ATGF. A sample size of 80 patients per group provided at least 80% power, with             α 
= 2.5% onesided, to detect this difference. Taking possible dropouts into account, the 
study was planned with 90 patients per group, requiring 180 patients in total. No 
interim analysis was planned nor performed in this study. 
We performed overall group comparisons using a chisquare test or Fisher exact test (if 
counts per group were below 5). For continuous variables, we used either an unpaired T 
test (normally distributed data) or a Wilcoxon MannWhitney U test (notnormally 
distributed data). All statistical tests were twosided, and p < 0.05 was considered 
statistically significant. Patients who underwent transplantation were evaluated in an 
intentiontotreat analysis. Because the number of patients was small, the primary and 
secondary endpoints were not analyzed within strata.  
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Figure 1. Enrolment of patients in the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
151 recipients of a DCDdonor renal allograft were assessed for eligibility 
97 patients were not included or 
did not provide informed consent 
 18 underwent previous 
transplantation 
5 received other induction 
therapy 
4 had a malignancy 
7 had other exclusion criteria 
14 could not provide informed 
consent (did not speak Dutch) 
17 did not give informed 
consent 
 
Due to a speedy transplant 
procedure, an additional 30 
eligible patients could not be 
included 
54 patients were randomized 
30 patients were randomized for 
treatment with ATGF 
24 patients were randomized for  
the control group 
28 patients were analyzed              
(1 patient did not receive ATGF) 
24 patients were analyzed 
2 patients did 
not undergo 
transplantation 
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present 3 weeks after transplant. Three patients (11%, 3/28) had a severe reaction when 
given ATGF, mainly hypotension. Moreover, an additional two patients in the ATGF 
group had signs of hemolysis the day after transplant, for which no other explanation 
than administering ATGF was available. Serum sickness was not reported, although 
one patient in the ATGF group was found to have a positive titer of antirabbit 
immunoglobulin antibodies (80 U/L) at the time of transplant (without known exposure 
to rabbit proteins or previous known positive antirabbit immunoglobulin antibodies). 
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present 3 weeks after transplant. Three patients (11%, 3/28) had a severe reaction when 
given ATGF, mainly hypotension. Moreover, an additional two patients in the ATGF 
group had signs of hemolysis the day after transplant, for which no other explanation 
than administering ATGF was available. Serum sickness was not reported, although 
one patient in the ATGF group was found to have a positive titer of antirabbit 
immunoglobulin antibodies (80 U/L) at the time of transplant (without known exposure 
to rabbit proteins or previous known positive antirabbit immunoglobulin antibodies). 
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Table 2. Primary and secondary endpoints at three months after renal 
transplantation.* 
 ATGF  
group  
(n = 28) 
Control 
group 
(n = 24) 
Absolute risk 
difference (95% 
CI) 
Primary  endpoint 
Incidence of delayed graft function, no (%) 22 (79) 13 (54) 25% (1 to 48) 
 
Secondary endpoints 
Duration of delayed graft function – days; 
(range) 
10.1  
(124) 
16.4  
(347) 
 
Incidence of primary nonfunction, no. (%) 1 (4) 3 (13) 9% (28 to 7) 
Incidence of treatment for rejection, no. (%) 6 (21) 7 (29) 8% (32 to 16) 
    Biopsy performed, no. (%) 12 (43) 11 (46) 3% (29 to 24) 
    Biopsyproven rejection, no. (%) 2 (7) 2 (8) 1% (20 to 16) 
Patient survival, no. (%) 28 (100) 23 (96) 4% (8 to 20) 
Graft survival, no. (%) 26 (96)  20 (83) 13% (9 to 30) 
Serum creatinine week 2, mol/l (range) 567 
(1151020) 
426 
112979) 
 
Serum creatinine month 1, mol/l (range) 289 
(123814) 
247 
(91586) 
 
Serum creatinine month 2, mol/l (range) 191 
(95562) 
238 
(79701) 
 
Serum creatinine month 3, mol/l (range) 178 
(103352) 
180 
(80437) 
 
Proteinuria month 1, g/l (range) 0.39  
(01.94) 
0.84  
(0.15.2) 
 
 
Proteinuria month 2, g/l (range) 0.24  
(00.58) 
0.34  
(01.56) 
 
Proteinuria month 3, g/l (range) 0.21  
(00.47) 
0.20  
(00.54) 
 
Incidence of hypertension, no (%) 23 (82%) 20 (83%) 1% (22 to 21) 
Number of antihypertensive drugs (range) 1.7 (13)  1.6 (13)  
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Table 1.  Baseline characteristics of renal allograft recipients.* 
 ATGF group (n 
= 28) 
Control group 
(n = 24) 
Mean age, years (range) 54 (2170) 56 (2468) 
Sex – no. (%)   
    Male 18 (64) 17 (71) 
    Female 10 (36) 7 (29) 
Cause of endstage renal disease, no. (%)   
    Glomerulonephritis 9 (32) 5 (21) 
    Polycystic kidney disease 6 (21) 4 (17) 
    Diabetic nephropathy 0 (0) 2 (8) 
    Hypertension 2 (7) 3 (13) 
    Other  11 (39) 10 (42) 
First warm ischemia time – min 18  4 19  6 
Cold ischemia time – hr 16.4  5.4 16.6  4.5 
Anastomosis time – min 33  11 31  11 
Stratification – no. (%)   
Recipient age º50 years and  
first warm ischemia time <30 min 
20 (71) 18 (75) 
Recipient age <50 years and  
first warm ischemia time <30 min  
8 (29) 4 (17) 
Recipient age º50 years and  
first warm ischemia time º30 min 
0 (0) 2 (8) 
Recipient age <50 years and  
first warm ischemia time º30 min  
0 (0) 0 (0) 
Leukocyte count, 109/l 8.4  2.5 7.8  2.4 
Absolute lymphocyte count, 109/l 1.7  0.9  1.5  0.7 
Thrombocyte count, 109/l 242  115 238  73 
 
* Values are given as means  SD, unless stated otherwise. There were no statistically significant differences between 
groups. 
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Table 2. Primary and secondary endpoints at three months after renal 
transplantation.* 
 ATGF  
group  
(n = 28) 
Control 
group 
(n = 24) 
Absolute risk 
difference (95% 
CI) 
Primary  endpoint 
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 
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Table 1.  Baseline characteristics of renal allograft recipients.* 
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0 (0) 2 (8) 
Recipient age <50 years and  
first warm ischemia time º30 min  
0 (0) 0 (0) 
Leukocyte count, 109/l 8.4  2.5 7.8  2.4 
Absolute lymphocyte count, 109/l 1.7  0.9  1.5  0.7 
Thrombocyte count, 109/l 242  115 238  73 
 
* Values are given as means  SD, unless stated otherwise. There were no statistically significant differences between 
groups. 
51 
Table 3. Serious adverse events reported during the study. 
 ATGF 
group  
(n = 28) 
Control 
group 
(n = 24) 
Incidence of serious adverse events, no. of patients (%)* 16 (57) 7 (29) 
Total number of reported serious adverse events (no.) 23 9 
Severity of serious adverse events   
Death  0 1 
Unsuccessful resuscitation after cardiac arrest at 
the fifth postoperative day 
0 1 
Lifethreatening 2 0 
Dissection of the thoracic and abdominal aorta on 
the third postoperative day 
1 0 
Intraoperative myocardial infarction 1 0 
New or prolonged hospitalization 13 6 
Bleeding requiring transfusion 1 0 
Chest pain 0 1 
Diarrhea 0 1 
Hypotension and anemia 1 0 
Meningitis and sepsis 1 0 
Operative removal hematoma 0 1 
Wound dehiscention requiring surgery 1 0 
Pyelonephritis / urinary tract infection 4 1 
Rectal prolaps with bleeding 1 0 
Graft removal 1 2 
Treatment for rejection 2 0 
Wound infection 1 0 
Medically significant 8 2 
Acute coronary syndrome 1 0 
Bleeding after surgery requiring two reoperations 
and intensive care admittance  
1 0 
Hemolysis 1 0 
Hypotension, pulmonary edema, hemolysis and 
severe thrombocytopenia 
1 0 
Medication error 0 2 
50 
Side effects 
Patients with at least one infection, no. (%) 17 (63) 9 (38) 25% (2 to 50) 
CMV infection, no. (%) 3 (11) 2 (8) 3% (17 to 21) 
Malignancies, no. (%) 0 (0) 0 (0) 0% 
Posttransplant diabetes mellitus, no. (%) 12 (46) 4 (20) 26% (2 to 50) 
 
* Values are given as means. There were no statistically significant differences between groups. 
 
Discussion 
The main objective of this randomized multicenter study was to test the efficacy of   
ATGF to reduce the incidence of delayed graft function after DCD donor renal 
transplantation. The premature termination of our study does not allow drawing firm 
conclusions related to our main objective. Nonetheless, our study indicates that the 
addition of a single intraoperative dose of ATGF to standard triple immunosuppressive 
therapy, with an unadjusted tacrolimus dose, is not effective to reduce the incidence or 
duration of delayed graft function and might even be associated with a higher incidence 
of serious adverse events.  
Interestingly, there was also no effect of ATGF on the incidence of acute rejection. In 
other studies, induction therapy with a single dose of ATGF or other antiTlymphocyte 
immunoglobulins universally reduced the incidence of acute rejection [126131]. Because 
we noticed a profound lymphocytopenia and a mild thrombocytopenia in the ATGF 
group, ineffectiveness of the ATGF itself seems an unlikely explanation for the lack of a 
beneficial effect on the incidence of delayed graft function and incidence of rejection. 
Rather, it appears that either the contribution of T cells in the pathogenesis and 
recovery of acute tubular necrosis after transplant with a DCD donor renal allograft is 
limited, or that the positive effect of ATGF is counterbalanced by the negative effect of 
other factors. The reaction that accompanied the infusion of ATGF could be one of those 
factors. Five patients had hypotension, thrombocytopenia, or fever. Although no 
cytokines were measured, these symptoms are known to be caused by a release of 
cytokines [132]. This cytokine release syndrome could have contributed to a more 
proinflammatory environment, leading to more severe ischemiareperfusion injury and 
worse outcomes. Hypotension, per se, also could have worsened ischemiareperfusion 
injury. All patients with an infusion reaction developed delayed graft function, although 
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with a reduced dose of the calcineurin inhibitor without ATGF induction. This is not 
feasible, however, because one would expose the patient to an unjustifiable high risk of 
graft rejection. 
Aside from the lack of efficacy, a higher incidence of serious adverse effects was reported 
in the ATGF group. However, the open design of our study does not exclude bias, 
especially in reporting serious adverse events. Of the adverse effects occurring during 
and after administration of ATGF, especially the thrombocytopenia and acute coronary 
syndrome, compromised patient safety. Another concern is the trend toward more 
infections in the ATGF group, which was not reported in other studies with ATGF. This 
could be either an effect of ATGF itself, or related to the unadjusted, relatively higher 
(compared with other studies) tacrolimus dose in our study. 
We prematurely terminated our study because of an unacceptable low recruitment rate. 
We initially aimed for the participation of seven Dutch transplant centers, but inclusion 
of study participants was initiated in only four of them. Moreover, the number of DCD 
donor renal allografts reported for transplant was smaller than estimated and more 
patients than expected met the exclusion criteria. Consequently, the study was 
underpowered to detect clinically meaningful differences in outcome parameters. 
However, based on the current findings with an incidence of delayed graft function of 
79% in the ATGF group and 54% in the control group, it is unlikely that expanding the 
study population from 54 to the planned number of 180 would yield a statistically 
significant benefit of ATGF (the chance to achieve this was calculated to be 4%). 
In conclusion, we are aware that our results must be considered with some caution, 
because our study was prematurely terminated. However, the intraoperative 
administration of a single highdose of ATGF in DCD donor renal allograft recipients, 
followed by triple immunosuppression with unadjusted tacrolimus dose, seems 
ineffective for reducing the incidence of delayed graft function. Because administration 
of ATGF was associated with a higher rate of serious adverse events, the use of ATGF 
in DCD donors to reduce the incidence of delayed graft function cannot be recommended.  
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Severe infection 2 0 
Urine leakage 2 0 
Serious adverse events reported during administration 
of ATGF 
  
Fever 1 0 
Hypotension 4 0 
Thrombocytopenia 3 0 
Acute coronary syndrome due to blood loss / hypotension 
during transplantation 
2 0 
 
* P = 0.043, absolute risk difference 28%, 95%CI 1% to 51% 
 
the duration of delayed graft function did not differ from patients without infusion 
reactions (data not shown).  
A difference in the type of donors (donation after brain death in most studies, compared 
to DCD in our study) also could explain the relatively high incidence of delayed graft 
function and the lack of a favorable effect of ATGF. A lower incidence of delayed graft 
function was reported for patients treated with ATGF in another study comparing ATG
F induction, basiliximab induction, or no induction (delayed graft function rate of 5.7%, 
24.1%, and 15.9%; p < 0.025). In this study, however, only allografts from donation after 
brain death donors were included [126]. 
Kaden et al. reported that induction therapy with a single dose of ATGF was correlated 
with a reduced incidence of delayed graft function, compared with a triple drug regimen 
with low cyclosporine dose (32.9% vs. 45.5%; p < 0.01) [127]. However, this was a 
retrospective study with potential bias. Other prospective studies evaluating the effect of 
a single intraoperative dose of ATGF did not find a difference between patients treated 
with ATGF, compared with a control group treated with either mycophenolate mofetil or 
standard dose cyclosporine [129, 133]. In the aforementioned studies, treatment with 
ATGF was accompanied by a dose adjustment of the calcineurin inhibitor [126, 127]. As 
stated in our introduction, the combined use of ATGF and adjustments of calcineurin 
inhibitors, makes it difficult to assess the separate effect of ATGF. Because we used a 
regular, unadjusted tacrolimus dose and did not see an effect on the incidence of delayed 
graft function, the beneficial effect in other studies could possibly be caused by the dose 
adjustment of the calcineurin inhibitor, instead of the administration of antiT
lymphocyte immunoglobulin. To investigate this hypothesis would require a study arm 
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Introduction 
The firstline treatment of established acute cellular allograft rejection is highdose 
steroids. When treatment with steroids fails or a rejection quickly recurs, treatment with 
antiT cell antibodies is often the next step. Most experience is based on the use of 
antithymocyte globulin (ATG) and MuromonabCD3 [134]. However, MuromonabCD3 is 
no longer available and currently, steroidresistant acute rejections are therefore mostly 
treated with a 10–14 days course of ATG [11, 13]. Although efficacious, this treatment 
has several drawbacks. First, ATG should be administered intravenously using a central 
venous catheter, high flow vein or arteriovenous fistula to prevent phlebitis. Second, the 
administration is associated with severe infusionrelated side effects like fever, chills, 
headache, dyspnea, myalgia and hypotension [15]. This limits its tolerability, especially 
in older individuals or those with significant cardiopulmonary comorbidity. 
Alemtuzumab is a depleting, humanized monoclonal antibody, directed specifically to the 
CD52 molecule, which is expressed on T cells and several other lymphoid and myeloid 
cell types [21]. Alemtuzumab is currently registered for the treatment of chronic 
lymphatic leukemia, but data on the safety and efficacy of treatment of acute rejection 
after organ transplantation are scarce. Several studies reported the results in small 
groups of patients, merely demonstrating that recurrent or steroidresistant rejection 
can be reversed with alemtuzumab [30, 31, 3436]. Randomized trials comparing 
alemtuzumab with other T celldepleting agents for the treatment of acute rejection have 
not been performed. In early trials with alemtuzumab as induction therapy, intravenous 
administration was frequently accompanied by infusion reactions. In more recent trials, 
in which alemtuzumab was given subcutaneously, infusionrelated side effects were rare 
or not reported [38, 63].  
We hypothesized that alemtuzumab might be preferred over ATG for steroidresistant 
rejection after renal transplantation. We analyzed our first experience with 
alemtuzumab in this setting, and compared this with results obtained in a historical 
cohort of patients treated with ATG. 
 
Patients and Methods 
All renal allograft recipients treated with alemtuzumab for steroidresistant rejection 
since 2008 were identified in three academic centers in the Netherlands. Subsequently, a 
control group was composed, consisting of patients that were treated with ATG for 
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Abstract 
Steroidresistant renal allograft rejections are commonly treated with rabbit 
antithymocyte globulin (RATG), but alemtuzumab could be an effective, safe and more 
convenient alternative. 
Adult patients with steroidresistant renal allograft rejection treated with alemtuzumab 
(15–30 mg s.c. on two subsequent days) from 2008 to 2012 (n = 11) were compared to 
patients treated with RATG (2.54.0 mg/kg bodyweight i.v. for 10–14 days; n = 20). We 
assessed treatment failure (graft loss, lack of improvement of graft function or need for 
additional antirejection treatment), infections during the first 3 months after treatment 
and infusionrelated side effects. 
In both groups, the median timeinterval between rejection and transplantation was 2 
weeks, and approximately 75% of rejections were classified as Banff IIA or higher. Three 
alemtuzumabtreated patients (27%) experienced treatment failure, compared to eight 
RATG treated patients (40%, p = 0.70). There was no difference in the incidence of 
infections. There were mild infusionrelated side effects in three alemtuzumab treated 
patients (27%), and more severe infusion related side effects in 17 RATGtreated 
patients (85%, p = 0.013). Drug related costs of alemtuzumab treatment were lower than 
of RATG treatment (€1050 vs. €2024; p < 0.01). 
Alemtuzumab might be an effective therapy for steroidresistant renal allograft 
rejections. In contrast to RATG, alemtuzumab is nearly devoid of infusionrelated side 
effects. These data warrant a prospective trial. 
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patients (27%), and more severe infusion related side effects in 17 RATGtreated 
patients (85%, p = 0.013). Drug related costs of alemtuzumab treatment were lower than 
of RATG treatment (€1050 vs. €2024; p < 0.01). 
Alemtuzumab might be an effective therapy for steroidresistant renal allograft 
rejections. In contrast to RATG, alemtuzumab is nearly devoid of infusionrelated side 
effects. These data warrant a prospective trial. 
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antirejection therapy or lack of improvement of graft function (defined as the absence of 
a drop in serum creatinine of 25% or more at any time within a 3 month interval after 
start of treatment). Furthermore, we analyzed the incidence of infusionrelated side 
effects and the drugrelated costs of both antibody treatments.  
We performed overall group comparisons using a chisquare test or Fisher exact test (if 
counts per group were below five). For continuous variables we used either an unpaired 
T test (normally distributed data) or a Wilcoxon test (notnormally distributed data). All 
statistical tests were twosided and p < 0.05 was considered statistically significant. 
 
Results 
From January 2008 to April 2012, we identified 14 patients treated with alemtuzumab 
and 28 patients treated with ATG. Of the 14 alemtuzumabtreated patients, two were 
treated earlier with other antiT cell antibodies (muromonabCD3 and ATG, 
respectively) after the current transplantation, and one was still on dialysis at start of 
antibody treatment. Therefore, 11 alemtuzumabtreated patients were included in the 
analysis. In five patients in the control group, no biopsy was performed to confirm the 
presence of rejection, and in one case there was only borderline rejection. Moreover, one 
patient had received ATG as induction therapy, and one was still on dialysis at start of 
antibody treatment. As a result, 20 ATGtreated patients were analyzed. 
In the majority of alemtuzumabtreated patients, the use of other antiT cell antibodies 
was considered to be unattractive for the following reasons: treatment with ATG after a 
previous transplantation (n = 4), positive test for antirabbit IgG antibodies (n = 2), fluid 
overload (n = 1) and recent cardiac ischemia (n = 1). In three cases, alemtuzumab was 
chosen without specific contraindication for other antiT cell antibodies. 
Baseline characteristics of alemtuzumab and ATGtreated patients are stated in     
Table 1. The number of HLA mismatches was lower in the alemtuzumabtreated 
patients. However, 55% of the alemtuzumabtreated patients underwent a retransplant 
compared to only 5% of the ATGtreated patients (p < 0.01). The majority of rejections in 
each group were classified as Banff IIA. The median time interval between 
transplantation and antibody treatment of rejection was 42 days in the alemtuzumab 
group (range 4–752) and 22 days in ATGtreated patients (range 6–849; p = 0.73).  
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steroidresistant acute rejection. For each alemtuzumabtreated patient, we selected the 
two ATGtreated patients in the same center of whom the transplantation date was most 
closely preceding and following that of the alemtuzumabtreated patient.  
Next, we excluded patients who never had a functioning graft (defined as urine 
production posttransplantation with a drop in serum creatinine without requirement of 
dialysis) before the onset of antibody therapy, or in whom there was no biopsy 
confirming the presence of acute cellular rejection. In addition, patients who already had 
received any antiT cell antibodies after the current transplantation (as induction 
therapy or treatment of prior rejection episode) were excluded. 
Consequently, none of the analyzed patients had received induction therapy with a 
depleting antiT cell agent. Some patients received basiliximab as induction therapy, and 
another part of the patients participated in an ongoing doubleblind randomized trial, 
comparing rituximab with placebo as induction therapy. Maintenance 
immunosuppression consisted of the combination of a calcineurin inhibitor, an 
antiproliferative agent, and steroids in all patients. In case of graft dysfunction without 
obvious pre or postrenal cause, a graft biopsy was performed. Pathologic examination of 
the biopsy tissue included C4d staining in all cases and rejections were classified 
according to Banff 97 criteria [10]. When a graft biopsy was not possible (e.g. because of 
the use of anticoagulant therapy) and the suspicion of rejection was strong, antirejection 
therapy was started without prior graft biopsy. Donorspecific antiHLA antibodies were 
not routinely measured. Firstline antirejection treatment consisted of 
methylprednisolone, with doses varying between 500 and 1000 mg during 3–6 days. 
When there was no successful response to steroids, or graft function deteriorated during 
or shortly after steroid therapy, the rejection episode was considered steroidresistant. In 
part of the cases a (re)biopsy was performed to confirm the persistence of rejection. 
Alemtuzumab (Campath1H Genzyme Europe BV, Naarden, The Netherlands) was 
given in 15–30 mg doses subcutaneously at two subsequent days. ATG (Thymoglobulin, 
Genzyme) was administered in a dosage of 2.5–4.0 mg/kg bodyweight intravenously for 
10–14 days, with adjustments based on lymphocyte or CD4+ T cell counts. In both 
groups patients were treated with antihistamines, steroids and acetaminophen before 
antibody therapy.  
We assessed the rate of treatmentfailure and infections during the first 3 months after 
the start of treatment with antiT cell antibodies, and recorded all malignancies during 
followup. Treatment failure was defined as graft loss, the need for additional 
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During followup, two ATGtreated patients developed a malignancy (one lymphoma at 
35 months and one squamouscell carcinoma at 30 months after treatment). One or more 
infusionrelated side effects occurred in three alemtuzumabtreated patients (27%). One 
patient developed malaise, dyspnea, myalgia and tachycardia, whereas the other two 
had either a local hematoma or a mild rash. In comparison, all but three ATGtreated 
patients experienced one or more infusionrelated side effects such as hypotension, fever, 
chills, nausea, malaise and thrombocytopenia (85%; p = 0.013). The median drugrelated 
costs of alemtuzumab treatment were €1050 (range €525–€1050), whereas the median 
drugrelated costs of ATG treatment were €2024 (range €855–€3875; p < 0.01). 
 
Table 2. Outcome in alemtuzumabtreated patients. 
ID Lowest serum 
creatinine 
posttransplantation  
(mol/l) 
Pre
treatment 
serum 
creatinine 
(mol/l) 
Three months 
posttreatment 
serum 
creatinine  
(mol/l) 
Efficacy within three months after 
treatment 
Graft 
loss 
Lack of 
improvement of 
graft function 
Need for 
further 
antirejection 
treatment 
1 584 781 247 No No No 
2 86 128 Patient died Yes Yes No 
3 331 332 200 No No No 
4 94 132 87 No No No 
5 603 658 165 No No No 
6 52 77 76 No No No 
7 523 889 255 No No No 
8 96 486 350 No No No 
9 96 138 131 No Yes No 
10 97 131 140 No Yes No 
11 110 166 171 No No No 
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Three alemtuzumabtreated patients (27%) experienced treatment failure, compared 
with eight ATGtreated patients (40%; p = 0.70), see Tables 2 and 3. Additional 
information on individual patients may be found in Tables 4 and 5. Serum creatinine 3 
months after start of antibody treatment was comparable between both groups (182  84 
vs. 187  101 ømol/L; p = 0.89). The median number of infections per patient within 3 
months after treatment was one in alemtuzumabtreated patients (range 0–6) and two in 
ATGtreated patients (range 0–6; p = 0.81). A cytomegalovirus (CMV) primary infection 
or reactivation occurred in four alemtuzumabtreated patients, compared to five among 
ATGtreated patients (36% vs. 25%; p = 0.68).  
Table 1. Baseline characteristics of patients treated with alemtuzumab or ATG.  
 Alemtuzumab 
(n = 11) 
ATG 
(n = 20) 
p values 
Recipient age, years (median, range) 49 (19 – 72) 48 (24 – 66) 0.93 
Sex – no. (%)   0.48 
    Male 5 (45) 12 (60)  
    Female 6 (55) 8 (40)  
Cause of endstage renal disease – no. (%)   0.32 
    Glomerulonephritis 6 (55) 6 (30)  
    Polycystic kidney disease 2 (18) 3 (15)  
    Diabetic nephropathy 0 (0) 2 (10)  
    Hypertension 1 (9) 1 (5)  
    Other  2 (18) 8 (40)  
Rank order of transplantation – no. (%)   <0.01 
     First 5 (45) 19 (95)  
     Second or more 6 (55) 1 (5)  
Peak value of panel reactive antibodies % 
(median, range) 
10 (0 – 83) 0 (0 – 92) 0.077 
HLA A, B, and DR mismatches – no.  
(median, range) 
2 (1 – 5) 5 (1 – 6) 0.029 
Donor age, years (median, range) 51 (10 – 74) 53 (36 – 66) 0.89 
Type of donor – no. (%)    0.32 
    Donation after brain death 5 (45) 4 (20)  
    Donation after circulatory death 1 (9) 2 (10)  
    Living 5 (45) 14 (70)  
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Table 3. Outcome in ATGtreated patients. 
ID Lowest serum 
creatinine 
posttransplantati
on  
(mol/l) 
Pre
treatment 
creatinine 
(mol/l) 
Three 
months 
post
treatment 
creatinine  
(mol/l) 
Efficacy within three months after 
treatment 
Graft 
loss 
Lack of 
improvement 
of graft 
function 
Need for 
further 
antirejection 
treatment 
12 246 345 108 No No No 
13 325 896 148 No No No 
14 468 562 158 No No No 
15 123 350 121 No No No 
16 171 278 102 No No No 
17 286 468 217 No No No 
18 112 490 181 No No Yes 
19 164 164 95 No No No 
20 120 126 130 No Yes No 
21 214 306 141 No No No 
22 105 350 413 No Yes No 
23 118 285 Patient died Patient 
died 
No No 
24 119 158 100 No No No 
25 153 164 141 No No No 
26 484 602 220 No No no 
27 245 485 264 No No Yes 
28 611 608 290 No No No 
29 168 224 238 No Yes No 
30 152 219 516 Yes Yes No 
31 94 301 201 No No Yes 
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Table 3. Outcome in ATGtreated patients. 
ID Lowest serum 
creatinine 
posttransplantati
on  
(mol/l) 
Pre
treatment 
creatinine 
(mol/l) 
Three 
months 
post
treatment 
creatinine  
(mol/l) 
Efficacy within three months after 
treatment 
Graft 
loss 
Lack of 
improvement 
of graft 
function 
Need for 
further 
antirejection 
treatment 
12 246 345 108 No No No 
13 325 896 148 No No No 
14 468 562 158 No No No 
15 123 350 121 No No No 
16 171 278 102 No No No 
17 286 468 217 No No No 
18 112 490 181 No No Yes 
19 164 164 95 No No No 
20 120 126 130 No Yes No 
21 214 306 141 No No No 
22 105 350 413 No Yes No 
23 118 285 Patient died Patient 
died 
No No 
24 119 158 100 No No No 
25 153 164 141 No No No 
26 484 602 220 No No no 
27 245 485 264 No No Yes 
28 611 608 290 No No No 
29 168 224 238 No Yes No 
30 152 219 516 Yes Yes No 
31 94 301 201 No No Yes 
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67 
Aside from these concerns, our data show great advantages of the use of alemtuzumab, 
namely the significantly lower incidence of infusionrelated side effects, the possibility to 
administer alemtuzumab subcutaneously and lower costs. This renders alemtuzumab a 
valuable alternative for ATG to treat acute rejection, especially in frail patients. We think that 
a randomized prospective trial to compare these two treatments is warranted.
66 
Discussion 
In this retrospective analysis, alemtuzumab appeared to be similarly effective as ATG in the 
treatment of steroidresistant renal allograft rejection. The incidence of infections was low and 
not different from that seen after ATG therapy. Importantly, treatment with alemtuzumab 
was associated with fewer infusionrelated side effects that were also considerably milder. 
 These results have to be interpreted with caution however, because of the nonrandomized and 
small nature of this study. Of note, there were some differences between both groups. There 
were more retransplanted patients in the alemtuzumab group, which could partly be 
explained by the fact that in a number of cases alemtuzumab was used to avoid repeated ATG 
treatment after prior use for an earlier graft. In general, retransplanted patients may be more 
sensitized and therefore more difficult to treat. However, despite the larger number of 
retransplants in the alemtuzumab group, the outcome was similar to that in the ATGtreated 
patients. Moreover, we noticed that within both groups there was considerable variation in the 
interval between transplantation and rejection. No difference in effectiveness of alemtuzumab 
was found in early versus late (defined as occurring more than 6 months posttransplant) 
rejections (data not shown), but the small numbers in these subgroups preclude firm 
conclusions. 
The incidence of infections was similar in both groups, including the incidence of primary 
CMV infection of reactivation. However, our followup period was relatively short, especially 
considering the longlasting T celldepletion that can be observed after alemtuzumab 
treatment [22]. The majority of literature data concern the use of alemtuzumab as induction 
therapy. In this regard, it is of interest that one of the trials on induction therapy with 
alemtuzumab showed less acute rejections but an increased incidence of CMV disease [50]. 
This was not confirmed in a larger cohort of 547 patients [51]. However, the latter study 
showed that the incidence of opportunistic infections was increased when patients received 
alemtuzumab for the treatment of allograft rejection compared with those who received 
alemtuzumab as induction therapy (21 vs. 4.5%; p < 0.01). In a noncomparative study with 40 
patients treated with alemtuzumab for steroidresistant or severe rejection, a total of 14 
patients (35%) had infectious complications, of whom two (5%) died [31]. In a recent article 
reporting longterm followup data, the Cambridge group also found an excess of early 
infectionrelated death in alemtuzumabtreated patients [30]. 
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Introduction 
With the combination of a calcineurin inhibitor, mycophenolate mofetil, and prednisolone as 
immunosuppressive treatment, the incidence of acute rejection after renal transplantation is 
acceptably low. Since acute rejection is one of the main predictors of chronic transplant 
glomerulopathy, further lowering of incidence of acute rejection, e.g. by the additional use of 
IL2 receptor antagonists or polyclonal antiT cell antibodies, might improve longterm 
outcome [85, 135, 136]. Increased attention for the role of B cells and antibodies in acute 
rejection has been elicited by the negative prognostic impact of donorspecific antiHLA 
antibodies, the presence of B cell clusters in biopsies of patients with severe rejection, and the 
frequent finding of capillary deposition of C4d in patients with acute rejection [2, 3]. B cells 
are the progenitors of plasma cells, are effective antigen presenting cells, and can secrete 
different cytokines to stimulate cellular immunity. Interfering with these pathways by antiB 
cell therapy has been shown to be effective in diseases that were considered to be mainly T cell 
driven, like rheumatoid arthritis [4, 5].  
Based on these considerations, we chose to investigate the effectiveness of the antiB cell 
monoclonal antibody rituximab as induction therapy after renal transplantation. Rituximab 
induces longlasting B cell depletion in peripheral blood with limited short and longterm 
toxicity [110, 137]. Most experience with rituximab in renal transplantation stems from its use 
in ABOincompatible transplantation, where low rates of acute rejection were observed [96]. 
At time of initiation of the current study, no data were available on the effect of rituximab on 
acute rejection in ABOcompatible transplantation. We tested the hypothesis that adding a 
single dose of rituximab to an immunosuppressive regimen consisting of tacrolimus, 
mycophenolate mofetil and steroids would reduce the incidence of biopsyproven acute renal 
allograft rejection (BPAR). 
 
Methods 
We performed a single center, randomized, doubleblind, placebocontrolled study at the 
Radboud University Medical Center, Nijmegen, The Netherlands, from December 2007 to 
June 2012. All patients of 18 years or older who were scheduled to receive a renal allograft 
from either a living or deceased ABO compatible donor were screened for eligibility by the 
nephrologist on call. To be included, the immunosuppressive treatment had to consist of a 
combination of tacrolimus, mycophenolate mofetil, and prednisolone. At the time of design of 
the study, induction therapy with IL2 receptor antagonists or anti T cell antibodies was not 
70 
Abstract 
We evaluated the efficacy and safety of rituximab as induction therapy in renal transplant 
patients. In a doubleblind, placebocontrolled study, 280 adult renal transplant patients were 
randomized between a single dose of rituximab (375 mg/m2) or placebo during transplant 
surgery. Patients were stratified according to panel reactive antibody (PRA) value and rank 
number of transplantation. Maintenance immunosuppression consisted of tacrolimus, 
mycophenolate mofetil, and steroids. The primary endpoint was the incidence of biopsyproven 
acute rejection (BPAR) within six months after transplantation.  
The incidence of BPAR was comparable between rituximabtreated (23/138, 16.7%) and 
placebotreated patients (30/142, 21.2%, p = 0.25). Immunologically highrisk patients (PRA 
>6% or retransplant) not receiving rituximab had a significantly higher incidence of rejection 
(13/34, 38.2%) compared to other treatment groups (rituximabtreated immunologically high
risk patients, and rituximab or placebotreated immunologically lowrisk (PRA ª6% or first 
transplant) patients (17.9%, 16.4%, and 15.7%, p = 0.004). Neutropenia (<1.5 × 109/L) occurred 
more frequently in rituximabtreated patients (24.3% vs. 2.2%, p < 0.001). After 24 months, 
the cumulative incidence of infections and malignancies was comparable. 
A single dose of rituximab as induction therapy did not reduce the overall incidence of BPAR, 
but might be beneficial in immunologically highrisk patients. Treatment with rituximab was 
safe. 
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Methods 
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Abstract 
We evaluated the efficacy and safety of rituximab as induction therapy in renal transplant 
patients. In a doubleblind, placebocontrolled study, 280 adult renal transplant patients were 
randomized between a single dose of rituximab (375 mg/m2) or placebo during transplant 
surgery. Patients were stratified according to panel reactive antibody (PRA) value and rank 
number of transplantation. Maintenance immunosuppression consisted of tacrolimus, 
mycophenolate mofetil, and steroids. The primary endpoint was the incidence of biopsyproven 
acute rejection (BPAR) within six months after transplantation.  
The incidence of BPAR was comparable between rituximabtreated (23/138, 16.7%) and 
placebotreated patients (30/142, 21.2%, p = 0.25). Immunologically highrisk patients (PRA 
>6% or retransplant) not receiving rituximab had a significantly higher incidence of rejection 
(13/34, 38.2%) compared to other treatment groups (rituximabtreated immunologically high
risk patients, and rituximab or placebotreated immunologically lowrisk (PRA ª6% or first 
transplant) patients (17.9%, 16.4%, and 15.7%, p = 0.004). Neutropenia (<1.5 × 109/L) occurred 
more frequently in rituximabtreated patients (24.3% vs. 2.2%, p < 0.001). After 24 months, 
the cumulative incidence of infections and malignancies was comparable. 
A single dose of rituximab as induction therapy did not reduce the overall incidence of BPAR, 
but might be beneficial in immunologically highrisk patients. Treatment with rituximab was 
safe. 
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After the operation prednisolone was continued intravenously for three days at 100 mg/day, 
followed by 15–25 mg/day prednisolone orally, according to bodyweight, and tapered to 0.1 
mg/kg/day. Tacrolimus (Prograft, Astellas Pharma) was given in a dose of 0.2 mg/kg/day, 
divided in two doses. The target trough levels were 15–20 ng/ml in the first two weeks 
posttransplant, 10–15 ng/ml during weeks 3–6, and 5–10 ng/ml thereafter. Mycophenolate 
mofetil (CellCept, HoffmanLa Roche) was started at 2000 mg/day, divided in two doses, and 
reduced to 1500 mg/day after two weeks unless patients weighed more than 90 kg. Additional 
treatment consisted of trimethoprim/sulfamethoxazole 480 mg/day for the first 3 months, and 
thrice weekly thereafter until one year posttransplant. Cytomegalovirus (CMV) seronegative 
patients who received a kidney from a CMV seropositive donor were treated prophylactically 
with valganciclovir during the first three months. Additionally, valganciclovir prophylaxis was 
given for two months after treatment with antiT cell antibodies when either the donor or 
recipient was CMV seropositive. 
Firstline antirejection therapy consisted of methylprednisolone for three consecutive days in a 
dose of 5001000 mg/day intravenously. Steroidresistant rejections were treated with antiT 
cell antibodies (Rabbit antithymocyte globulin [Thymoglobulin], Genzyme; MuromonabCD3 
[OKT3], JanssenCilag; alemtuzumab [Campath], Genzyme) according to local practice. 
Rejection was considered steroidresistant if no stabilization or improvement of graft function 
occurred within five days after the first methylprednisolone dose. 
 
Efficacy and safety 
The primary end point was the incidence and severity of BPAR within the first six months 
after transplantation. For patients with more than one biopsy available during a single 
rejection episode, the biopsyscore with the highest Banff grade was used for analysis. 
Borderline rejections were excluded. Biopsies were scored independently by two blinded 
pathologists according to the updated Banff 07 criteria [140]. In case of different conclusions, 
biopsies were reevaluated collectively. Protocol graft biopsies were not performed. 
Secondary end points included the estimated glomerular filtration rate (eGFR) at six months 
in patients with a functioning graft, cumulative incidence of infections and malignancies at six 
and 24 months, and patient and graft survival at six months and at end of followup. All 
serious adverse events were recorded during 24 months.  
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part of our hospital protocol, and was therefore not used in this trial. Other exclusion criteria 
were: a HLAidentical living donor; hemolytic uremic syndrome as original kidney disease; 
focal segmental glomerulosclerosis that had recurred in a previous graft; three or more 
previously failed grafts; a current or historic panel reactive antibody (PRA) value º85%; total 
white blood cell count <3.0 × 109/L; platelet count <75 × 109/L; active infection with hepatitis B, 
hepatitis C, or HIV; a history of tuberculosis; and previous treatment with rituximab. Female 
patients at risk for pregnancy had a negative serum pregnancy test before randomization and 
agreed to use contraception for 12 months. The PRA value was defined as the percentage of 
panel cells that reacts with patient serum in the complementdependent cytotoxicity 
screening. The panel cells consisted of lymphocyte suspensions obtained from 60 different 
healthy individuals selected for HLA A, B, DR, and DQ as to achieve a maximum ability to 
detect antiHLA antibodies [138]. 
All patients had negative B and T cell complementdependent lymphocytotoxic crossmatches 
with current and historic sera at time of transplantation. All patients provided written 
informed consent before study entry. The study was approved by the Committee on Human
Related Research Arnhem–Nijmegen, conducted according to the Declaration of Helsinki and 
good clinical practice guidelines, and reported according to CONSORT guidelines [139]. 
Patients were randomized in a 1:1 ratio to treatment with rituximab or placebo. Since we 
hypothesized that the effects of rituximab could be unequal in immunologically high and low 
risk patients, we stratified upfront for PRA according to the Eurotransplant cutoff value of 
6% for allosensitization, and history of prior transplantation (first vs. retransplant). For 
allocation, a computergenerated list of random numbers was used for each of the four strata, 
prepared by an independent investigator. This list containing study number and treatment 
allocation was only accessible for authorized nurses, who signed confidentiality statements. 
For every new included patient, the lowest available study number was handed to one of the 
authorized nurses, who prepared study medication according to the randomization list. 
Patients randomized to rituximab received a single dose of 375 mg/m2 intravenously during 
surgery. The required dose was diluted in a 500 ml bag of 0.9% sodium chloride. In placebo
treated patients infusion consisted of an identical 500 ml bag. Both bags had an identical 
appearance and were labeled Âstudy medicationÊ. 
At the start of the operation patients received standard antibiotic prophylaxis next to 100 mg 
prednisolone and 2 mg clemastine intravenously to prevent allergic reactions to rituximab. 
Infusion of study medication was started 30 minutes thereafter at a rate of 60 ml/hour, 
increased every 30 minutes to a maximum rate of 200 ml/hour. 
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immunological risk groups was performed by oneway ANOVA, KruskalWallis, and chi
square tests. All data were analyzed on an intentiontotreat basis. Analyses were performed 
with IBM SPSS Advanced Statistics 20.0. This study is registered with ClinicalTrials.gov 
register, number NCT00565331. 
 
Results 
Between December 2007 and June 2012, 488 adult renal transplant candidates were 
evaluated for eligibility and 281 patients were included, of whom 139 patients were 
randomized to rituximab and 142 to placebo (Figure 1). One patient did not undergo 
transplantation and was therefore excluded from all analyses. Overall, the groups were well 
balanced with respect to demographic, clinical, and donor characteristics (Table 1).  
Infusion with rituximab was well tolerated and all but six patients received the full dose 
(Figure 1). One patient experienced an anaphylactic reaction during surgery, which was 
attributed to rituximab. She recovered uneventfully. Temporary interruption of the infusion, 
mainly due to hypotension, occurred in seven rituximabtreated patients (5.1%) compared to 
five placebotreated patients (3.5%, p = 0.57 by FisherÊs exact test). 
Analysis of B cells in peripheral blood in 20 CMVnegative patients without BPAR, confirmed 
nearly complete depletion in rituximabtreated patients as compared to placebotreated 
patients at six months after transplantation (median CD19+ B cells and range; 0.6/øl (0/øl – 
16.4/øl) vs. 141/øl (31/øl – 458/øl); p < 0.001). The primary outcome, BPAR within six months 
after transplantation, occurred in 23 of the 138 rituximabtreated patients (16.7%), compared 
to 30 of 142 placebotreated patients (21.1%, p = 0.25 by logrank test, Figure 2A). Based on 
the prespecified stratification according to PRA value and rank number of transplantation, 
we grouped the four strata to form an immunologically lowrisk group (n = 218) and an 
immunologically highrisk group (n = 62). Immunologically highrisk patients receiving 
placebo had a significantly higher incidence of acute rejection within the first six months 
compared to immunologically lowrisk patients (rituximab or placebotreated) and rituximab
treated immunologically highrisk patients (38.2% vs. 16.4%, 15.7%, and 17.9%, p = 0.004 by 
logrank test, Figure 2B). This effect persisted at two years after transplantation (data not 
shown). When the group of immunologically highrisk patients was analyzed separately, there 
was a clear trend towards a lower incidence of BPAR with rituximab treatment as compared 
to placebo (17.9% vs. 38.2% during the first six months, p = 0.06 by logrank test).
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Number and phenotype of B cells 
Blood was taken immediately before transplantation. Peripheral blood mononuclear cells 
(PBMCs) were isolated by gradient centrifugation using Lymphoprep (Lucron, Dieren, The 
Netherlands) and stored in liquid nitrogen until further use. Cell phenotypes were analyzed 
by 10color flow cytometry (Navios, BeckmanCoulter, Fullerton, USA). The following 
fluorochromeconjugated monoclonal antibodies were used to study B cells: CD19(J3119)APC 
Alexa Fluor 750, CD24(ALB9), CD27(1A4CD27)PeCy5.5, CD38(L49843), CD45(J.33)
Krome Orange and IgD(IADB6)FITC (BeckmanCoulter). Isotype controls or unstained cells 
were used for gate settings. Data were analyzed using Kaluza software (BeckmanCoulter). 
The B cell phenotype was analyzed in immunologically highrisk patients (for definition see 
below), based on availability of the samples (n = 26). For comparison we selected 28 
immunologically lowrisk matched for age, gender, type of dialysis, and CMV status. 
 
Statistical analysis 
The primary efficacy endpoint was biopsy confirmed acute rejection within the first six months 
after transplantation. Trials performed before the start of our study showed an incidence of 
this endpoint of about 15% in patients treated with tacrolimus, mycophenolate mofetil and 
steroids. Although the benefit of additional rituximab treatment was not known (no literature 
data at the time of trial design), using data concerning ABOincompatible transplantations, 
we assumed that the incidence of biopsyproven rejection could drop to about 5% [96]. To 
detect a decrease in rejection incidence from 15% to 5% with a twosided 5% significance level 
and a power of 80%, the required sample size was 140 patients per treatment arm. The trial 
was not powered to test superiority in the different strata. After 70 patients had reached a 
followup of six months, a planned interim safety analysis was performed to test the 
cumulative incidence of infections and malignancies [141]. This interim analysis was not 
performed to test efficacy or futility. 
Statistical testing was performed according to distribution and type of data (unpaired T test, 
MannWhitney U, or FisherÊs exact tests). Time to first BPAR, allograft loss, and death were 
analyzed with the Kaplan–Meier method, and differences were assessed by the logrank test.  
The four prespecified strata were grouped as follows: patients with a retransplant or PRA 
value >6% were considered to be immunologically highrisk, and those with a first transplant 
and PRA value ª6% were regarded as immunologically lowrisk. Comparison of different 
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Figure 1. Trial profile of all patients. 
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Figure 1. Trial profile of all patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
488 Patients were assessed for eligibility 141 Were ineligible 
18 Received a HLAidentical kidney 
9 Had HUS 
1 Had a history of primary FSGS with recurrence 
6 Had a PRA >85% 
3 Had more than three previous transplant 
7 Were treated with rituximab before or had 
participated in the current trial before 
10 Had diabetes mellitus and were not treated with 
insulin 
5 Had a history of HIV, Hepatitis B or Hepatitis C 
7 Had a history of  TBC  
30 Participated in another clinical trial 
11 Underwent an ABOincompatible transplantation 
27 Were unable to give informed consent (either due 
to language or impaired cognition) 
7 Were stated on an incompatible 
immunosuppressive regimen (mostly basiliximab 
induction) 
66 Were eligible but were excluded 
59 Did not provide informed consent 
5 Were overlooked for randomization 
2 Were withdrawn by clinician 
139 Were assigned to receive rituximab 142 Were assigned to receive placebo 
281 Underwent randomization 
1 Did not undergo 
transplantation 
0 Did not undergo 
transplantation 
138 Underwent transplantation 142 Underwent transplantation 
138 Were included in the analysis 
6 Did not receive the 
full dose 
   3 Had side effects 
   during infusion 
   2 Had anesthesia  
   problems before    
   infusion 
   1 Had infusion    
   terminated after  
   finding a mass in the  
   caecum 
1 Did not receive the 
full dose 
   1 Had side effects 
   during infusion 
142 Were included in the analysis 
132 Received 
the full dose 
141 Received 
the full dose 
79 
Since our data suggested that a potential effect of rituximab was limited to immunologically 
highrisk patients, we compared B cell number and phenotype in pretransplant blood samples 
of immunologically high and lowrisk patients. Interestingly, the number of CD19+ B cells, 
especially CD27+ memory B cells, was higher in the immunologically highrisk patients 
(CD19+CD27+ memory B cells 35 cells/øl [12152] vs. 24 cells/øl [578], p = 0.02 by Mann
Whitney U test, Figure 3). The number of CD24++CD38++ transitional B cells was 
comparable in both patient groups. 
Most rejections were T cell mediated according to the Banff classification (Table 2). 
Rituximabtreated patients tended to have less antibody mediated rejections (ABMR), 
compared to placebotreated patients (4/138, 2.9% vs. 11/142, 7.7% p = 0.11 by FisherÊs exact 
test). At six months, the dose of mycophenolate mofetil and trough level of tacrolimus were 
somewhat lower in the rituximabtreated patients (Table 3). 
Patient and graft survival (at six months, and after a median duration of followup of 4.0 
years, range 1.9 – 6.4 years) as well as graft function and proteinuria (at six months and at 24 
months) were comparable between the rituximab and placebo group (Table 4).  
The incidence of delayed graft function did not differ between rituximab and placebotreated 
patients, but within the immunologically highrisk subgroup, a trend towards a lower 
incidence was seen in rituximabtreated patients (5/28, 17.9% vs. 12/34, 35.3% p = 0.13 by chi
square test). 
One rituximabtreated patient was diagnosed with progressive multifocal 
leukoencephalopathy and died shortly thereafter. The overall incidence of infections or 
malignancies was not higher after treatment with rituximab compared to placebo. During the 
first six months after transplantation, treatment with rituximab was associated with a 
significantly higher cumulative incidence of grade 2 or more severe leucopenia (19.0% vs. 
1.4%, p < 0.001 by FisherÊs exact test) and neutropenia (24.3% vs. 2.2%, p < 0.001 by FisherÊs 
exact test, Table 4). Consequently, the number of patients in whom mycophenolate mofetil 
was (temporarily) discontinued during the first six months tended to be higher in the 
rituximab group than in the placebo group (18/131 vs. 8/128, p = 0.06 by FisherÊs exact test), 
but interruption of treatment with this drug was not correlated with the occurrence of acute 
rejection.  
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Figure 2A.  Cumulative probability of biopsyproven acute rejection in all patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B.  Cumulative probability of biopsyproven acute rejection in immunologically low 
vs. highrisk patients.  
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Figure 2A.  Cumulative probability of biopsyproven acute rejection in all patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B.  Cumulative probability of biopsyproven acute rejection in immunologically low 
vs. highrisk patients.  
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Figure 3. Pretransplant levels of B cells in immunologically high vs. lowrisk 
patients.*  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Absolute numbers (with medians) of total CD19+, naive (CD19+IgD+CD27) and memory (CD19+CD27+) and 
transitional (CD19+CD24++CD38++) B cells in pre transplantation blood samples of 26 immunologically highrisk and 28 
matched immunologically lowrisk patients. P values are calculated with the MannWhitney U test.  
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patients.*  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Absolute numbers (with medians) of total CD19+, naive (CD19+IgD+CD27) and memory (CD19+CD27+) and 
transitional (CD19+CD24++CD38++) B cells in pre transplantation blood samples of 26 immunologically highrisk and 28 
matched immunologically lowrisk patients. P values are calculated with the MannWhitney U test.  
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previously shown that memory B cells are more resistant to depletion by rituximab than 
naive B cells [145, 146].  
We have also noticed that in vitro rituximab can affect B cell phenotype and its antigen 
presenting function, resulting in an altered outcome of BT cell interaction [147]. After in 
vivo treatment with one dose of rituximab, we found that a B cell population remains in 
secondary lymphoid organs, despite complete depletion in peripheral blood [146]. These 
remaining B cells mainly consist of switched memory (IgDCD27+) B cells, and have 
different functional capacities as compared to B cells obtained from lymph nodes of 
patients not treated with rituximab. Taken together, these data indicate that rituximab 
can have effects beyond pure B cell depletion, but in general these effects appear to be 
insufficient to reduce the incidence of BPAR after renal transplantation. 
Although rituximab does not directly target the antibody producing plasma cells, 
prolonged B cell depletion might lead to a decrease in the concentration of donorspecific 
antiHLA antibodies. A recent study shows that elimination of peripheral HLAspecific B 
cells of sensitized patients prevented an amnestic antibody response posttransplant 
[148]. The routine measurement of these antibodies was not part of standard clinical 
care at the time of initiation of the current study, and not included in the trial design. 
Another drawback of our study was that protocol biopsies were not performed. Together 
with the routine measurement of donorspecific antiHLA antibodies this could have 
provided additional information on the risk of development of chronic ABMR and 
subsequent future graft loss [149]. 
Our study confirmed previous observations of a high incidence of leucopenia and 
neutropenia after treatment with rituximab [112]. The cause of this so called lateonset 
neutropenia remains incompletely understood. The higher incidence of neutropenia did 
not lead to more infections, which is in accordance with the results of other studies [97, 
150, 151]. Potentially worrisome are the 3year followup data from Tydéns study, 
suggesting an increased mortality in rituximabtreated patients [152]. We could not 
confirm these results in our study, and overall, the addition of rituximab to a 
combination of tacrolimus, mycophenolate mofetil and steroids appeared to be safe. 
Nonetheless, these data, together with the study of Clatworthy, underline that B cell 
depletion must be undertaken with caution. 
During the course of this clinical trial, the use of interleukin2 receptor antagonists and 
depleting antiT cell antibodies as induction therapy has become more common and is 
recommended in the KDIGO guidelines from 2009. The safety of combining rituximab 
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Discussion 
Our data show that induction therapy with a single dose of rituximab at the time of 
renal transplantation is safe but ineffective to reduce the incidence of BPAR in a broad 
population of renal transplant patients. The prespecified stratification of our patients 
according to retransplantation and PRA, enabled comparison of immunologically high 
and lowrisk patients. We observed that within the whole population, immunologically 
highrisk patients who did not receive rituximab had the highest incidence of BPAR. A 
separate analysis on the subpopulation of immunologically highrisk patients showed a 
clear trend towards a lower incidence of BPAR with rituximab therapy as compared to 
placebo. Notably, the study was not sufficiently powered for this analysis. Interestingly, 
the incidence of ABMR tended to be lower after rituximab, especially in immunologically 
highrisk patients. Furthermore, within the immunologically highrisk subgroup, the 
incidence of delayed graft function tended to be lower in rituximabtreated patients, 
which could have contributed to a lower rate of rejection. Altogether, these results 
suggest a protective effect of rituximab against acute rejection in patients who are at 
higher immunological risk. With the current median duration of followup of 4.0 years, 
this beneficial effect has not resulted in improved graft function or graft survival.  
Two recent randomized studies have reported on the effect of rituximab as induction 
therapy. In the first study, with 140 patients, Tydén et al. also showed no significant 
effect of rituximab on the incidence of BPAR within six months after transplantation, 
although a tendency toward fewer and milder rejection episodes in the rituximab group 
was observed (11.8% vs. 17.6%, p = 0.32) [106]. In the current study, we included twice 
as many patients and stratified for immunological risk. The other study by Clatworthy et 
al. was prematurely terminated after the inclusion of 13 patients because of an excess 
incidence of acute rejection in rituximabtreated patients [107]. In this study however, 
two doses of rituximab were given and maintenance immunosuppression was steroid
free. As possible explanation for their findings it was suggested that proinflammatory 
cytokine release associated with B cell depletion might prime antigenpresenting cells. 
It is tempting to speculate that a protective effect of rituximab in immunologically high
risk patients could be explained by reducing the relatively high pretransplant levels of 
memory B cells in our immunologically highrisk patients. Indeed, an increase in 
circulating memory B cells has been associated with acute rejection in pediatric renal 
transplant recipients, while heart transplant recipients with higher percentages of naive 
B cells had a lower risk of acute rejection [143, 144]. However, we and others have 
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with these agents needs to be established formally, although in a retrospective analysis 
and uncontrolled cohort study the combination of pretransplant rituximab, as part of 
desensitization therapy, and posttransplant induction therapy with antiT cell agents 
appeared to be safe [153, 154]. 
In conclusion, our randomized and placebocontrolled study has demonstrated that 
addition of rituximab induction therapy to a triple drug immunosuppressive regimen 
does not reduce the incidence of BPAR in immunologically lowrisk patients. Therefore, 
we do not recommend the use of rituximab induction therapy in a population of 
unselected renal transplant recipients. However, our data suggest that treatment with 
rituximab may reduce the incidence of BPAR in immunologically highrisk patients to a 
level comparable to that in immunologically lowrisk patients, thereby indicating a 
potential direction to improve the treatment of this specific group of patients. The results 
need to be confirmed in a multicenter clinical study focused on immunologically high
risk patients, with special attention for the combination or comparison with other 
induction agents, like basiliximab or antithymocyte globulin. 
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Introduction 
Rituximab is a monoclonal antibody against the CD20 antigen present on different types 
of B cells. It is currently used in renal transplantation in different settings [155]. After 
administration of a single dose it quickly induces complete and longlasting B cell 
depletion in the peripheral blood [110]. However, in secondary lymphoid organs, like 
lymph nodes and spleen, B cell depletion after a single dose of rituximab is incomplete 
[145, 146]. 
During acute allograft rejection, different cell types can infiltrate the graft, such as T 
cells, NK cells, monocytes, and also B cells. The clinical relevance of infiltrating B cells is 
a matter of debate. Some studies show an association with a poorer response to anti
rejection therapy and hence worse graft outcome, while other studies do not show a 
negative impact of B cell infiltration on graft outcome [101, 156158]. Many case series 
have suggested a beneficial effect of rituximab in the treatment of (antibody mediated) 
renal allograft rejection, but these results are difficult to interpret without a control 
group. In a small randomized trial (n=20), treatment with rituximab (next to anti
thymocyte globulin and/or highdose steroids) resulted in a larger improvement of graft 
function and of biopsy rejection scores at six months posttreatment, compared to 
treatment with anti thymocyte globulin and/or high dose steroids alone [151]. This 
improvement was accompanied by complete intragraft B cell depletion in all rituximab
treated patients at followup. Although rituximab had no apparent effect on donor 
specific antibody levels, reappearance of C4d deposition was not seen on followup 
biopsies after rituximab treatment. These findings suggest a pathogenic role of 
intragraft B cells in acute renal allograft rejection. 
Next to its use for the treatment of rejection, rituximab has been studied in the setting of 
prevention of acute rejection. We have recently performed a doubleblind, placebo
controlled study, in which 280 adult renal transplant patients were randomized between 
a single dose of rituximab (375 mg/m2) or placebo during transplant surgery [159]. 
Patients were stratified according to panel reactive antibody (PRA) value and rank 
number of transplantation. Maintenance immunosuppression consisted of tacrolimus, 
mycophenolate mofetil, and steroids. This study showed that a single dose of rituximab 
as induction therapy did not reduce the overall incidence of biopsy proven acute 
rejection, but might be beneficial in immunologically highrisk patients. 
Here we report the effect of rituximab on graft histology during acute rejection, with 
emphasis on the type of rejection (T cell mediated versus antibody mediated) and the 
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Abstract 
The pathophysiological role of intragraft B cells during renal allograft rejection is 
unclear. We studied B cell infiltration during acute rejection in 30 patients who 
participated in a clinical trial in which adult renal transplant patients were randomized 
between a single dose of rituximab (375 mg/m2) or placebo as induction therapy. Biopsies 
were examined  independently by two blinded pathologists according to the Banff 
classification and scored for the presence of B cells and plasma cells using CD79a and 
CD138 as markers. The majority of acute rejections was T cell mediated. The proportion 
of acute rejections with an antibody mediated component did not differ between 
rituximabtreated patients (2/11, 18.2%) and placebotreated patients (6/19, 31.6%; 
P=0.67), and there were also no differences in t, v, i, or gscores of the Banff 
classification. However, biopsies of rituximabtreated patients had a significantly lower  
B cell score (0.08, range 0.00 – 0.50) than placebotreated patients (2.00, range 0.70 – 
3.30, P<0.001). There was no difference in the plasma cell score. Depletion of intragraft 
B cells during acute rejection did not affect steroidresistance, proteinuria,  graft 
function, or patient and graft survival at 4 years. In conclusion, these data do not 
support a pathogenic role for intragraft B cells  during acute allograft rejection. 
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antibody mediated rejection (ABMR) [140]. According to the Banff 07 classification, 
diffuse C4d staining (i.e. >50% of peritubular capillaries) was defined as positive. To 
differentiate between clusters and scattered positive cells, CD79a+ cells were scored in a 
manner as previously described (for CD20+ and CD3+ cells) and CD138+ cells were 
scored as the number of positive cells per high power field [158]. Per biopsy specimen the 
whole cortex was examined. A cluster of cells was defined as more than 30 
immunohistochemically positive cells without the interposition of tubules. For each high
power field, the scattered CD79a+ cells were scored according to an ordinal scale ranging 
from 0 to 5, as defined in Table 1. In each biopsy specimen, the total scores for CD79a+ 
cells, and the total numbers of CD79a+ clusters were divided by the number of high
power fields that were examined. 
Statistical testing was performed according to distribution and type of data (unpaired T 
test, MannWhitney U test, chisquare test, or FisherÊs exact test). Allograft loss and 
death were analyzed with the Kaplan–Meier method, and differences were assessed by 
the logrank test. Correlation between histological scoring of CD79a and CD138 with 
clinical outcome was performed with a SpearmanÊs rho correlation coefficient.  Analyses 
were performed with IBM SPSS Advanced Statistics 21.0 and GraphPad Prism 5.03. 
Table 1. Histological scoring of interstitial CD79a+ cells 
Histological scoring No. positive cells per high power field 
0 
1 
2 
3 
4 
5 
0 – 2 
3 – 10 
11 – 20 
21 – 40 
41 – 80 
>80 
 
Results 
The clinical parent study included 280 renal transplant patients (138 rituximabtreated 
vs. 142 placebotreated). Overall, the groups were well balanced with respect to 
demographic, clinical, and donor characteristics [159]. One or more renal biopsies were 
performed in  46 of the 138 rituximabtreated patients (33%) as compared to 60 of the 
142 placebotreated patients (42%, p=0.12 by chisquare test). In half of the cases 
(53/106) the biopsy showed acute rejection. Twentythree cases were excluded because 
treatment with high dose steroids was started more than 1 day before the biopsy was 
taken. The remaining 30 patients (11 rituximabtreated and 19 placebotreated) were 
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intragraft presence or absence of B cells. Important research questions were whether the 
presence of B cells was associated with a higher extent of steroidresistance and worse 
graft function after followup and whether this was influenced by rituximab. 
 
Patients and methods 
The full details of the original clinical trial have been described elsewhere [159]. In brief, 
280 patients were randomized to treatment with a single dose of 375 mg/m2 body surface 
area rituximab (n=138) or placebo (n=142) added to standard immunosuppression 
consisting of tacrolimus, mycophenolate mofetil, and steroids. In this trial, biopsies were 
only performed on clinical indication. First line treatment of acute rejections consisted of 
methylprednisolone, followed by antiT cell antibodies in case of steroidresistance. 
We selected all patients who had a biopsy proven acute rejection within six months post
transplantation. To rule out an effect of earlier antirejection treatment on graft 
histology, we only analyzed the first biopsy in each patient and excluded patients who 
received antirejection treatment with steroids for more than 1 day preceding the biopsy. 
The biopsy material was bouinfixated and fourmicrometer sections were processed for 
routine histologic stains including hematoxylineosin, JonesÊ silver stain, Masson 
Trichrome, and periodic acidic Schiff after diastase treatment. Staining for C4d was 
performed on frozen sections using immunofluorescence technique, with a mouse 
polyclonal antihuman C4d antibody (Biogenesis Inc., Ede, The Netherlands). Four
micrometer sections were incubated with monoclonal antibodies directed at the B cell 
marker CD79a (M7050, clone JCB117 by Dako, Glostrup, Denmark) and plasma cell 
marker CD138 (ILM3825c1 – clone BA38 by Immunologic, Klinipath, Duiven, The 
Netherlands). As secondary antibody we used powervision PolyHRPanti 
Mouse/Rabbit/Rat IgG (Immunologic, Klinipath, Duiven, The Netherlands). Detection 
was carried out with the use of peroxidase as label and diaminobenzidine as substrate. 
We did not stain for CD20, since that staining could be falsely negative due to blockage 
of CD20 by rituximab. Moreover, we also did not use CD19 as a B cell marker, because a 
monoclonal antibody against CD19 for use in bouinfixated tissue is not available. Since 
CD79a is also expressed on plasma cells we performed a immunohistochemical staining 
for CD138 to differentiate between B cells and plasma cells.  
Biopsies were scored in a blinded fashion by two independent pathologists. Rejection was 
scored according to the Banff 07 criteria for T cell mediated rejection (TCMR) and 
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treatment with high dose steroids was started more than 1 day before the biopsy was 
taken. The remaining 30 patients (11 rituximabtreated and 19 placebotreated) were 
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intragraft presence or absence of B cells. Important research questions were whether the 
presence of B cells was associated with a higher extent of steroidresistance and worse 
graft function after followup and whether this was influenced by rituximab. 
 
Patients and methods 
The full details of the original clinical trial have been described elsewhere [159]. In brief, 
280 patients were randomized to treatment with a single dose of 375 mg/m2 body surface 
area rituximab (n=138) or placebo (n=142) added to standard immunosuppression 
consisting of tacrolimus, mycophenolate mofetil, and steroids. In this trial, biopsies were 
only performed on clinical indication. First line treatment of acute rejections consisted of 
methylprednisolone, followed by antiT cell antibodies in case of steroidresistance. 
We selected all patients who had a biopsy proven acute rejection within six months post
transplantation. To rule out an effect of earlier antirejection treatment on graft 
histology, we only analyzed the first biopsy in each patient and excluded patients who 
received antirejection treatment with steroids for more than 1 day preceding the biopsy. 
The biopsy material was bouinfixated and fourmicrometer sections were processed for 
routine histologic stains including hematoxylineosin, JonesÊ silver stain, Masson 
Trichrome, and periodic acidic Schiff after diastase treatment. Staining for C4d was 
performed on frozen sections using immunofluorescence technique, with a mouse 
polyclonal antihuman C4d antibody (Biogenesis Inc., Ede, The Netherlands). Four
micrometer sections were incubated with monoclonal antibodies directed at the B cell 
marker CD79a (M7050, clone JCB117 by Dako, Glostrup, Denmark) and plasma cell 
marker CD138 (ILM3825c1 – clone BA38 by Immunologic, Klinipath, Duiven, The 
Netherlands). As secondary antibody we used powervision PolyHRPanti 
Mouse/Rabbit/Rat IgG (Immunologic, Klinipath, Duiven, The Netherlands). Detection 
was carried out with the use of peroxidase as label and diaminobenzidine as substrate. 
We did not stain for CD20, since that staining could be falsely negative due to blockage 
of CD20 by rituximab. Moreover, we also did not use CD19 as a B cell marker, because a 
monoclonal antibody against CD19 for use in bouinfixated tissue is not available. Since 
CD79a is also expressed on plasma cells we performed a immunohistochemical staining 
for CD138 to differentiate between B cells and plasma cells.  
Biopsies were scored in a blinded fashion by two independent pathologists. Rejection was 
scored according to the Banff 07 criteria for T cell mediated rejection (TCMR) and 
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Figure 2. Histological scores of biopsies during acute allograft rejection 
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balanced with respect to demographic and clinical characteristics, but the number of 
living donors was substantially lower in the rituximabtreated patients (Table 2 and 
Figure 1). The median time from transplantation to rejectionbiopsy was approximately 
21 days (range 7 – 180 days). The results of the histological examination are shown in 
Table 3 and Figure 2. With respect to the type of rejection, ABMR and ABMR combined 
with TCMR  was less frequent in rejectionbiopsies from patients treated with rituximab, 
but this was not statistically significant (18.2% versus 31.6% p=0.67 by FisherÊs exact 
test). No differences between groups were seen in other rejectionrelated items of the 
Banff scheme such as tubulitis, (tscore), arteritis (vscore), inflammation (iscore), and 
glomerulitis (gscore) (Figure 2). 
Figure 1. Trial profile of all patients. 
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patients with CD79a+ cell clusters in their biopsies, three had functioning grafts at the 
end of followup, while one patient died after three years with a functioning graft. No 
difference was found in CD138 staining of biopsies  between rituximabtreated patients 
(median 0.15, range 0 – 1.90) and placebotreated patients (median 0.4, range 0 – 7.50;  
P = 0.45 by MannWhitney U test, Figure 3). Clusters of CD138+ were found in the 
biopsies of two placebotreated patients, and not in biopsies of rituximabtreated 
patients. None of the biopsies showed evidence of the formation of ectopic lymphoid 
tissue (tertiary lymphoid organs). 
 
Figure 3. CD79a+ and CD138+ scores in renal biopsies during acute allograft 
rejection 
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Table 2. Baseline characteristics of renal transplant recipients, having received 
either rituximab or placebo induction therapy, with biopsyproven acute rejection * 
Variable Rituximab 
(n=11) 
Placebo 
(n=19) 
Age (yr) 48.8  10.6 50.4  8.2 
Male sex (%) 54.5 47.4 
White race (%)† 90.9 94.7 
Cause of endstage renal disease (no. of patients)   
Glomerulonephritis 2 10 
Diabetes mellitus 1 1 
Urological disorder 1 3 
Hypertension / vascular damage 2 0 
Polycystic kidney disease 3 3 
Uncertain or other 2 2 
Type of donor (%)   
Living 27.3 57.9 
Deceased – donation after circulatory death 9.1 15.8 
Deceased – donation after brain death  63.6 26.3 
Donor age (yr) 53.4  7.7 51.7  9.1 
HLA mismatches  A, B, and DR (no.) 2.73  1.10 3.42  1.12 
Panelreactive antibody titer  highest assessment 3 (0 – 42) 2 (0 – 47) 
Patients with retransplant (%) 0.0 15.8 
Coldischemia time  deceased donors only (hr) 15.3  4.2 16.0  4.9 
Days between transplantation and rejectionbiopsy 
(days) 
20 (7 – 180) 21 (7 – 138) 
Estimated GFR at time of rejection – ml/min§ 23 (0 – 35) 18 ( 0 – 48 ) 
 
* Values are presented as mean  standard deviation or median (range). Overall group differences were not significant. 
† Race was determined by the investigator. 
§ For the estimated GFR on the basis of abbreviated Modification of Diet in Renal Disease criteria, the following formula 
was used: estimated GFR (ml/min/1.73 m2) = 175 x (serum creatinine/88.4)1.154 x (Age)0.203 x (0.742 if female) × (1.212 if 
African American). In case of continued dialysis treatment a GFR of 0 ml/min was used [142]. 
 
Remarkably, the score for interstitial CD79a+ cells was significantly lower in rituximab
treated patients (median 0.08, range 0.00 – 0.50), compared to placebotreated patients 
(median 2.00, range 0.70 – 3.30, P<0.001 by MannWhitney U test, Figure 3). Clusters of 
CD79a+ cells were found in the biopsies of four placebotreated patients while these 
were never present in biopsies of rituximabtreated patients. Of the four placebotreated 
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Table 4. Outcomes after transplantation in patients with biopsyproven acute 
rejection* 
Variable Rituximab 
(n=11) 
Placebo 
(n=19) 
Patients with steroidresistant rejection (no – %) 4 (36.4) 9 (47.4) 
Estimated GFR at two years in patients with a functioning 
graft – ml/min† 
34 (31 – 49) 38 (16 – 64) 
Improvement of GFR from time of rejection till two years 
posttransplant in patients with a functioning graft at two 
years – ml/min 
11 (7 – 35) 14 (5 – 55) 
Proteinuria at two years – g/10 mmol creatinine 0.10 (0.1 – 0.8) 0.10 (0.1 – 4.0) 
Allograft survival at end of followup (%)Ú   
Censored for death of patients with functioning graft  81.8 89.5 
Uncensored for death of patients with functioning graft 63.6 78.9 
Patient survival at end of followup (%)Ú 72.7 84.8 
 
* Values are presented as mean  standard deviation or median (range). 
† For the estimated GFR on the basis of abbreviated Modification of Diet in Renal Disease criteria, the following formula 
was used: estimated GFR (ml/min/1.73 m2) = 175 x (serum creatinine/88.4)1.154 x (Age)0.203 x (0.742 if female) × (1.212 if 
African American) [142]. 
Ú median duration of followup of 4.1 years, range 2.0–6.2 years. 
 
Discussion 
Infiltration of B cells is a frequent finding in biopsies of patients with acute renal 
allograft rejection. Our data show that in renal transplant patients who received a single 
dose of rituximab as induction therapy, intragraft B cells were nearly absent during 
episodes of acute allograft rejection. Moreover, the relative frequency of pure ABMR or 
combined ABMR and TCMR was lower than in placebotreated patients. No differences 
were seen in the severity of tubulitis, arteritis, or the extent of the cellular infiltrate. 
We and others previously showed that a single dose of rituximab at time of renal 
transplant surgery results in a rapid and long lasting depletion of B cells in the 
peripheral blood [110, 160]. Even at two years after transplantation, the absolute 
number of B cells in peripheral blood was still quite low as compared to patients not 
treated with rituximab [160]. We also showed that despite complete depletion of B cells 
in the peripheral blood the number of B cells in secondary lymphoid organs remained 
unaffected [146]. Others have confirmed that in the near absence of B cells in peripheral 
blood there is a varying degree of reduction, but no complete depletion, of B cells in 
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Table 3. Incidence and type of biopsy proven acute rejection (BPAR) at six months* 
Variable Rituximab 
(n=11) 
Placebo 
(n=19) 
T cell mediated rejection (no.)   
     Type IA 4 4 
     Type IB 1 1 
     Type IIA 3 7 
     Type IIB 1 1 
Antibody mediated rejection (ABMR; no.) 0 1 
Combined rejections (no.)   
     ABMR + Type IIA 1 5 
     ABMR + Type IIB 1 0 
   
C4d positive (no – %) 2 (18.2) 6 (31.6) 
 
* Biopsies were independently scored by two pathologists according to the Banff 07 classification [140]. A diagnosis of 
ABMR required positive immunostaining for C4d, combined with either signs of microvascular inflammation (g>0 and/or 
ptc>0) or intimal arteritis (v>0) 
 
Although induction with a single dose of rituximab led to an almost complete absence of 
intragraft CD79a+ cells, this did not translate into a beneficial effect on clinical 
outcomes in these patients with biopsyproven acute rejection. The percentage of steroid
resistant rejections did not differ between rituximab and placebotreated patients (36.4% 
versus 47.4%, P=0.71 by FisherÊs exact test). Furthermore, there was no difference in 
proteinuria or graft function, at two years posttransplant. Patient and graft survival 
were comparable in both groups (Table 4). In the placebotreated patients, the biopsy 
score for interstitial CD79a+ cells was not correlated with either improvement of eGFR 
(from moment of rejection to 24 months posttransplant; SpearmanÊs correlation co
efficient 0.007, P=0.98) or absolute eGFR at 24 months posttransplant (SpearmanÊs 
correlation coefficient 0.20, P=0.48). Interestingly, in placebotreated patients the score 
for interstitial CD79a+ cells was significantly lower in patients with ABMR (median 
1.25, range 0.70 – 2.00) than in patients without ABMR (median 2.00, range 1.40 – 3.30, 
P=0.005 by MannWhitney U test). In placebotreated patients, neither the presence of 
clusters of CD79a+ cells nor of CD138+ cells showed a significant correlation to clinical 
outcome.  
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To conclude, induction therapy with rituximab strongly reduced the number of 
infiltrating B cells during acute renal allograft rejection. This did not have an effect on 
the severity of tubulitis, arteritis or the extent of the cellular infiltrate, nor did it 
improve clinical outcome after treatment of the rejection during a followup of 4 years. 
These data do not support previous findings suggesting that intragraft B cells which are 
present during acute allograft rejection are harmful to the graft. 
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spleen, lymph nodes, and synovial tissue after treatment with rituximab [110, 161163]. 
Together with our current findings, these data suggest that rituximab inhibits the egress 
of B cells from secondary lymphoid organs, thereby impairing the migration to 
peripheral tissues such as the renal allograft. 
Earlier studies by Hippen et al. [101] and Sarwal et al. [3], demonstrated that the 
presence of CD20+ B cell infiltrates in the graft at time of rejection is a bad prognostic 
sign. It was suggested that this could be explained by the antigen presenting function of 
infiltrating B cells. Based on these findings, it could be expected that the absence of 
intragraft B cells in rituximabtreated patients had resulted in a lower rate of steroid
resistance and better graft survival. However, our data do not indicate that absence of 
intragraft B cells during acute rejection, as observed in rituximabtreated patients, 
translates into better outcome. A potential bias hampering the interpretation of this 
finding could have been a selection of more severe rejections occurring despite B cell 
depletion in the rituximab group. This was unlikely however, since Banff scores for 
tubulitis, arteritis, inflammation, and glomerulitiswere similar in biopsies of rituximab
treated and placebotreated patients. Also within the placebotreated patients there was 
no correlation between the diffuse and scattered or clustered presence of B cells on the 
one hand and the clinical course on the other hand. In four placebotreated patients B 
cell clusters were found, and after a median followup of 4 years three of the four 
patients still had a good and stable graft function. Notably, other authors also could not 
demonstrate that intragraft B cells were associated with a poorer response to high dose 
steroids or worse graft survival [157, 158, 164166]. 
In the parent clinical trial overarching this study, a clear trend towards less ABMR was 
seen in rituximabtreated patients, compared to placebotreated patients (4/138, 2.9% vs. 
11/142, 7.7% p = 0.11 by FisherÊs exact test). The near complete depletion of intragraft B 
cells could have been the mechanism responsible for this finding. However, as stated 
above, data about B cells in other lymphoid compartments are essential for correct 
interpretation. This is underlined by the finding that placebotreated patients with 
ABMR had lower scores for interstitial CD79a+ cells than placebotreated patients 
without ABMR, which suggests that B cells and plasma cells which are involved in the 
process of ABMR are residing outside the graft. Taken together, the findings in our 
study question the pathologic role of intragraft B cells in the acute phase of renal 
allograft rejection. Yet, it remains unclear why intragraft B cells are present in some 
circumstances, but not in others. 
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Introduction 
Monoclonal antibodies are widely used in the treatment of malignancies, transplant 
rejections, as well as a range of autoimmune diseases. For several of these monoclonal 
antibody, administration has been associated with acute infusion reactions, caused by 
various mechanisms, including systemic inflammatory response syndrome [167]. 
Rituximab, a chimeric antiCD20 monoclonal antibody, is an effective treatment for 
malignant lymphomas and various autoimmune diseases [168]. It is also used in organ 
transplant patients for desensitization and treatment of antibodymediated rejection 
[105]. Rituximab can deplete B cells via antibodydependent cellular cytotoxicity 
(ADCC), complementdependent cytotoxicity (CDC), and apoptosis [169]. The observation 
that polymorphisms in the FcγRIIIa gene affect the effectiveness of rituximab, indicates 
that ADCC plays an important role [170]. NK cells express the Fcreceptor FcγRIIIa 
(CD16) which has a high affinity for binding to IgG1, the isotype of rituximab [171]. 
FcγRIIIa appears in two allelic forms that differ by the amino acid on position 158. 
FcγRIIIa homozygous for valine (VV) has a higher affinity for IgG1 than FcγRIIIa with 
phenylalanine at that position (VF or FF) [172]. Patients with the high affinity receptor 
show a better clinical response to rituximab [173175].  
However, administration of rituximab can be followed by acute infusion reactions due to 
the release of cytokines, especially in patients with high B cell counts like lymphoma 
patients, although not every patient with elevated levels of cytokines develops clinical 
symptoms [167, 176178]. After stimulation, B cells can produce virtually any cytokine 
[179]. Although the role of these cytokines in the regulation of other cell types is not 
completely understood, a rise in the level of (proinflammatory) cytokines could lead to 
activation of the immune system and therefore be of clinical relevance. When using 
rituximab as induction therapy to prevent acute rejection, a cytokine release could 
potentially contribute to the risk of rejection.  
Currently, it is unknown to which extent cytokine release occurs in patients with normal 
B cell numbers, and the cell type responsible for the cytokine release has not been 
identified. In a doubleblind placebocontrolled study, we measured the release of various 
cytokines after administration of rituximab to renal transplant recipients. In addition, 
we studied the mechanism of this cytokine release in vitro.  
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Abstract 
Background. Treatment with rituximab may be accompanied by a systemic cytokine 
release. We studied the effects of a single dose of rituximab on cytokine levels in 
transplant patients and examined the underlying mechanism. 
Methods. Twenty renal transplant recipients (10 rituximabtreated, 10 placebotreated) 
were recruited from a randomized clinical trial. Rituximab or placebo was infused during 
surgery and blood samples were taken before, during, and after surgery and analyzed for 
IL2, IL4, IL6, IL10, IL12, IL17, IFNγ, MIP1β, TGFβ, and TNFα. In vitro, healthy 
donor peripheral blood mononuclear cells, purified B cells, monocytes, NK cells, or 
combinations thereof were incubated with rituximab, rituximabF(abÊ)2, or medium and 
MIP1β, IL10, IFNγ, and TNFα levels were measured in the supernatant.  
Results. Rituximabtreated patients had higher serum levels of IL10 (101  35 pg/ml vs. 
41  9 pg/ml; p < 0.01) and MIP1β (950  418 pg/ml vs. 125  32 pg/ml; p < 0.001) 
compared to placebotreated patients at 2 hours after start of infusion. There was no 
difference in the level of other cytokines. In vitro, the addition of rituximab, but not 
rituximabF(abÊ)2 fragments, only led to significantly increased levels of MIP1β in co
cultures of B and NK cells. Levels of MIP1β were higher in patients with a high affinity 
Fcreceptor compared to those with a lower affinity FcγRIIIa (1356  184 pg/ml vs. 679  
273 pg/ml; p < 0.01). 
Conclusions. In addition to B cell depletion, rituximab can modulate the immune 
response by inducing cytokine secretion, especially IL10 and MIP1β. Rituximab
induced MIP1β secretion depends on the combined presence of B cells and FcRbearing 
cells, especially NK cells. 
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isolated by density gradient centrifugation (Lymphoprep; Nycomed Pharma, Roskilde, 
Denmark). CD14+ Monocytes and CD19+ B cells were positively selected using specific
magnetic microbeads, and NK cells were negatively selected using the NK cell isolation 
kit II (all from Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in a purity of 
more than 95% for all lymphocyte subsets.  
Culture conditions 
Whole blood culture was used to determine the cytokine production in vitro. Therefore, 
whole blood was diluted 1:5 with culture medium in 24well plates (Greiner BioOne, 
Frickenhausen, Germany). To study the cytokine production by different lymphocyte 
subsets, 2 × 105 PBMCs, B cells, NK cells, and/or monocytes were cultured in RPMI1640 
medium supplemented with pyruvate (0.02 mM), glutamax (2 mM), penicillin (100 
U/ml), streptomycin (100 g/ml) (all from Gibco, Paisley, United Kingdom), and 10% 
fetal bovine serum (FBS) in 96well round bottom plates (Greiner BioOne) in a 37°C, 
95% humidity, 5% CO2 incubator. In selected conditions, 250 øg/ml rituximab or 250 
øg/ml rituximabF(abÊ)2 (provided by Genmab, Utrecht, The Netherlands) was added to 
the culture medium. Supernatant was collected after 14 hours and/or 24 hours and 
stored at 20■C until analysis.  
Cytokine measurements 
Serum and culture supernatant levels of IL2, IL6, IL10, IL12, IL17, IFNγ, TGFβ, 
TNFα (eBioscience, San Diego, CA), and MIP1β (Invitrogen, Carlsbad, CA) were 
determined by ELISA according to the manufacturerÊs instructions. IL4 levels were 
determined by Luminex according to the manufacturerÊs instructions (Biorad, 
Veenendaal, The Netherlands). 
FcγRIIIa158 genotype analysis 
DNA was extracted from peripheral blood of 10 rituximabtreated patients using a DNA 
isolation kit (Qiagen, Valencia, CA). Genotyping of FcγRIIIa158 (rs396991) was 
performed using the TaqManAllelic discrimination method with a specific probe for 
rs396991 designed for single nucleotide polymorphism (SNP) of FcγRIIIa and results 
were analyzed using the Allelic Discrimination software program according to the 
manufacturerÊs instructions (all from Applied Biosystems, Foster City, CA).  
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Materials and Methods 
Patients 
For this study, patients were recruited from the rituximab in Renal Transplantation 
trial (ClinicalTrials.gov, NCT00565331), which evaluated the efficacy and safety of 
rituximab (MabThera, HoffmannLa Roche, Basel, Switzerland) when added to standard 
immunosuppression in renal transplant recipients. At the start of transplant surgery, 
patients received 1000 mg acetaminophen, 100 mg prednisolone and 2 mg clemastine i.v. 
next to the standard treatment with 2000 mg ceftriaxone as antibiotic prophylaxis. After 
30 minutes, rituximab (375 mg/m2) or placebo was administered at an increasing 
infusion rate. The total infusion time was approximately 4 hours.  
For logistic reasons, only recipients of a living donor kidney were selected for this study. 
Peripheral blood samples were collected from 20 patients (10 rituximabtreated, 10 
placebotreated) a few hours before the transplantation (baseline), at 2 and 4 hours after 
starting the rituximab infusion (t = 2h and t = 4h), and the next morning (t = 24h). Sera 
were stored at 80■C until analysis. Table 1 summarizes the patient characteristics.  
Table 1. Patient characteristics* 
 Patient groups 
 
Rituximab 
(n = 10) 
Placebo  
(n = 10) 
Age; mean  SD 46.7  12.5 44.7  12.5 
Sex; male : female, no. 6 : 4 9 : 1 
HLA mismatches; mean  SD 2.9  1.3 3.3  1.3 
Immunosuppression before transplantation; no. 0 1 
Patients with panel reactive antibody > 6%; no. 1 3 
Renal replacement therapy 
 none / hemodialysis / peritoneal dialysis; no. 3 / 6 / 1 2 / 7 / 1 
 
* There were no statistical differences between the rituximab and placebo group. 
 
Healthy donors and cell isolation 
For in vitro experiments, peripheral blood samples were obtained from healthy donors 
after written informed consent. Peripheral blood mononuclear cells (PBMCs) were 
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Figure 1. In vivo cytokine release after rituximab infusion.  
 
 
Serum levels of IL2, IL6, IL10, IL12, IL17, IFNγ, MIP1β, TGFβ, and TNFα in patients who underwent renal 
transplantation. 20 patients received a single dose of rituximab (375 mg/m2) or placebo during transplant surgery. 
Concomitant immunosuppression consisted of tacrolimus, mycophenolate mofetil (MMF) and steroids. Blood samples were 
taken a few hours before transplantation (t = baseline), 2 and 4 hours after the start of infusion of rituximab or placebo, 
and the next morning after transplantation (t = 24 hours). Results are depicted as mean  SD. Significant differences 
between placebo and rituximabtreated patients at the different time points are indicated by asterisks: **p < 0.01,        
***p < 0.001. 
 
To pinpoint the cells that produced MIP1β after rituximab administration, MIP1β 
levels were measured in the culture supernatant of freshly isolated PBMC, B cells, NK 
cells, or monocytes that were exposed to rituximab for 14 hours. In addition, MIP1β was 
measured in cocultured BNK cells and cocultured B cellmonocytes upon rituximab 
treatment. rituximab did not increase the MIP1β levels in cultures of B cells, NK cells or 
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Statistical analysis 
Cytokine concentrations are presented as mean  SD. Nonparametric tests were used to 
compare variables. Oneway ANOVA was used to compare the different groups over 
time, followed by DunnÊs multiple comparison test for posttesting. To test the difference 
between the cultured cells with rituximab or without (culture medium) the Wilcoxon 
signed rank test was performed. P < 0.05 was considered statistically significant. 
Statistical analysis was performed using GraphPad Prism 5.03 (GraphPad Software Inc., 
La Jolla, CA, USA). 
  
Results 
Rituximab infusion is associated with specific cytokine release 
The infusion of rituximab induced a temporary rise in the levels of IL10 and MIP1β. At 
2 hours after the start of the infusion, the serum levels of these cytokines were 
significantly higher in rituximabtreated patients than in placebotreated patients (IL10 
(101  35 pg/ml vs. 41  9 pg/ml; p < 0.01) and MIP1β (950  418 pg/ml vs. 125  32 
pg/ml; p < 0.001; Figure 1). However, rituximab infusion did not increase the levels of IL
2, IL4, IL6, IL12, IL17, IFNγ, TGFβ, or TNFα levels as compared to placebo treatment, 
suggesting that rituximab infusion is associated with a specific cytokine release. Of note, 
the serum levels of IL4 were below 1.2 pg/ml, which is the detection limit of the assay. 
None of the patients experienced any clinical symptoms associated with cytokine release. 
Exposure to rituximab induces a B cell dependent secretion of MIP1β by NK cells 
Using in vitro studies with blood from healthy donors, we next analyzed which cells were 
responsible for the cytokine production after exposure to rituximab. We used whole blood 
cultures next to PBMC, to stay as close to the in vivo situation as possible [180]. In a 24 
hours whole blood culture as well as in isolated PBMC culture, addition of rituximab 
induced elevated MIP1β levels as compared to the medium alone (whole blood culture: 
592  218 pg/ml vs. 79  68 pg/ml; p = 0.06 and PBMC culture: 500  450 pg/ml vs. 23  6 
pg/ml; p < 0.05), whereas IL10, IFNγ, and TNFα were not detectable in this system 
(Figure 2A).  
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Figure 2. Cytokine release after exposure to rituximab is Fcreceptor mediated. 
 
 
(A) Production of MIP1β, IL10, TNFα and IFNγ from whole blood cultures (n = 5) and PBMCs of healthy donors (n = 4) 
incubated with medium or 250 g/ml rituximab for 24 hours. 
(B) Production of MIP1β by PBMCs, isolated CD19+ B cells, CD3CD56+ NK cells, CD14+ Monocytes, and a coculture of B 
cells with NK cells or monocytes of healthy donors (n = 10) incubated with medium or 250 g/ml rituximab after 14 hours. 
(C) Production of MIP1β by PBMCs of healthy donors 24 hours after incubation with medium, 250 g/ml rituximab or 
rituximabF(abÊ)2. 
(D) Serum levels of MIP1β and IL10 in patients with the high affinity receptor SNP158VV (n = 4) and the low affinity 
receptor SNP158VV/VF group (n = 6) 2 hours after the start of the rituximab infusion. Significant differences are 
indicated by asterisks: *p < 0.05, **p < 0.01. 
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monocytes alone, nor in cocultures of B cellsmonocytes. In contrast, rituximabtreated 
cocultures of B cells and NK cells revealed significantly enhanced MIP1β levels as 
compared to the medium control (597  321 pg/ml vs. 30  23 pg/ml; p < 0.05; Figure 2B). 
Intracellular MIP1β staining of the cocultured BNK cells showed that NK cells 
produce MIP1β upon exposure to rituximab for 14 hours, while B cells do not (Figure 3). 
Taken together, this suggests that after exposure to rituximab the observed increase in 
MIP1β is mainly due to secretion by NK cells in a B celldependent manner. 
MIP1β secretion after exposure to rituximab is Fcreceptor dependent 
To establish if the MIP1β secretion caused by exposure to rituximab is Fcreceptor 
dependent, PBMCs were incubated with rituximab, rituximabF(abÊ)2 or in culture 
medium alone. PBMCs cultured with rituximabF(abÊ)2 did not show increased MIP1β 
secretion (Figure 2C), indicating that MIP1β secretion is Fcreceptor dependent.  
It is known that single nucleotide polymorphisms (SNP) of the FcγRIIIa gene at position 
158 result in an altered Fcreceptor function, where FcγRIIIa homozygous for valine 
(VV) has a higher affinity for IgG1 than FcγRIIIa with phenylalanine at that position 
(VF or FF) [172]. We therefore wondered whether the MIP1β secretion after treatment 
with rituximab in vivo could be correlated to the genotype of the Fcreceptor FcγRIIIa 
(CD16) present on NK cells. To this end, we determined the SNP at position 158 in 10 
rituximabtreated renal transplant patients. Interestingly, rituximabtreated patients in 
the high affinity group (VV) revealed higher serum levels of MIP1β as compared to the 
lower affinity group (VF/VV) at 2 hours after the start of the rituximab infusion (1356  
184 pg/ml vs. 679  273 pg/ml; p < 0.01) (Figure 2D). Although not significant, a similar 
trend was observed for IL10 levels (288  111 pg/ml vs. 184  35 pg/ml; p = 0.17). These 
findings support our conclusion from the in vitro studies that the cytokine release is Fc
receptor dependent. 
Discussion 
In this study, we showed that rituximab infusion leads to a specific cytokine release in 
renal transplant recipients. At 2 hours after the start of the infusion, IL10 and MIP1β 
serum levels were significantly higher in rituximabtreated patients as compared to 
placebotreated patients, whereas the levels of IL2, IL4, IL6, IL12, IL17, IFNγ, 
TGFβ, and TNFα remained unaffected. Additional in vitro data revealed that NK cells 
were largely responsible for the MIP1β release in a B cell and Fcreceptor dependent 
manner.  
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Figure 2. Cytokine release after exposure to rituximab is Fcreceptor mediated. 
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indicated by asterisks: *p < 0.05, **p < 0.01. 
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Although rituximab is usually well tolerated, the first infusion may be accompanied by 
severe side effects, which are correlated with complement activation and with the 
number of circulating B cells, as more side effects occur in patients with high B cell 
counts, like lymphoma patients [176, 181]. There is limited data on the cytokine 
releasing effects of rituximab in patients with B cell counts in the normal range, like 
renal transplant recipients or patients with autoimmune diseases. In our study cohort, 
we found elevated cytokine levels after rituximab infusion. The type of cytokines 
secreted was different from that observed in other cohorts treated with distinct 
monoclonal antibodies [171, 182]. The cytokine release syndrome associated with OKT3 
treatment is characterized by the release of the inflammatory cytokines IL2, TNFα, and 
IFNγ, while treatment with the humanized antiCD52 monoclonal antibody 
alemtuzumab was accompanied with elevated levels of IL6, TNFα, and IFNγ [182, 183]. 
In these cases, it is believed that the release of inflammatory cytokines is due to direct T 
cell activation or dependent on Fcreceptor ligation on phagocytic cells, such as 
monocytes, macrophages, and NK cells [182, 184]. We found that exposure to rituximab, 
without further stimulus, only led to significantly increased MIP1β levels in cocultures 
of purified B and NK cells. Intracellular MIP1β staining of the cocultured BNK cells 
showed that NK cells produce MIP1β upon 14 hours exposure to rituximab, while B cells 
do not, suggesting that the cytokine release observed in vivo is coming from NK cells and 
largely dependent on the binding of these cells to rituximabcoated B cells. Upon 
recognition, NK cells can quickly release chemokines, such as MIP1β, whereas the 
release of TNFα and IFNγ occurs hours later, which might explain the lack of TNFα and 
IFNγ production in our in vitro cultures [185]. Finally, incubation of PBMCs with 
rituximabF(abÊ)2 did not lead to an increased MIP1β secretion, indicating that the 
cytokine release is indeed Fcreceptor dependent. 
In patients with autoimmune diseases, several single nucleotide polymorphisms (SNPs) 
in Fcγreceptors have been associated with the clinical response after treatment with 
monoclonal antibodies such as rituximab [170, 171, 186]. NK cells express the Fc
receptor FcγRIIIa (CD16) which has a high affinity for binding to IgG1, the isotype of 
rituximab [171]. FcγRIIIa appears in two allelic forms that differ by the amino acid on 
position 158. SNPs at position 158 result in an altered Fcreceptor function and have 
been associated with clinical response to rituximab [170, 187]. FcγRIIIa homozygous for 
valine (VV) has a higher affinity for IgG1 than FcγRIIIa with phenylalanine at that 
position (VF or FF) [172]. Interestingly, we found that MIP1β levels in patients treated 
with rituximab correlated to the FcγRIIIa158 SNP. Patients with the high affinity SNP 
112 
Figure 3. Intracellular MIP1β expression in cocultures of B and NK cells of four 
different (A to D) healthy donors.  
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produced higher levels of MIP1β. This observation fits with previous data showing that 
the degree of NK cell activation and the clinical response upon rituximab treatment are 
influenced by the FcγRIIIa158 SNP [188].  
The observed rise in IL10 and MIP1β could be of clinical relevance, since it may well 
modulate the (allo)immune response influencing the transplantation outcome. IL10 is a 
wellknown antiinflammatory cytokine which plays an important role in immune 
regulation [189]. In a mouse model, MIP1β was shown to be the most potent 
chemoattractant for regulatory T cells within a range of chemokines, suggesting that 
increased secretion might down modulate the immune response [190]. On the other 
hand, MIP1β can be produced by lymphocytes that are involved in inducing immune 
reactivity, including NK cells and B cells [191]. Moreover, MIP1β recruits monocytes, T 
cells, and dendritic cells to the site of injury or inflammation via the chemokine receptor 
CCR5, which is highly expressed by monocytes and has a lower expression on T cells and 
dendritic cells. Therefore, in renal transplantation increased MIP1β levels might 
contribute to activation of the immune response, and thus graft injury. Indeed, in a 
previous study with rituximab as induction therapy in renal transplantation, an 
increased rate of acute rejection was associated with elevated levels of proinflammatory 
cytokines in some of the patients one week after transplantation [107]. This suggests 
that rituximab might also have delayed effects on the cytokine production. In that report 
no data are provided on MIP1β levels.  
In summary, results from this study indicate that rituximab does not only lead to B cell 
depletion, but also results in the release of cytokines, especially IL10 and MIP1β, which 
might modulate the immune response. The MIP1β secretion appears to be B cell and Fc
receptor dependent. 
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Introduction 
Since the early 2000's, Th17 cells have been recognized as a separate T helper subset 
characterized by the expression of interleukin (IL)17. IL17 is a proinflammatory 
cytokine that induces chemokine production and promotes recruitment of neutrophils to 
the site of inflammation. Although their origin and precise function remain incompletely 
defined, recent studies have shown that Th17 cells are involved not only in the immune 
response against fungi and extracellular bacteria, but also in the pathogenesis of 
autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis [192194]. 
We recently found that treatment with the B cell depleting antibody rituximab in 
patients with RA leads to a reduction of Th17 cells in synovial tissue [5]. Moreover, we 
showed that stimulation of peripheral blood mononuclear cells (PBMCs) in vitro in the 
presence of rituximab decreases Candidainduced IL17 production and the number of 
IL17 producing cells. These results indicate that B cells contribute to the Candida
induced Th17 response, possibly mediated by their antigen presenting potential or by the 
production of specific cytokines. 
In renal transplantation, T cells play an important role in allograft rejection. During 
rejection episodes the inflammatory infiltrates contain CD4+ and CD8+ T cells, and 
antibody therapies directed against T cells, are effective in the prevention and treatment 
of allograft rejection [195]. Initially, T helper 1 (Th1) cells were believed to be the main T 
helper subset driving allograft rejection, based on increased urinary protein levels of the 
IFNγ inducible chemokines MIG (CXCL9) and IP10 (CXCL10), and increased Tbet 
mRNA levels in renal tissue during allograft rejection [196, 197]. However, recently this 
idea has been challenged since IFNγ knockout mice experience accelerated graft 
rejection and increased parenchymal necrosis [198, 199]. Interestingly, IFNγ can inhibit 
Th17 cells in vitro, suggesting that IL17 can play an important role in allograft rejection 
[200, 201]. Indeed, in a mouse cardiac transplantation model, blocking or deficiency of 
IL17, in mice mainly produced by γδT cells, resulted in significantly increased graft 
survival [202, 203]. Loong et al. reported elevated IL17 mRNA and protein levels in 
infiltrating mononuclear cells in renal biopsies and in mononuclear cells from urinary 
sediments from patients with borderline kidney graft rejection [204]. Furthermore, van 
Kooten et al. demonstrated the presence of IL17 mRNA and protein in graftinfiltrating 
CD4+ and CD8+ T cells in biopsies of acutely rejected human kidney grafts [205]. 
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Abstract 
In renal transplantation, IL17 production by T cells might be dependent on the presence 
of B cells. Therefore, the effect of in vivo B cell depletion on ex vivo IL17 production was 
investigated. 
Twenty patients undergoing livingdonor renal transplantation were recruited from a 
larger cohort of patients participating in a randomized, doubleblind trial. All patients 
were allocated to a single intraoperative dose of either placebo or rituximab (375 mg/m2) 
added to the standard immunosuppressive therapy. Blood was collected at baseline, at 
one day, and at one month after surgery. The healthy kidney donors also gave blood at 
baseline. Peripheral blood mononuclear cells were stimulated ex vivo in different 
manners (heat killed Candida albicans yeast, heat killed Staphylococcus aureus, or 
αCD3αCD28 coated beads), to address the role of B cells in ex vivo cytokine responses. 
The concentration of monocyte and T cellderived cytokines (IL1β, IL6, TNFα, IFNγ, IL
17 and IL22) was measured in supernatants. 
Of the 20 recruited patients, 13 received treatment with rituximab and 7 received 
placebo. In all patients, IL17 was produced by CD4positive, γδTCRnegative cells. After 
stimulation, there was no difference between patients and healthy controls in ex vivo 
production of IL17 or other cytokines. In all patients there was a general decrease of 
monocyte and T cellderived cytokines after transplantation, except for IL17. There was 
no difference between patients who received rituximab and patients who received 
placebo. 
A single dose of rituximab treatment added to standard immunosuppressive therapy in 
renal transplant patients did not influence the production of IL17 or other monocyte or 
T cell derived cytokines after ex vivo stimulation. 
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study was approved by the Central Committee on Research involving Human Subjects 
(The Hague, The Netherlands) and the Medical Research Ethics Committee Arnhem
Nijmegen (Nijmegen, The Netherlands). All patients gave written informed consent for 
the parent study, which also implied consent for the current study. 
Reagents 
The following materials were used for the isolation of PBMCs: FicollPaque (GE 
Healthcare, Diegem, Belgium); RPMI 1640 Dutch modifications (SigmaAldrich) 
supplemented with 1% gentamicin, 1% lglutamine and 1% pyruvate (Life Technologies, 
Nieuwekerk, The Netherlands). The following stimuli were used to induce a strong Th17 
response in vitro [206]: AntiCD3 and antiCD28 coated (αCD3αCD28) beads were 
prepared from a T cell activation/expansion kit (MACS Milteny Biotec, Bergisch 
Gladbach, Germany); Candida albicans ATCC MYA3573 (UC 820) was grown overnight 
in Sabouraud broth at 37°C [207]. C. albicans was heatkilled (HK) for 1 hour at 100°C; 
and S. aureus (ATCC) 25923 was heatkilled for 30 minutes at 100°C. The following 
antibodies were used for FACS analysis: αTCR PANγδPE (Beckman Coulter, Breda, The 
Netherlands), αCD4FITC (BD Pharmingen, Erembodegem, Belgium), αIL17Alexa647 
(BD Pharmingen), αCD19APCAlexa Fluor 750 (BeckmanCoulter) and αCD45Krome 
Orange (BeckmanCoulter). 
Ex vivo cytokine production 
PBMCs were isolated by density gradient centrifugation of PBSdiluted blood (1:1) over 
FicollPaque, washed twice with saline, and suspended in culture medium. The cells 
were counted in a Coulter Counter (Beckman Coulter, Woerden, The Netherlands). 5 × 
105 PBMCs in a volume of 100 L per well were incubated at 37°C in roundbottom 96
well plates (Greiner, Nurnberg, Germany). PBMCs were primed, for one, two or seven 
days, with RPMI, C. albicans, S. aureus or αCD3αCD28 beads. These stimuli are known to 
induce high IL17 production in PBMC. AntiCD3α/antiCD28 can induce IL17 
production in T cells without the need for any other costimulatory signals and/or 
antigen presentation. In contrast, both HK C. albicans and S. aureus require to be 
processed by antigenpresenting cells first, before they can induce IL17 production in T 
cells. In blocking experiments, PBMCs were preincubated for 1 h with 10 g/mL 
rituximab. When cells were cultured for seven days, this was done in the presence of 10% 
human serum. After one, two or seven days, supernatants were collected and stored at 
−20°C until assayed. 
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Based on our previous findings, we hypothesized that B cell depletion might interfere 
with the induction of Th17 cells and IL17 production after renal transplantation. In that 
case, addition of rituximab to the immunosuppressive treatment might improve the 
outcome of transplantation. In a clinical trial we are evaluating the effectiveness and 
safety of rituximab for the prevention of acute rejection after renal transplantation. This 
provided the opportunity, to study cytokine production upon ex vivo stimulation of 
PBMCs obtained from a subgroup of patients who participated in the abovementioned 
trial. We expected to find that the in vivo depletion of B cells, would reduce the ex vivo 
Candida or Staphylococcus aureus induced IL17 production by PBMCs. Reporting on 
the main outcome of the clinical trial is beyond the scope of this manuscript and will 
follow once the trial has been completed. We hypothesize that in vivo B cell depletion 
will decrease ex vivo IL17 production in cells from renal transplant patients. 
 
Materials and methods 
Subjects 
Between April 2009 and May 2010, twenty patients were recruited from a cohort of 
patients participating in a randomized, doubleblind, placebocontrolled trial evaluating 
the effectiveness and safety of rituximab for the prophylaxis of acute allograft rejection 
after renal transplantation. In the clinical trial, patients were treated either with a 
single intraoperative dose of rituximab (375 mg/m2) or placebo, added to standard 
immunosuppressive therapy, consisting of tacrolimus, mycophenolate mofetil and 
prednisone. Patients did not receive induction therapy with antiT cell agents. A detailed 
description of this trial can be found on Clinicaltrials.gov, trial number NCT00565331. 
For logistic purposes, only patients that underwent a planned renal transplantation (e.g. 
only those with a living donor) were included in the current study on ex vivo cytokine 
production. 
For ex vivo cytokine stimulation, venous blood was collected at baseline i.e. a few hours 
(maximum 6) before surgery, 24 h later, and one month after the operation by 
venipuncture into 10 mL EDTA tubes (367525, BD, Plymouth, UK). Moreover, to 
evaluate B cell depletion, 10 mL of blood was also collected at one week after surgery. 
When a biopsyproven rejection or graft loss occurred, only the samples collected before 
this event were analyzed. The living kidney donors of each recipient acted as healthy 
controls and in these subjects blood was drawn 1 to 2 h before their surgery. The parent 
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Results 
Between April 2009 and May 2010, we included 20 patients (fourteen males and six 
females, age (mean  SD): 47  12 years). Ten patients were treated with hemodialysis 
before transplantation, two with peritoneal dialysis, and eight underwent a preemptive 
transplantation. Thirteen patients were treated with rituximab and seven with placebo. 
One patient lost the graft due to venous thrombosis the day after surgery, and was 
excluded from further analysis. One week after surgery the percentage of CD19+ B cells 
within the CD45+ lymphocyte fraction was (mean  SD) 0.24  0.22 in patients who had 
received rituximab, compared to 23.0  21.9 in patients who had received placebo during 
surgery (p < 0.01). Three patients had biopsyproven rejection, all within the first month 
after transplantation, and were excluded from the analysis at one month after surgery. 
The 20 healthy kidney donors (seven males and thirteen females) had an age (mean  
SD) of 55  10 years. 
In order to determine the cell type responsible for IL17 production in our in vitro 
system, PBMCs were stimulated for 7 days, in the presence of 10% human serum, with 
HK C. albicans, S. Aureus, or antiCD3/antiCD28. Intracellular IL17 was measured 
using FACS. IL17 expression could especially be detected after C. albicans and S. 
aureus stimulation. All IL17 positive cells were CD4 positive and γδTCR negative 
(Figure 1). 
First we wanted to assess whether renal transplant recipients are comparable to healthy 
controls to rule out any effect on cytokine production caused by the underlying kidney 
disease. There were no differences in the ex vivo production by the PBMCs of IL1β, IL6, 
TNFα, IFNγ, IL17 and IL22 upon stimulation with HK C. albicans yeast, HK S. aureus, 
or antiCD3/antiCD28 coated beads between the 20 patients and the 20 healthy kidney 
donors (Figure 2A). Furthermore, in vitro preincubation with rituximab decreased 
Candidainduced IL17 production in healthy controls to a similar extent in renal 
transplant recipients (Figure 2B). 
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Flow cytometry IL17+cells 
PBMCs were stimulated for 7 days as described above. After 7 days the supernatant was 
removed and replaced with RPMI with Golgiplug (555029, BD Biosciences, Breda, The 
Netherlands), PMA (50 ng/mL) (P8139, SigmaAldrich), and ionomycin (1 g/mL) (I0634, 
Sigma Aldrich) for 4 h. Subsequently, the cells were labeled with antiCD4FITC and 
antiγδTCRPE according to the instructions of the manufacturer. Fix & Perm 
(GAS001S100 and GAS002S100, Invitrogen) were used to stain intracellularly with 
antiIL17Alexa647. The cells were resuspended in 200 L 1% BSA and fluorescence was 
measured on a Cytomics FC500 FACS machine (Beckmann Coulter, Woerden, The 
Netherlands). 
Flow cytometry B cells 
PBMCs were isolated by density gradient centrifugation using Lymphoprep (Nycomed 
Pharma, Roskilde, Denmark) and cryopreserved in liquid nitrogen until analysis. Cells 
were labeled with αCD19 (J3119)APCAlexa Fluor 750 and αCD45Krome Orange. The 
cell phenotype was analyzed by tencolor flow cytometry (Navios) and data were 
analyzed using Kaluza software (all from BeckmanCoulter). 
Cytokine assays 
The concentrations of IL1β, IL17, IL22 and TNFα (R&D Systems, Abingdon, UK) and 
IL6 and IFNγ (Sanquin, Amsterdam, The Netherlands) were measured in cell culture 
supernatants using ELISA, according to the instructions of the manufacturer. Based on 
previous experience, IL1β, IL6 and TNFα were measured after 24 h of stimulation, 
IFNγ after 48 h and IL17 and IL22 after seven days of stimulation [206]. 
Statistical analysis 
Experiments were performed in duplicate, and supernatants of the duplicates were 
pooled. The differences between groups were analyzed using the Wilcoxon ranksum test 
(Figure 2 and Figure 3). Trends in cytokine production over time were analyzed using 
repeated measures analysis (Figure 3). Violation of sphericity (Mauchly's p < 0.05) was 
corrected using the Greenhouse–Geisser correction. All p values were adjusted for 
multiple testing, using the Bonferroni correction. The level of significance was set on      
p < 0.002 (Figure 2), p < 0.002 (main ANOVA Figure 3), p < 0.004 (contrasts Figure 3), 
and p < 0.0007 (Figure 3). Data are presented as mean  SD (standard deviation). 
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Figure 2. Cytokine production in patients with endstage renal failure versus 
healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Human PBMCs isolated before surgery were stimulated with RPMI, C. albicans (1 × 106/mL), Staphylococcus aureus (1 
× 107/mL), or antiCD3/antiCD28 beads (1.25 × 106/mL). Cytokine concentrations were measured in cell culture 
supernatants using ELISA. IL1β, IL6 and TNFα were measured after 24 hours of stimulation, IFNγ after 48 hours, and 
IL17 and IL22 after seven days of stimulation. When cells were stimulated for seven days, this was done in the presence 
of 10% human serum. Experiments were performed with cells from 20 healthy volunteers and 20 patients with endstage 
renal failure. Data are presented as mean  SD. 
(B) Human PBMCs from five healthy volunteers and five patients with endstage renal failure, isolated before surgery, 
were stimulated for seven days in the presence of 10% human serum with C. albicans (1 × 106/mL), in the absence () or 
presence (+) of rituximab (10 g/mL). IL17 was measured in cell culture supernatants using ELISA. Data are presented 
as mean  SD. 
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Figure 1. Source of IL17 production in vitro.  
 
 
Human PBMC were stimulated for 7 days with C. albicans (1 × 106/mL), Staphylococcus aureus (1 × 107/mL), or anti
CD3/antiCD28 beads (1.25 × 106/mL), in the presence of 10% human serum. Expression of CD4, γδTCR and intracellular 
IL17 were determined with FACS analysis. Figure is representative for four healthy volunteers from two different 
experiments. 
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the occurrence of a shortlived cytokine release syndrome after the administration of 
rituximab or the use of clemastine and steroids before the infusion of rituximab/placebo 
[177]. Both mechanisms might prohibit the production of cytokines when PBMCs are 
(re)stimulated ex vivo [208]. 
 
Figure 3. Effect of rituximab on ex vivo cytokine production in renal transplant 
patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human PBMCs isolated before (T0), one day after (T1), or one month (T2) after renal transplantation, were stimulated 
with RPMI, C. albicans (1 × 106/mL), Staphylococcus aureus (1 × 107/mL), or antiCD3/antiCD28 beads (1.25 × 106/mL). 
Cytokine concentrations were measured in cell culture supernatants using ELISA. IL1β, IL6 and TNFα were measured 
after 24 hours of stimulation, IFNγ after 48 hours, and IL17 and IL22 after seven days of stimulation. When cells were 
stimulated for 7 days, this was done in the presence of 10% human serum. Experiments were performed with cells from 13 
rituximabtreated patients and 7 placebotreated patients (T0), or 13 rituximabtreated patients and 6 placebotreated 
patients (T1), or 11 rituximabtreated patients and 5 placebotreated patients (T2). Data are presented as mean  SD. 
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In all patients, there was a general decrease of production of IL1β, TNFα, and IFNγ at 
the day after surgery and one month later (Figure 3). A recovery was seen in the 
production of IFNγ, but only in the case of stimulation with the antiCD3/antiCD28 
coated beads. The production of IL6 and IL22 was also decreased at one day after 
surgery, but was mostly recovered at one month after transplantation. Notably, the 
general decrease in cytokine production at day one after surgery was not observed for IL
17. Candidainduced IL17 production tended to increase the day after transplantation, 
and even more at one month after transplantation, although this rise was not 
statistically significant (Figure 3). 
Despite a nearly complete B cell depletion in the rituximab group, there was no 
difference in cytokine production (with any stimulus at any time point) between patients 
treated with rituximab and patients treated with placebo (Figure 3). Cytokine 
production, including IL17 production, was not associated with the occurrence of 
rejection (n = 3), the occurrence of one or more infections (n = 15), or baseline patient 
characteristics, although the numbers were too small for statistical analysis (data not 
shown). 
 
Discussion 
In this study, administration of a single dose of rituximab resulted in nearly complete B 
cell depletion, but did not have an effect on ex vivo cytokine production, including IL17. 
We therefore could not confirm our hypothesis that B cells contribute to the in vivo Th17 
response. 
We previously showed that in vitro addition of rituximab to PBMCs obtained from 
healthy individuals reduces the IL17 inducing potential of C. albicans [5]. After 
reconfirming these findings, we evaluated whether in vivo B cell depletion by rituximab, 
which is clinically more relevant, also results in a reduced capacity of PBMC to produce 
IL17 and other cytokines upon ex vivo stimulation. Despite a profound in vivo B cell 
depletion, we could not reproduce the effects observed after a similar degree of B cell 
depletion upon adding rituximab in vitro. The detection of an effect of rituximab 
treatment on ex vivo cytokine production might have been hampered by the general 
decrease in cytokine responses that we observed after transplantation. This decrease 
may be related to the use of the immunosuppressive drugs tacrolimus, mycophenolate 
mofetil, and steroids. The decrease at 24 hour after transplantation could be related to 
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Interestingly, we found no decrease in IL17 production, both at one day and at one 
month after transplantation. Previously it was shown that treatment of myasthenia 
gravis patients with tacrolimus resulted in a reduced production of IFNγ and IL17 by 
PBMCs [209]. Therefore, the finding that IL17 production was not suppressed in this 
study (in which all 20 patients were treated with tacrolimus next to mycophenolate 
mofetil and steroids) is remarkable. However, it is difficult to dissect the separate effects 
of different drugs on ex vivo cytokine production. Furthermore, regulation of IL17 
production is quite different from other proinflammatory cytokines. For example, IL17 
production is increased by PGE2, in contrast to the production of TNFα and IFNγ, which 
are suppressed by PGE2 [210214]. Regardless of the exact mechanism of a lack of IL17 
suppression, our observation pinpoints IL17 as a potential novel target for prophylaxis 
against graft rejection. 
We were not able to show a correlation between ex vivo IL17 production and the 
occurrence of graft rejection. However, rejection occurred in only three patients, which 
precludes statistical analysis. Notably, we also found an increase in IL17 production in 
PBMCs from patients without graft rejection. 
In conclusion, treatment with a single perioperative dose of rituximab added to the 
standard immunosuppressive therapy does not influence ex vivo cytokine production, 
including IL17. We therefore could not confirm our hypothesis that B cell depletion 
might interfere with the induction of Th17 cells. 
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system. At Mount Sinai Hospital (New York), a trial has recently been started which 
evaluates the effect of eculizumab on the incidence of delayed graft function within the 
first seven days after renal transplantation (clinicaltrials.gov number NCT01919346). 
Patients transplanted with a kidney at high risk of severe ischemiareperfusion injury 
(ischemia time more than 18 hours or kidneys from donors aged 60 years or older, or 
aged 5059 years with comorbidity) will be randomized to two doses of eculizumab or 
placebo. Unfortunately, donors after circulatory death, the type of donor used in our 
trial, are excluded.  
Another approach to reduce the incidence of delayed graft function could be the 
interference with the tolllike receptors. They form a group of receptors that recognize 
pathogen or damageassociated molecular patterns. One of these receptors is tolllike 
receptor 2 (TLR2), which is expressed on innate immune cells and renal epithelial cells 
and can be activated by ligands that are released following ischemic injury. 
Experimental data indicate that activation of TLR2 is involved in the inflammatory 
cascade leading to ischemiareperfusion injury. Specific inhibition of TLR2 by a 
monoclonal antibody named OPN305 could therefore reduce the incidence of delayed 
graft function [210]. A placebocontrolled, double blind trial with OPN305, has been 
initiated in various countries. In this study, next to recipients of a DBD kidney with a 
long cold ischemia time or from extended criteria donors, patients receiving a kidney 
from a donor after circulatory death are included (NCT01794663). 
Finally, a different and possibly more attractive approach to alleviate the problem of 
ischemiareperfusion injury is to reduce ischemia time by more rapid allocation and 
transportation of organs. Nevertheless, there will always remain a time interval between 
organ procurement and implantation in the recipient. The usual way to protect organs 
during this period is to store them at melting ice after perfusion with a preservation 
fluid. An alternative is continuous, pulsatile perfusion with a cold (18 °C) preservation 
fluid. In a recent trial one kidney of each donor was randomly assigned to hypothermic 
machine perfusion and the contralateral kidney to cold storage. Machine perfusion was 
associated with a substantial reduction in the incidence of delayed graft function [215]. 
An even more physiological approach would be normothermic (and oxygenated) machine 
perfusion, and the first small series in renal transplantation demonstrates that this 
technique is both feasible and safe [216].  
Chapter 5 reports that alemtuzumab appeared to be equally effective as ATG
Thymoglobulin in the treatment of steroidresistant renal allograft rejection, with a more 
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For patients with endstage renal disease a renal transplantation is the best option for 
improvement of quality of life and life expectancy and is therefore generally preferred 
over treatment with dialysis. Over the last decades, great improvement has been 
achieved, but important issues remain to be solved. 
The first issue investigated in this thesis is the high incidence of delayed graft function 
in patients transplanted with a kidney donated after circulatory death. In the study 
presented in chapter 4 it is shown that a single intraoperative dose of ATGFresenius 
(ATGF) added to standard triple immunosuppressive regimen, with an unadjusted 
tacrolimus dose, was not effective to reduce the incidence or duration of delayed graft 
function and was associated with a higher incidence of serious adverse events. This is in 
contrast to other studies with ATGF in which a reduced incidence of delayed graft 
function was seen [86, 126131]. However, in these studies, the addition of ATGF was 
accompanied by a reduction in the tacrolimus dose. In such a trial design it is unclear 
whether the beneficial effect on delayed graft function should be attributed to the 
addition of ATGF or to the reduction of the tacrolimus dose. For this reason we used an 
unadjusted tacrolimus dose in our trial. 
The lack of effect of ATGF on delayed graft function questions the effectiveness of   
ATGF itself. Although we noticed lymphocytopenia and mild thrombocytopenia in   
ATGFtreated patients, we did not find an effect on the incidence of allograft rejection. 
In other trials with ATGF and also with ATGThymoglobulin, this was universally the 
case. This lack of effect on both delayed graft function and allograft rejection argues for 
insufficient effectiveness of ATGF. 
We noticed a higher incidence of serious adverse events and a trend towards more 
infections in the ATGFtreated patients. This study was not performed in a blinded 
fashion and therefore a bias towards reporting side effects in ATGFtreated patients 
could have occurred. A higher incidence of infections has not been reported in other 
studies with ATGF and could be the consequence of using an unadjusted dose of 
tacrolimus in combination with ATGF. In conclusion, the use of ATGF without 
adjustment of the tacrolimus dose cannot be recommended to reduce the incidence of 
delayed graft function in patients transplanted with a DCDdonor kidney.  
Currently, much research is directed to the prevention of delayed graft function after 
renal transplantation: a search on clinicaltrials.gov on Âdelayed graft functionÊ and ÂrenalÊ 
resulted in more than 40 running clinical trials. Most trials investigate currently 
available drugs, like eculizumab, a monoclonal antibody targeting the complement 
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cell properties, either directly by depletion through different receptors, like CD5 or HLA
DR, or indirectly by eliminating CD4+ T cell help [16, 218]. In contrast, alemtuzumab 
targets specifically the CD52 molecule, which is expressed on T, NK cells, monocytes, 
macrophages, dendritic cells, and on B cells. This specific targeting could contribute to 
the clinical effect of alemtuzumab in treating steroidresistant rejection. The increasing 
knowledge on the role of B cells and antibodies in graft rejection has led to growing 
attention to antiB cell therapy. Nonetheless the number of clinical trials with antiB cell 
therapy in renal transplantation is limited. 
In chapter 6 we present the data of a randomized clinical trial in which the effect of anti
B cell therapy on the incidence of acute allograft rejection was investigated. A single 
dose of rituximab or placebo was added to standard maintenance immunosuppression of 
tacrolimus, mycophenolate mofetil and steroids in 280 renal transplant patients. 
Although treatment with rituximab was safe, it was ineffective to reduce the incidence of 
acute rejection in a broad population of renal transplant patients. During the design of 
the trial, we hypothesized that the effects of rituximab could be different between 
subgroups of patients. Therefore we stratified our included patients for the presence of 
antiHLA antibodies (as reflected by the panel reactive antibody (PRA) value) and rank 
order of transplantation. When these strata were combined to form an immunologically 
lowrisk (PRAª6% and first transplantation) and an immunologically highrisk (PRA>6% 
or retransplantation) population, a clear trend towards a lower incidence of acute 
allograft rejection with rituximab therapy as compared to placebo was observed in the 
immunologically highrisk subgroup. Interestingly, the incidence of antibody mediated 
rejection tended to be lower after rituximab, especially in immunologically highrisk 
patients. However, the study was not sufficiently powered for these analyses, and 
therefore caution is required. Nonetheless, these results suggest a protective effect of 
rituximab against acute rejection in patients who are at higher immunological risk. This 
can possibly be explained by depleting the memory B cells, which were present in higher 
frequencies in this group. With the current median duration of followup of 4 years, the 
beneficial effect on allograft rejection incidence has not resulted in improved graft 
function or graft survival. Furthermore, it remains to be answered whether treatment 
with rituximab can reduce the development of donorspecific antiHLA antibodies (DSA). 
While the routine measurement of DSA posttransplant was not part of standard clinical 
care at the time of the initiation of the current study and was not included as a study 
endpoint, the results of measurement of these antibodies in stored followup sera will 
become available in the near future. 
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favorable side effect profile. However, these results have to be interpreted with caution, 
since these data were not derived from a prospective trial. Baseline characteristics of 
both groups were not completely comparable, mainly because the alemtuzumab groups 
contained more patients with a retransplantation. These patients had been treated with 
ATG during a previous transplantation, and the avoidance of repeated exposure to ATG 
was the main reason for treatment with alemtuzumab. Nonetheless, this imbalance 
would be expected to favor the ATG group, since patients undergoing a retransplantation 
may be more sensitized and therefore more difficult to treat. Another point of concern is 
the limited followup of three months. The T cell depleting effect of ATG lasts 
approximately 12 months. This can even be longer after alemtuzumab treatment. Late 
side effects, especially infections or malignancies could therefore occur later than three 
months after administration of either drug. Consequently, this study does not provide 
sufficient evidence to recommend alemtuzumab as the firstline therapy in steroid
resistant rejection. A formal, randomized controlled trial, with longterm followup is 
warranted. Of special interest is a recent report in which the use of alemtuzumab 
appears to be associated with an increased risk of the development of donorspecific 
HLAantibodies [217]. This could negatively influence longterm graft survival. Despite 
these concerns, alemtuzumab can be considered the treatment of choice for patients with 
a steroidresistant rejection in whom ATG is an unattractive option. This can be based 
on prior ATG administration or on cardiopulmonary problems or other comorbidity 
which might jeopardize the patient when a firstdose reaction after administration of 
ATG would occur. 
As mentioned above, a drawback of both ATG and alemtuzumab is the long lasting non
specific depletion of T cells. Ideally, new antibodies should be developed which target 
only alloreactive T cells without longlasting depletion of nonalloreactive cells and 
without causing cytokine release. Currently, no trials are planned or ongoing with antiT 
cell antibodies in established allograft rejection, although antiT cell antibodies (mainly 
directed against CD3) are currently under investigation in autoimmune diseases like 
type 1 diabetes mellitus. 
Although equally effective in treating steroidresistant allograft rejection, the 
mechanism of action of ATG and alemtuzumab is not identical. The antibodies present in 
ATG are mainly directed against T cellspecific molecules like CD2, CD3, and CD8, 
although a variety of other of antibodies directed to antigens expressed on NK cells and 
endothelial cells are also present [163, 218]. Some studies show no significant amount of 
antibodies against B cell markers like CD19 or CD20 in ATG. However, ATG has antiB 
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numbers of naive and transitional B cells in the blood and an upregulation of CD20 
mRNA in renal cells extracted from urine of drugfree transplant patients supports the 
regulatory function of certain B cell subsets [224, 225]. Nonselective B cell depletion 
could therefore also lead to depletion of these immunoregulatory B cells, with potentially 
deleterious effects. 
Next to the discovery of B cell subsets, our understanding of the factors that determine B 
cell activation, differentiation, and proliferation has increased. Specific B cell growth 
factors such as BLyS (B lymphocyte stimulator) and APRIL (a proliferation inducing 
ligand) play an important role in B cell development and survival [226228]. In a murine 
cardiac transplant model, BLySdeficient mice show prolonged cardiac allograft survival 
[229]. In vivo BLyS neutralization effectively induced tolerance and promoted longterm 
islet allograft survival in mice [230]. In humans, increased BLyS levels appeared to be a 
risk factor for renal allograft dysfunction and development of donorspecific antibodies 
[231]. Moreover BLySreceptor positive T and B cells have been found in allografts with 
chronic rejection [229]. Therefore, new therapies that (additionally) target BLyS could be 
beneficial to prevent allograft rejection. In clinical trials, belimumab, a fully human anti
BLyS antibody, has been investigated in severe lupus arthritis. Belimumab was given at 
monthly doses for 72 weeks. In a dose dependent manner, it led to a significant reduction 
in disease activity, relapse rates and reduced requirement of steroids compared to 
placebo. The incidence of serious infections was not increased [232]. The benefits of this 
kind of antiB cell intervention to prevent allograft rejection in renal transplantation are 
currently investigated in a clinical trial in Cambridge (NCT01536379). Given the results 
of our rituximab study, trials testing newer antiB cell strategies should especially focus 
on immunologically highrisk patients. The endpoints of these studies should include 
longterm safety and graft survival and the presence of (donorspecific) antiHLA 
antibodies.  
Rituximab can effectively deplete B cells from the peripheral blood, as we have shown in 
chapter 6. However in lymph nodes a B cell population remains after administration of a 
single dose of rituximab, although this population has different functional capacities 
[146]. The question whether rituximab can reduce B cell infiltration of the allograft 
during rejection, was investigated in chapter 7. To this end, the extent of B cell 
infiltration was scored in biopsies showing acute rejection according to the Banff 
classification. In patients treated with the standard immunosuppressive regimen 
consisting of tacrolimus, mycophenolate mofetil and steroids, we found varying degrees 
of B cell infiltration. However, when rituximab was added as induction therapy, the 
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An aspect that deserves attention is the dose and intensity of rituximab therapy. The 
lack of effect in the broad population of renal transplant patients could justify an 
intensified (increased or repeated dose) treatment regimen. It has been demonstrated 
that a single dose of rituximab, depletes B cells in peripheral blood, but not in secondary 
lymphoid organs and it is known that repeated doses of rituximab are required for full 
depletion of B cells from lymph nodes [146, 219]. However, we noticed that after a single 
dose of rituximab B cell depletion in the peripheral blood lasted more than 12 months. 
An intensified regimen could lead to even longer B cell depletion, potentially increasing 
the risk of unwanted effects like infections or malignancies. On the other hand, the 
minimal dose at which rituximab leads to B cell depletion appears to be much lower than 
the usual dose of 375 mg/m2. A Japanese study has shown that doses as low as 1535 
mg/m2 were still able to cause prolonged B cell depletion in the peripheral blood and 
spleen [220]. Lower doses could not only be economically attractive, but could also lead to 
a shorter period of B cell depletion and the effect of shorter B cell depletion is not known. 
Given these and the abovementioned issues, it would be premature to recommend the 
incorporation of rituximab into clinical practice in immunologically highrisk patients. 
The incidence of infections and malignancies was not increased in rituximabtreated 
patients despite a prolonged B cell depletion in the peripheral blood and a transient 
neutropenia in about 25% of patients. The absolute incidence of infections was high (75
80% of patients had one or more infections within the first 24 months posttransplant) in 
both groups, which could obscure an additional effect of rituximab. However, we did not 
find a difference in the type or severity of infections and length of hospitalization. The 
absence of a clear increase in the incidence of infections after treatment with rituximab 
is remarkable since B cells are required for an optimal defense against microbial 
pathogens. For example, inborn errors of B cell development result in 
agammaglobulinemia, leading to recurrent (upper) respiratory tract infections [221]. An 
explanation for our findings could be that a single dose of rituximab only partially 
depletes B cells. It has been demonstrated that a single dose of rituximab, depletes B 
cells in peripheral blood, but not in secondary lymphoid organs [146]. Moreover, in other 
trials in renal transplant patients, treatment with rituximab was not associated with a 
decrease in immunoglobulin levels [106]. Altogether, despite these concerns, a single 
dose of rituximab appears to be safe. 
During the last years it has become clear that specific B cell subsets, characterized by 
the ability to produce IL10, can have immunoregulatory effects resulting in a potential 
protective effect against graft rejection [222, 223]. The demonstration of elevated 
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numbers of naive and transitional B cells in the blood and an upregulation of CD20 
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10 and of MIP1β can have opposing effects on the immune response and the clinical 
consequences of these findings are yet unclear.  
In the final study of this thesis, presented in chapter 9, the attention is focused on the 
interaction of B cells with T cells. Nowadays, it is obvious that there is no absolute 
lineage commitment of T cells, but that T cell subset show considerable plasticity driven 
by numerous signals, including different interleukins [233]. Th17 cells are a relatively 
recently described subset of T cells, characterized by the production of certain cytokines, 
especially IL17 and IL21. Th17 cells play a role in the protection against extracellular 
pathogens, are involved in various autoimmune diseases, and recent data suggest that 
they might also play a role in allograft rejection. Based on previous studies we 
hypothesized that B cells are involved in the induction of a Th17 response. To test this 
hypothesis, we obtained PBMCs in a subset of patients participating in our rituximab 
trial. We stimulated PBMCs ex vivo and measured different monocyte and T cell derived 
cytokines. Although in all patients the production of most cytokines was decreased after 
transplantation as compared to before transplantation, no additional effect of rituximab 
on ex vivo cytokine production was observed, despite a profound B cell depletion. These 
findings indicate that B cells are not required for the induction of a Th17 response, 
which does not fit with a previously observed decrease in the Th17 response after in vitro 
addition of rituximab to normal PBMCs [5]. However, we administered rituximab in an 
in vivo setting which did fundamentally differ from the controlled in vitro environment. 
One of the differences is the use of the immunosuppressive drugs tacrolimus, 
mycophenolate mofetil, and steroids, next to the additional use of antihistamines [177, 
208]. The use of these drugs could explain why a general decrease in cytokine production 
was found after the transplantation. Additionally in rituximabtreated patients, the 
occurrence of shortlived cytokine release after the administration of rituximab (with 
increased levels of IL10 and MIP1β as found in chapter 8) could have exhausted pre
formed stores of cytokines and could thereby prohibited the release of cytokines when 
PBMCs are (re)stimulated ex vivo. An interesting finding in this study was that ex vivo 
IL17 production was not decreased, both at one day and at one month after 
transplantation, despite the use of the abovementioned immunosuppressive drugs. If a 
pathophysiological role of IL17 and Th17 cells in renal allograft rejection becomes more 
established in the future, these data suggest that different immunosuppressive 
strategies are necessary to suppress the IL17 response and that rituximab will probably 
not be beneficial to achieve this goal.  
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rejection biopsies contained virtually no B cells. No difference was seen in the severity of 
tubulitis, arteritis or the extent of the cellular infiltrate in rituximabtreated patients, as 
compared to placebotreated patients. In previous studies, the presence of intragraft B 
cells during acute allograft rejection was associated with a higher chance of steroid
resistance of the rejection and of subsequent graft loss. In our cohort, the lack of B cell 
infiltration in rituximabtreated patients was not associated with a better response to 
steroids or improved graft outcome. This questions the pathophysiological role of 
intragraft B cells in the acute phase of allograft rejection. Our data suggest that the 
presence of intragraft B cells during acute allograft rejection could be considered an 
epiphenomenon rather than a contributing pathological factor. 
Activation of B cells can lead to the release of a wide range of cytokines [179]. Treatment 
with rituximab in lymphoma patients who have high B cell counts, is well known for a 
clinical syndrome of fever, chills and hypotension, caused by a massive release of 
cytokines [137]. In chapter 8 it is evaluated whether a comparable cytokine release 
occurs after rituximab infusion in renal transplant patients. We indeed found that 
cytokines were released in the serum, especially IL10 and MIP1β, but none of the 
patients experienced clinical signs of a cytokine release syndrome. Compared with 
placebotreated patients, rituximabtreated patients had increased levels of IL10 and 
MIP1β at 2 and 4 hours after the start of the infusion. Within 24 hours, the 
concentrations of these cytokines had returned to baseline levels. In additional in vitro 
experiments where rituximab was added to various populations of peripheral blood 
mononuclear cells (PBMCs) we found that MIP1β was only secreted when rituximab 
was added to a coculture of B cells and NK cells. Intracellular staining of MIP1β 
showed that NK cells, and not B cells produce MIP1β. Incubation of PBMCs with 
rituximabF(abÊ)2 did not lead to an increased MIP1β secretion, indicating that the 
cytokine release was Fcreceptor dependent. 
The transient increase in IL10 and MIP1β levels could be of clinical relevance, since 
this might modulate the alloimmune response thereby influencing the transplantation 
outcome. IL10 is generally thought to be an antiinflammatory cytokine [189]. The role 
of MIP1β appears to be more ambivalent. In mouse models it was shown to be the most 
potent chemoattractant for regulatory T cells, but in other models MIP1β secreted by 
NK or B cells recruited monocytes, T cells, and dendritic cells to the site of injury or 
inflammation via the chemokine receptor CCR5 [190, 191]. Therefore, the release of IL
135 
10 and of MIP1β can have opposing effects on the immune response and the clinical 
consequences of these findings are yet unclear.  
In the final study of this thesis, presented in chapter 9, the attention is focused on the 
interaction of B cells with T cells. Nowadays, it is obvious that there is no absolute 
lineage commitment of T cells, but that T cell subset show considerable plasticity driven 
by numerous signals, including different interleukins [233]. Th17 cells are a relatively 
recently described subset of T cells, characterized by the production of certain cytokines, 
especially IL17 and IL21. Th17 cells play a role in the protection against extracellular 
pathogens, are involved in various autoimmune diseases, and recent data suggest that 
they might also play a role in allograft rejection. Based on previous studies we 
hypothesized that B cells are involved in the induction of a Th17 response. To test this 
hypothesis, we obtained PBMCs in a subset of patients participating in our rituximab 
trial. We stimulated PBMCs ex vivo and measured different monocyte and T cell derived 
cytokines. Although in all patients the production of most cytokines was decreased after 
transplantation as compared to before transplantation, no additional effect of rituximab 
on ex vivo cytokine production was observed, despite a profound B cell depletion. These 
findings indicate that B cells are not required for the induction of a Th17 response, 
which does not fit with a previously observed decrease in the Th17 response after in vitro 
addition of rituximab to normal PBMCs [5]. However, we administered rituximab in an 
in vivo setting which did fundamentally differ from the controlled in vitro environment. 
One of the differences is the use of the immunosuppressive drugs tacrolimus, 
mycophenolate mofetil, and steroids, next to the additional use of antihistamines [177, 
208]. The use of these drugs could explain why a general decrease in cytokine production 
was found after the transplantation. Additionally in rituximabtreated patients, the 
occurrence of shortlived cytokine release after the administration of rituximab (with 
increased levels of IL10 and MIP1β as found in chapter 8) could have exhausted pre
formed stores of cytokines and could thereby prohibited the release of cytokines when 
PBMCs are (re)stimulated ex vivo. An interesting finding in this study was that ex vivo 
IL17 production was not decreased, both at one day and at one month after 
transplantation, despite the use of the abovementioned immunosuppressive drugs. If a 
pathophysiological role of IL17 and Th17 cells in renal allograft rejection becomes more 
established in the future, these data suggest that different immunosuppressive 
strategies are necessary to suppress the IL17 response and that rituximab will probably 
not be beneficial to achieve this goal.  
 
134 
rejection biopsies contained virtually no B cells. No difference was seen in the severity of 
tubulitis, arteritis or the extent of the cellular infiltrate in rituximabtreated patients, as 
compared to placebotreated patients. In previous studies, the presence of intragraft B 
cells during acute allograft rejection was associated with a higher chance of steroid
resistance of the rejection and of subsequent graft loss. In our cohort, the lack of B cell 
infiltration in rituximabtreated patients was not associated with a better response to 
steroids or improved graft outcome. This questions the pathophysiological role of 
intragraft B cells in the acute phase of allograft rejection. Our data suggest that the 
presence of intragraft B cells during acute allograft rejection could be considered an 
epiphenomenon rather than a contributing pathological factor. 
Activation of B cells can lead to the release of a wide range of cytokines [179]. Treatment 
with rituximab in lymphoma patients who have high B cell counts, is well known for a 
clinical syndrome of fever, chills and hypotension, caused by a massive release of 
cytokines [137]. In chapter 8 it is evaluated whether a comparable cytokine release 
occurs after rituximab infusion in renal transplant patients. We indeed found that 
cytokines were released in the serum, especially IL10 and MIP1β, but none of the 
patients experienced clinical signs of a cytokine release syndrome. Compared with 
placebotreated patients, rituximabtreated patients had increased levels of IL10 and 
MIP1β at 2 and 4 hours after the start of the infusion. Within 24 hours, the 
concentrations of these cytokines had returned to baseline levels. In additional in vitro 
experiments where rituximab was added to various populations of peripheral blood 
mononuclear cells (PBMCs) we found that MIP1β was only secreted when rituximab 
was added to a coculture of B cells and NK cells. Intracellular staining of MIP1β 
showed that NK cells, and not B cells produce MIP1β. Incubation of PBMCs with 
rituximabF(abÊ)2 did not lead to an increased MIP1β secretion, indicating that the 
cytokine release was Fcreceptor dependent. 
The transient increase in IL10 and MIP1β levels could be of clinical relevance, since 
this might modulate the alloimmune response thereby influencing the transplantation 
outcome. IL10 is generally thought to be an antiinflammatory cytokine [189]. The role 
of MIP1β appears to be more ambivalent. In mouse models it was shown to be the most 
potent chemoattractant for regulatory T cells, but in other models MIP1β secreted by 
NK or B cells recruited monocytes, T cells, and dendritic cells to the site of injury or 
inflammation via the chemokine receptor CCR5 [190, 191]. Therefore, the release of IL
137  
Chapter 11 
 
Samenvatting en algemene discussie 
136 
To conclude, the aim of this thesis was to investigate the safety and efficacy of novel 
approaches in renal transplantation. We found that ATGF was ineffective to reduce the 
incidence of delayed graft function, and was associated with an increased incidence of 
severe adverse events. Therefore different strategies to reduce the incidence of delayed 
graft function are necessary. In patients with a steroidresistant rejection, ATG
Thymoglobulin will remain the firstline treatment, although alemtuzumab was effective 
and safe and can therefore be considered a reasonable alternative when there are anti
ATG antibodies or when treatment with ATG is perceived too harmful. Our trial with 
rituximab to deplete B cells has shown that only a subset of immunologically highrisk 
patients might benefit from induction therapy with a single dose of rituximab. We did 
not observe an effect on the incidence of acute allograft rejection in immunologically low
risk patients. Despite an increased incidence of neutropenia, treatment with rituximab 
was safe and did not lead to an increased risk of infection or malignancies. Rituximab 
was able to effectively deplete peripheral blood B cells and intragraft B cells, although a 
beneficial effect of the latter on the allograft affected by acute rejection was not observed. 
A small but noticeable effect of rituximab on the serum levels of IL10 and MIP1β could 
be found in vivo, while the clinical relevance of this shortlived cytokine release is 
currently uncertain. Ex vivo, MIP1β was secreted by NK cells when rituximab was 
added to a coculture of B cells and NK cells, and appeared to be dependent on the 
interaction of rituximab with Fcreceptors. Finally, in vitro experiments have shown that 
antiB cell therapy does not impair the induction of a Th17 response. 
The studies presented in this thesis have contributed to the further understanding of the 
effects of antiT cell therapy with ATGF in delayed graft function and the benefits of 
alemtuzumab in the treatment of steroidresistant rejection. Furthermore the clinical 
trial with rituximab and the additional experiments, have provided a better 
understanding of the role of B cells in the alloimmune response and have demonstrated 
that antiB cell therapy could become a novel approach in selected conditions in renal 
transplantation. 
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studies met ATGF niet gemeld en kan het gevolg zijn van de combinatie van ATGF met 
een nietgereduceerde tacrolimusdosering. Concluderend kan het gebruik van ATGF 
met een nietgereduceerde tacrolimusdosering niet worden aanbevolen om de incidentie 
van delayed graft function te verlagen bij patiënten die een transplantatie ondergaan 
met een nier van een DCDdonor. 
Momenteel wordt er veel onderzoek verricht naar de preventie van delayed graft 
function na niertransplantatie; een zoektocht op clinicaltrials.gov leverde meer dan 40 
lopende studies op. De meeste studies maken gebruik van reeds bestaande 
medicamenten, zoals eculizumab, een monoklonaal antilichaam dat de werking van het 
complement systeem remt. In het Mount Sinai Hospital in New York is recent een studie 
gestart die het effect van eculizumab op de incidentie van delayed graft function in de 
eerste week na transplantatie onderzoekt (clinicaltrials.gov nummer NCT01919346). 
Patiënten die een niertransplantatie ondergaan waarbij het risico op ischemiereperfusie 
schade hoog is (donornieren met een koude ischemie tijd van meer dan 18 uur of nieren 
van donoren 60 jaar en ouder of 5059 jaar met comorbiditeit), worden gerandomiseerd 
tussen behandeling met twee doses eculizumab of placebo. Helaas worden patiënten die 
een nier van een DCDdonor ontvangen, de onderzoekspopulatie van onze studie, niet in 
deze studie geïncludeerd. 
Tot slot zou snellere allocatie en transport van organen een andere, potentieel 
aantrekkelijkere optie zijn om de incidentie van delayed graft function te verlagen. Er 
zal echter altijd een tijdsinterval blijven bestaan tussen uitname bij de donor en 
implantatie van het donororgaan bij de ontvanger. De gangbare preservatiemethode is 
het bewaren van de nieren op smeltend ijs na perfusie met een koude vloeistof (18 °C). 
Een alternatieve preservatiemethode is continue, pulsatieve perfusie met koude 
perfusievloeistof met behulp van een machine. In een recente studie is één nier van een 
donor gerandomiseerd voor machinale perfusie, terwijl de contralaterale nier werd 
bewaard op smeltend ijs. In deze studie was machinale perfusie geassocieerd met een 
substantiële reductie van de incidentie van delayed graft function [215]. Een volgende, 
meer fysiologische, stap is normotherme (en eventueel geoxygeneerde) machinale 
perfusie. De eerste resultaten bij niertransplantatie laten zien dat deze techniek 
haalbaar en veilig is [216]. 
In hoofdstuk 5 wordt een tweede probleem van orgaantransplantatie beschreven; 
behandeling van steroïdresistente. Uit het onderzoek beschreven in dit hoofdstuk blijkt 
dat de monoklonale antistof alemtuzumab even effectief lijkt als ATGThymoglobuline 
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Voor patiënten met eindstadium nierfalen biedt een niertransplantatie de beste 
verbetering van kwaliteit van leven en levensverwachting en is daarom te verkiezen 
boven dialyse. Gedurende de afgelopen decennia is er grote vooruitgang geboekt, maar 
een aantal belangrijke problemen is onopgelost gebleven. In dit proefschrift worden de 
veiligheid en effectiviteit van nieuwe behandelmethoden van een drietal van deze 
problemen besproken, te weten de hoge incidentie van het vertraagd op gang komen van 
de transplantaatnierfunctie, de behandeling van steroïdresistente acute rejectie en tot 
slot de preventie van acute rejectie.  
Het eerste probleem dat in dit proefschrift is onderzocht is de hoge incidentie van het 
vertraagd op gang komen van de transplantaatnierfunctie (delayed graft function) bij 
patiënten die een transplantatie hebben ondergaan met een nier die bij een overleden 
donor is uitgenomen na een periode van circulatiestilstand (DCDdonor). Uit de studie 
die in hoofdstuk 4 wordt beschreven, blijkt dat een eenmalige intraoperatieve gift van 
antistoffen tegen T cellen (ATGFresenius; ATGF), toegevoegd aan standaard 
drievoudige immuunsuppressie niet effectief was in het verminderen van de incidentie of 
de duur van delayed graft function, maar wel geassocieerd was met een hogere incidentie 
van serieuze bijwerkingen. Deze bevindingen verschillen met andere studies waarin met 
ATGF wél een reductie van de incidentie van delayed graft function werd bereikt [86, 
126131]. Echter, in deze studies werd de behandeling met ATGF gevolgd door 
behandeling met tacrolimus in een gereduceerde dosis terwijl deze dosisreductie niet 
plaatsvond in onze studie. Door die studieopzet is het onduidelijk of het positieve effect 
op de incidentie van delayed graft function aan moet worden toegeschreven aan de ATG
F of aan de reductie van de tacrolimusdosering. Daarom is in onze studie niet voor een 
gereduceerde tacrolimusdosering gekozen. 
Het ontbreken van een effect van ATGF op de incidentie van delayed graft function 
trekt de effectiviteit van het middel ATGF in twijfel. Alhoewel er lymfocytopenie en een 
milde trombocytopenie optraden, had dit geen effect op de incidentie van acute rejectie. 
In andere studies met ATGF trad dit vrijwel altijd wel op. Het ontbreken van een effect 
van ATGF op de incidentie van zowel delayed graft function als rejectie wijst op 
onvoldoende effectiviteit van ATGF. 
Opvallend was de hogere incidentie van serieuze bijwerkingen en de trend naar een 
hogere incidentie van infecties bij met ATGF behandelde patiënten. Deze studie was 
niet geblindeerd, waardoor bijwerkingen bij met ATGF behandelde patiënten mogelijk 
eerder en vaker werden gemeld. De hogere incidentie van infecties werd in andere 
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met een nier van een DCDdonor. 
Momenteel wordt er veel onderzoek verricht naar de preventie van delayed graft 
function na niertransplantatie; een zoektocht op clinicaltrials.gov leverde meer dan 40 
lopende studies op. De meeste studies maken gebruik van reeds bestaande 
medicamenten, zoals eculizumab, een monoklonaal antilichaam dat de werking van het 
complement systeem remt. In het Mount Sinai Hospital in New York is recent een studie 
gestart die het effect van eculizumab op de incidentie van delayed graft function in de 
eerste week na transplantatie onderzoekt (clinicaltrials.gov nummer NCT01919346). 
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Alhoewel alemtuzumab en ATG dus ongeveer even effectief lijken te zijn ter bestrijding 
van steroïdresistente rejectie, is hun werkingsmechanisme niet identiek. De antistoffen 
in het ATG preparaat binden vooral aan T cel specifieke moleculen zoals CD2, CD3 en 
CD8, hoewel ATG ook een grote variëteit aan antistoffen gericht tegen NK cellen en 
endotheelcellen bevat [163,218]. Sommige studies tonen dat ATG geen significante 
hoeveelheden antistoffen tegen B cel antigenen zoals CD19 of CD20 bevat. ATG heeft 
echter wel degelijk antiB cel activiteit, waarschijnlijk direct door depletie van cellen met 
CD5 of HLADR op hun celmembraan, of indirect door het depleteren van CD4+ T cellen 
en het daarmee elimineren van T cel hulp aan B cellen [16,218]. Alemtuzumab bindt 
specifiek aan het CD52 molecuul, dat tot expressie komt op T en NK cellen, monocyten, 
macrofagen, dendritische cellen en B cellen. Deze specifieke interactie met CD52 en 
directe B cel depletie, zou kunnen bijdragen aan het effect van alemtuzumab bij de 
behandeling van steroïdresistente rejectie. De toenemende kennis over de rol die B 
cellen en antistoffen spelen in acute rejectie heeft de belangstelling voor antiB cel 
therapie vergroot. Het aantal klinische studies met antiB cel therapie bij 
niertransplantatiepatiënten is echter beperkt. 
De resterende hoofdstukken van dit proefschrift beschrijven onderzoeken met als 
centrale thema het probleem rejectie en diverse aspecten van antiB cel therapie. In 
hoofdstuk 6 staan de uitkomsten beschreven van een gerandomiseerde klinische studie 
waarin het effect van antiB cel therapie op de incidentie van acute rejectie werd 
onderzocht. Een eenmalige gift rituximab of placebo werd toegevoegd aan standaard 
immuunsuppressie bestaande uit tacrolimus, mycofenolaat mofetil en prednison in een 
groep van 280 niertransplantatiepatiënten. Hoewel behandeling met rituximab veilig 
was, leidde het niet tot een vermindering van het aantal afstotingsreacties in de hele 
onderzoekspopulatie. Bij het opzetten van dit onderzoek hielden we er rekening mee dat 
de effecten van rituximab niet voor alle patiënten gelijk zouden kunnen zijn. Daarom 
zijn de geïncludeerde patiënten gestratificeerd naar de aan of afwezigheid van antiHLA 
antistoffen (weerspiegeld door de PRA [panel reactive antigen] waarde) en naar eerste of 
volgende transplantatie. Wanneer deze strata werden gecombineerd tot een 
immunologisch laagrisico groep (PRAª6% en eerste transplantatie) en een 
immunologisch hoogrisico groep (PRA>6% of retransplantatie), was er in de 
immunologisch hoogrisico groep een duidelijke trend tot minder afstotingsreacties 
waarneembaar in met rituximab behandelde patiënten, vergeleken met patiënten die 
placebo kregen toegediend. Opmerkelijk was ook de trend tot minder antistof
gemedieerde rejectie, vooral in met rituximab behandelde hoogrisico patiënten. Deze 
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als behandeling van steroïdresistente acute rejectie, terwijl het een gunstiger 
bijwerkingsprofiel heeft. De resultaten zijn echter niet afkomstig van een prospectieve 
studie en moeten daarom met gepaste terughoudendheid beoordeeld worden. De 
patiëntkarakteristieken kwamen in beide groepen niet helemaal overeen, vooral omdat 
in de met alemtuzumab behandelde groep meer patiënten een retransplantatie hadden 
ondergaan. Deze patiënten waren na een vorige transplantatie reeds behandeld met 
ATG en het voorkómen van herhaalde blootstelling aan ATG was de belangrijkste reden 
om te behandelen met alemtuzumab. Deze disbalans zou echter in het nadeel van de 
alemtuzumab behandelde patiënten kunnen zijn, omdat patiënten die een 
retransplantatie ondergaan vaak geïmmuniseerd zijn en daarom lastiger zijn te 
behandelen voor hun rejectie. Een andere beperking van het onderzoek was de relatief 
korte followup van drie maanden. Het T cel depleterende effect van ATG duurt ongeveer 
12 maanden en na toediening van alemtuzumab kan dit zelfs nog langer aanhouden. 
Late bijwerkingen, met name infecties en maligniteiten, kunnen daardoor later dan drie 
maanden na toediening van ATG of alemtuzumab ontstaan. Tot slot blijkt uit een recent 
artikel dat het gebruik van alemtuzumab mogelijk geassocieerd is met het ontwikkelen 
van donorspecifieke antiHLA antistoffen [217]. Op grond van deze overwegingen biedt 
onze studie onvoldoende argumenten om alemtuzumab als eerstelijns behandeling in te 
zetten bij steroïdresistente rejectie. Een prospectieve gerandomiseerde en 
gecontroleerde studie met lange termijn followup is hiervoor onontbeerlijk. 
Desalniettemin kan alemtuzumab de voorkeursbehandeling zijn voor patiënten met 
steroïdresistente rejectie waarbij ATG een onaantrekkelijke optie is, bijvoorbeeld na 
eerdere blootstelling aan ATG of bij aanwezigheid van (cardiovasculaire) comorbiditeit 
die in het geval van een infusiereactie na toediening van ATG tot problemen zou kunnen 
leiden. 
Zoals reeds vermeld is het T cel depleterende effect van ATG en alemtuzumab langdurig 
en aspecifiek. Idealiter richten nieuwe monoklonale antistoffen zich alleen op targets op 
alloreactieve T cellen, zonder langdurige depletie van nietalloreactieve T cellen, en 
zonder het vrijkomen van grote hoeveelheden cytokines. Helaas zijn er op dit moment 
geen studies gaande of gepland met nieuwe monoklonale antiT cel antistoffen ter 
behandeling van rejectie. Bij sommige autoimmuunziekten zoals diabetes mellitus 
worden wel enkele studies gedaan met antiT cel antistoffen (meestal gericht tegen 
CD3). 
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optreden van een tijdelijke neutropenie bij 25% van de patiënten. De absolute incidentie 
van infecties was hoog (7580% van de patiënten had één of meerdere infecties 
doorgemaakt in de eerste 24 maanden na transplantatie) en dat kan een additioneel 
effect van rituximab hebben gemaskeerd. We vonden echter ook geen verschil in het type 
of de ernst van de infecties, noch een verschil in ziekenhuisopname en opnameduur. Het 
uitblijven van een verhoogde incidentie van infecties is opmerkelijk, gezien de rol die B 
cellen spelen in de afweer tegen microorganismen. Aangeboren afwijkingen aan B cellen 
leiden vaak tot agammaglobulinemie, wat zich kenmerkt door recidiverende (bovenste) 
luchtweginfecties [221]. Een mogelijke verklaring voor onze bevindingen is de 
gedeeltelijke depletie van B cellen. Immers, zoals hier boven vermeld leidt een eenmalige 
toediening van rituximab tot B cel depletie in het perifere bloed, maar niet in de 
secundaire lymfoïde organen [146]. Bovendien is bij andere studies met rituximab in 
niertransplantatiepatiënten geen daling van immunoglobulineconcentraties 
waargenomen. Al met al lijkt eenmalige toediening van rituximab een veilige 
behandeling. 
Rituximab leidt tot effectieve depletie van B cellen in het perifere bloed, zoals getoond in 
hoofdstuk 6. Echter in lymfeklieren blijft een populatie B cellen achter met andere 
functionele eigenschappen [146]. De vraag of rituximab ook in staat is B cel infiltratie in 
de nier te verminderen (gedurende rejectie), is onderzocht in hoofdstuk 7. Om deze vraag 
te beantwoorden is de mate van B cel infiltratie gescoord in biopten waarin acute rejectie 
volgens de Banff classificatie zichtbaar was. Biopten van patiënten die behandeld 
werden met de standaard immunosuppressiva, bestaande uit tacrolimus, mycofenolaat 
mofetil en prednison, toonden een wisselende mate van B cel infiltratie. Echter, in 
biopten van met rituximab behandelde patiënten, was er nagenoeg geen B cel infiltratie. 
Er werd geen verschil gezien in de ernst van de tubulitis, arteritis of de uitgebreidheid 
van het cellulaire infiltraat in beide groepen. In voorgaande studies was de 
aanwezigheid van B cellen in het infiltraat tijdens een periode van rejectie geassocieerd 
met een hogere kans op steroïdresistentie en transplantaatverlies. In ons cohort was de 
afwezigheid van B cellen in het infiltraat echter niet voorspellend voor een betere 
respons op behandeling of verbeterde uitkomsten. Deze bevinding trekt de 
pathofysiologische rol van B cellen tijdens de acute fase van een rejectie in twijfel. Onze 
data suggereren dat de aanwezigheid van B cellen in het transplantaat ten tijde van 
acute rejectie meer als een epifenomeen kan worden beschouwd, dan als een bijdragende 
pathologische factor. 
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studie was echter niet ontworpen voor deze laatste analyse, waardoor voorzichtigheid 
geboden is bij de interpretatie van de resultaten. Desalniettemin suggereren deze 
resultaten een beschermend effect van rituximab bij patiënten met een hoog 
immunologisch risico. Deze bevinding kan mogelijk verklaard worden door depletie van 
memory B cellen, aangezien deze vaker voorkwamen bij immunologisch hoogrisico 
patiënten. Echter, uit onderzoek van onder meer onze eigen onderzoekgroep blijkt dat 
memory B cellen minder gevoelig zijn voor depletie door rituximab dan naïeve B cellen 
[145,146]. Met een huidige mediane followup van 4 jaar, heeft dit gunstige effect van 
rituximab op de incidentie van rejectie niet geleid tot een verbetering van transplantaat 
of patiëntoverleving. Bovendien is het nog onduidelijk of behandeling met rituximab ook 
leidt tot een verminderde vorming van donorspecifieke antiHLA antistoffen (DSA). Het 
routinematig meten van deze DSAÊs was geen onderdeel van de huidige studie en was 
daarom niet meegenomen als secundair uitpunt. Momenteel worden bloedmonsters die 
gedurende de studie verzameld zijn onderzocht op de aanwezigheid van DSAÊs op 
verschillende tijdstippen na transplantatie. Gezien de bestaande onzekerheden is het 
nog te vroeg om behandeling met rituximab toe te voegen aan de standaardbehandeling 
voor immunologisch hoogrisico patiënten. 
Een aspect dat speciale aandacht behoeft is de dosis en intensiteit van de behandeling 
met rituximab. Het uitblijven van een effect in de gehele onderzoekspopulatie, 
rechtvaardigt mogelijk een intensiever behandelingsschema, bijvoorbeeld een hogere 
dosering of een herhalingsdosis. In eerder onderzoek is aangetoond dat een eenmalige 
toediening van rituximab leidt tot volledige B cel depletie in het perifere bloed, maar niet 
in de secundaire lymfoïde organen en dat meerdere doses rituximab nodig zijn om B 
cellen uit lymfeklieren te verwijderen [146,219]. Echter, wij zagen dat na een eenmalige 
gift rituximab de depletie van B cellen in het perifere bloed langer dan 12 maanden 
aanhield. Een intensiever behandelingsschema zou mogelijk tot nog langere depletie van 
B cellen in het perifere bloed kunnen leiden, waardoor het risico op infecties of 
maligniteiten zou kunnen toenemen. Aan de andere kant kan ook met doseringen lager 
dan de standaarddosering van 375 mg/m2 B cel depletie in het perifere bloed worden 
bereikt. Zo werd aangetoond dat doseringen van 1535 mg/m2 leidden tot langdurige B 
cel depletie in het perifere bloed en de milt [220]. Wat het meest optimale 
doseringsschema is, is op dit moment dus nog niet duidelijk. 
De incidentie van infecties en maligniteiten was niet verhoogd bij met rituximab 
behandelde patiënten, ondanks de langdurige B cel depletie in het perifere bloed en het 
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studie was echter niet ontworpen voor deze laatste analyse, waardoor voorzichtigheid 
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verkregen bij een subset van patiënten uit de rituximabstudie. We hebben deze PBMCÊs 
ex vivo gestimuleerd en maten hierna in het kweekmedium diverse cytokines afkomstig 
uit monocyten en T cellen. Alhoewel bij alle patiënten de productie van de meeste 
cytokines was onderdrukt, vergeleken met de periode voor de transplantatie, werd er 
geen additioneel effect van rituximab aangetoond, ondanks een uitgesproken B cel 
depletie. Deze bevindingen wijzen er op dat B cellen niet noodzakelijk zijn voor de 
inductie van een Th17 respons, wat in tegenspraak is met de bevindingen uit eerder 
onderzoek waarin een afname in de Th17 respons gezien werd na toevoeging van 
rituximab in vitro aan normale PBMCÊs [5]. Echter, wij voegden rituximab niet in vitro, 
maar in vivo toe; twee situaties die fundamenteel van elkaar verschillen. Een 
interessante bevinding in deze studie is dat ex vivo de IL17 productie niet onderdrukt 
was, noch op één dag, noch op één maand na transplantatie, ondanks het gebruik van 
bovengenoemde immuunsuppressiva. Indien een pathologische rol van IL17 en Th17 
cellen bij niertransplantaat afstoting in de toekomst bewezen wordt, zullen andere 
immuunsuppressiva noodzakelijk zijn om deze reactie te onderdrukken. Behandeling 
met rituximab zal daar waarschijnlijk geen positieve bijdrage aan kunnen leveren. 
 
Het doel van dit proefschrift was om de veiligheid en effectiviteit van nieuwe 
behandelmethoden bij niertransplantatie te onderzoeken. Wij vonden dat ATGF niet in 
staat was om de incidentie van delayed graft function te verminderen, terwijl het wel 
geassocieerd was met een verhoogde incidentie van serieuze bijwerkingen. Daarom is 
een andere aanpak noodzakelijk om de incidentie van delayed graft function te 
verminderen. Bij patiënten met een steroïdresistente rejectie zal ATGThymoglobuline 
de eerstelijns behandeling blijven, alhoewel alemtuzumab effectief en veilig was en 
daarom een rationeel alternatief kan zijn in aanwezigheid van antiATG antistoffen of in 
gevallen waarin behandeling met ATG te risicovol wordt geacht. Onze studie waarin 
rituximab is toegediend om B cellen te depleteren, toonde dat alleen immunologisch 
hoogrisico patiënten mogelijk baat hebben van inductietherapie met een eenmalige gift 
rituximab. Bij immunologisch laagrisico patiënten konden wij geen effect van rituximab 
op de incidentie van rejectie vinden. Ondanks een verhoogde incidentie van neutropenie 
was behandeling met rituximab veilig en leidde het niet tot een verhoogde incidentie van 
infecties of maligniteiten. Inductietherapie met rituximab was in staat om effectief B 
cellen te depleteren in het perifere bloed en ten tijde van rejectie in nierweefsel. Voor het 
transplantaat had dit laatste echter geen bewezen positief effect. In vivo kon een klein 
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Activatie van B cellen kan leiden tot de afgifte van een scala aan cytokines [179]. 
Behandeling met rituximab bij lymfoompatiënten die hoge aantallen B cellen hebben, is 
berucht om een klinisch syndroom van koorts, rillingen en hypotensie. Dit wordt 
veroorzaakt door een massale afgifte van cytokines [137]. In hoofdstuk 8 is onderzocht of 
een vergelijkbare uitstoot van cytokines optreedt na infusie van rituximab aan 
niertransplantatiepatiënten. We vonden inderdaad een tijdelijke verhoging van de 
concentraties van cytokines in het serum, vooral van IL10 en MIP1β 2 en 4 uur na start 
van de infusie, maar geen van de patiënten ervoer het bovenbeschreven klinische 
syndroom. Bij aanvullende in vitro experimenten waarin rituximab werd toegevoegd aan 
verschillende populaties PBMCÊs (perifere bloed mononuclaire cellen) vonden we dat 
MIP1β alleen werd afgegeven als rituximab werd toegevoegd aan een cocultuur van B 
cellen en NK cellen. Intracellulaire kleuring van MIP1β liet zien dat de NK cellen en 
niet de B cellen het MIP1β produceerden. Incubatie van PBMCÊs met rituximabF(abÊ)2 
leidde niet tot een verhoogde afgifte van MIP1β, wat erop duidt dat deze cytokine afgifte 
door de NK cellen gemedieerd werd via de Fcreceptor . 
De tijdelijke toename van de concentratie van IL10 en MIP1β kan klinische relevant 
zijn, omdat deze cytokines het immuunsysteem kunnen moduleren en daarmee de 
uitkomst na transplantatie kunnen beïnvloeden. IL10 wordt in het algemeen als een 
antiinflammatoir cytokine beschouwd [189]. De rol van MIP1β lijkt meer ambivalent te 
zijn. In muizenmodellen is het een krachtige chemotactische factor voor regulatoire T 
cellen, maar in andere modellen zorgt MIP1β, uitgescheiden door NK of B cellen, via de 
CCR5 chemokine receptor voor rekrutering van monocyten, T cellen en dendritische 
cellen naar de plaats van ontsteking [190,191]. Daarom kan de afgifte van IL10 en MIP
1β tegengestelde effecten hebben op het immuunsysteem. De klinische consequenties 
van deze bevindingen zijn dus nog onduidelijk. 
In de laatste studie van dit proefschrift, beschreven in hoofdstuk 9, wordt de aandacht 
gevestigd op de interactie van B cellen met T cellen. Tegenwoordig is het duidelijk dat er 
geen absolute differentiatie van T cellen is, maar dat T cel subsets aanzienlijke 
plasticiteit vertonen, afhankelijk van een scala aan signalen [233]. Th17 cellen zijn een 
relatief nieuwe subpopulatie die wordt gekenmerkt door de productie van bepaalde 
cytokines, te weten IL17 en IL21. Th17 cellen spelen een rol in de bescherming tegen 
extracellulaire pathogenen, in diverse autoimmuunziekten en volgens recente data ook 
in acute rejectie. Gebaseerd op voorgaand onderzoek was onze hypothese dat B cellen 
betrokken zijn bij een Th17 respons. Om deze hypothese te testen, hebben we PBMCÊs 
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maar duidelijk effect van rituximab worden aangetoond op de serumconcentraties van 
IL10 en MIP1β, alhoewel de gevolgen hiervan momenteel onduidelijk zijn. Ex vivo werd 
MIP1β afgegeven door NK cellen wanneer rituximab werd toegevoegd aan een co
cultuur van B cellen en NK cellen. Deze afgifte was afhankelijk van de interactie tussen 
rituximab en de Fcreceptoren van NK cellen. Tot slot hebben in vitro experimenten 
aangetoond dat antiB cel therapie niet in staat is om een Th17 respons te 
onderdrukken. 
De studies in dit proefschrift hebben bijgedragen aan een beter begrip van de effecten 
van antiT cel therapie met ATGF ter preventie van delayed graft function en de waarde 
van alemtuzumab bij de behandeling van steroïdresistente rejectie. Bovendien heeft de 
klinische studie met rituximab samen met de aanvullende experimenten een beter beeld 
gegeven van de rol die B cellen spelen in de alloimmuun respons. Deze onderzoeken 
hebben laten zien dat antiB cel therapie in bepaalde gevallen een nieuwe behandelwijze 
kan worden bij niertransplantatiepatiënten. 
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samen met Tilla veel plezier en een lang en gelukkig leven. 
Prof. J.F.M. Wetzels, beste Jack. Je kennis dijt net als het universum nog dagelijks uit 
en ik ben dankbaar dat je mij hebt opgeleid tot nefroloog. Jouw oprechte, sterke en 
duidelijke mening, ook als het gaat om de zorg voor patiënten in bredere zin, heb ik erg 
gewaardeerd en de gedachte dat we eigenlijk maar heel weinig dingen zeker weten heb 
ik als een bevrijding ervaren. Ik wens jou en Amanda veel geluk toe. 
Verder wil ik de andere nefrologen (Ine Dooper, Heinrich Kloke, Tom Nijenhuis, Gerald 
Vervoort, Ruud de Sévaux, Henk van Hamersvelt, Jeroen Deegens, Gerben van Boekel 
en Julia Hofstra) bedanken, niet alleen voor mijn opleiding tot nefroloog, maar ook voor 
de alertheid om mij (midden in de nacht) te bellen bij een potentiële niertransplantatie. 
Ik dank jullie ook voor alle supervisie die jullie mij de afgelopen jaren hebben gegeven en 
de mogelijkheid die ik heb gekregen om mijn eigen stijl te ontwikkelen. Hierbij bedank 
ik ook Jannie van Lieshout, die als bedrijfsleidster een belangrijke bijdrage levert aan 
het succes van de afdeling. 
Elena Kamburova, je hebt de rituximabstudie een extra dimensie gegeven met al je 
onderzoeken en ontdekkingen in het laboratorium. Bedankt voor de momenten van 
overleg en samenwerking, waardoor we jouw en mijn proefschrift tot een succes konden 
maken. Zonder jou waren veel effecten van rituximab onbekend gebleven. Irma Joosten 
en Hans Koenen, hartelijk dank voor jullie bijdrage aan mijn en ElenaÊs onderzoeken, 
jullie kritische blik op de manuscripten en het constructief overleg. Bram van 
Cranenbroek, Marina van Welie, Esther Fasse, Esther Rijssen, Jos Ruiter en Ronald van 
Beek, dank voor het opwerken van de cellen en de mogelijkheid en ondersteuning om dit 
ook in het weekend zelf te kunnen doen. 
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De lezer die dit dankwoord en de vele personen die erin opgesomd zijn ziet, zal zich 
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Allereerst zijn dat mijn promotoren, copromotor en de manuscriptcommissie.  
Prof. L.B. Hilbrands, beste Luuk, je hebt me in 2007 aangenomen om aan de rituximab 
en ATGstudie te werken. Dat was voor mij een enorme uitdaging, maar door continue 
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opleiding en mijn onderzoek tijd door te brengen met Kasia en de extra maanden die ik 
na mijn opleiding heb kunnen besteden aan dit proefschrift. Ik wens je het allerbeste en 
veel succes als hoofd van een fantastische nefrologieafdeling. 
Prof. A.J. Hoitsma, beste Andries. Van jou heb ik geleerd om netwerken op te bouwen. Ik 
dank je voor de patiëntenproblemen die ik bij je neer kon leggen en de (vaak 
relativerende) discussie die er nadien op volgde. Je hebt me laten zien hoe mooi en 
bijzonder werken in de transplantatienefrologie is, en daarbij optimistisch, humoristisch 
en bescheiden te blijven. Ik wens je met Stieneke nog veel mooie jaren in Friesland toe. 
Dr. M.C. Baas, beste Marije. Dank voor je bijdrage aan de rituximabstudie en de enorme 
hoeveelheid werk die je hebt verricht en nog gaat verrichten met het bepalen van de 
donor specifieke antistoffen. Dank voor de zeer kritische houding en revisie van de 
manuscripten. Ik wens je het allerbeste en geniet van Nijmegen. 
175 
Schipper, Joy Lips, Edwin den Deurwaarder, Margarita van der Hoeven en Jeroen 
Aalten) die de afgelopen jaren met mij hebben doorgebracht. We hebben veel van elkaar 
geleerd en in de niokamer was het heerlijk om onbelemmerd en ongenuanceerd over 
medische en nietmedische zaken te ÂoverleggenÊ. Met veel plezier kijk ik terug op de 
diverse nioetentjes, vooral in Tante Koosje. 
De afgelopen jaren waren heel anders verlopen als ik niet de continue steun en 
vriendschap had gehad van Michiel en Brenda. Ik heb jullie relatie zien groeien en 
bloeien met als hoogtepunten de geboortes van jullie drie fantastische dochters Lisa, 
Nina en Milou. Ons leven is vervlochten en we staan altijd voor elkaar klaar. Bedankt 
voor alles wat jullie voor mij en Kasia betekenen. 
Mijn broers Frank en Jeroen bedank ik voor de interesse in mijn onderzoek, ook al moet 
het voor jullie vaak abracadabra zijn geweest. Na de scheiding van onze ouders hebben 
we het erg moeilijk gehad en een ieder heeft dit op zijn eigen manier verwerkt. Ik ben 
ontzettend blij dat ik de afgelopen jaren met jullie allebei contact hebt gehouden en ik 
hoop dat dat in de toekomst zo blijft. Ik wens jullie veel geluk, liefde en gezondheid 
samen met jullie partners Desiree en Hilde en jullie (toekomstige) kinderen. 
Mama, de afgelopen periode is erg zwaar geweest voor jou. Onze band is sterk en ik dank 
je voor alles wat je voor mij hebt betekend. Zonder jouw steun (en een weekje Leiden) 
had ik nooit kunnen gaan studeren, was ik nooit waar ik nu was en was dit proefschrift 
er zeker nooit gekomen. Dat de toekomst ongewis is, weet jij als geen ander. Ik hoop dat 
we nog lang op elkaar kunnen blijven steunen.  
Tot slot richt ik mij tot mijn allerliefste; Kasia. Het was de Hesperis Course in november 
2009 in Sitges waar wij elkaar hebben ontmoet. Ook op deze manier brengt 
orgaantransplantatie mensen bij elkaar! Jij bent de liefde van mijn leven en mijn rots in 
de branding. Dank voor alle momenten die we samen hebben meegemaakt in heel 
Europa. Werken als vrouwelijke chirurg in Polen is ongelooflijk zwaar en ik heb respect 
voor de manier waarop je dat doet. Je heldere kijk op het leven is één van je sterkste 
eigenschappen en een voorbeeld voor mij. De afstand Oosterhout/Rotterdam – Warszawa 
is er voor ons alleen op papier. Ik hoop dat we binnenkort samen een toekomst kunnen 
opbouwen in Nederland. Prawdziwa miłość pokona wszystko! 
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Ik dank alle secretaresses (Ilse Hilgers, Erna FranssenKokke, Mary Hakvoort
Hendriks, Linda Kusters, Cecile van Lunenburg, Coby Haverkort, Miranda Bremer, 
Jacqueline WillemsRoos, Lisa Pieris, Ria Reijmer en Jose Enning) voor het maken van 
talloze afspraken en het opzoeken en weer wegbrengen van vele dikke dossiers. Miranda, 
ik hoop dat we nog jarenlang tuintips uit blijven wisselen. 
Eric Steenbergen en Sandrine Florquin, heel hartelijk dank voor alle biopten die jullie 
bekeken en nogmaals bekeken hebben. Jullie deskundigheid is van ongekende klasse en 
de hoeksteen van het werk van elke (transplantatie)nefroloog. Dank voor jullie kunde. 
Ook bedank ik Henry Dijkman and Brigith Willemsen voor hun aanvullende analyses. 
Bij dezen wil ik ook alle coauteurs (Dennis Hesselink, Willem van Son, Willem Weimar, 
Marcia Kho, Alferso Abrahams, Arjan van Zuilen, JanStephan Sanders, Marja van Dijk, 
Sanne Smeekens, Frank van de Veerdonk, Mihia Netea en Leo Joosten) bedanken voor 
hun bijdrage aan de uitgevoerde onderzoeken. Ik hoop dat we de komende jaren samen 
onderzoek zullen blijven doen. 
De toediening van rituximab en ATG geschiedde op de operatiekamer en ik dank alle 
anesthesisten en anesthesiemedewerkers voor hun cruciale bijdrage aan deze twee 
onderzoeken. Mijn dank gaat ook uit naar alle andere medewerkers van het OKcomplex, 
van de verkoeverkamer en intensive en medium care en het chirurgische team, 
bestaande uit vaatchirurgen en urologen. 
Daarnaast dank ik alle verpleegkundigen van afdeling E22 die door de jaren heen, in 
momenten van grote drukte, nog tijd moesten vinden om ATG, rituximab of placebo 
klaar te maken. Evenzo dank ik alle andere medewerkers op E22 en de 
verpleegkundigen en ondersteunend personeel van polikliniek geel / groen en de dialyse; 
mijn waardering voor jullie inzet voor de patiëntenzorg is groot. 
Een speciale dank gaat ook uit naar alle transplantatiecoördinatoren die regelmatig 
tijdens de niertransplantatie aanwezig waren en cruciale gegevens hebben verzameld 
voor mijn onderzoeken. In het bijzonder wil ik Willem Hordijk danken, die voor mij ook 
een goede vriend is geworden. Willem, ik hoop dat we nog vaak samen gaan eten.  
Veel respect heb ik voor mijn (ex)collegae nefrologen (in opleiding) (Joan Doornebal, 
Ellen van Ommen, Rutger Maas, Harmke Korpershoek, Youlia Ahmed, Chantal Bosma, 
Charlotte de Bruijn, Kim Bunthof, Angèle Kerckhoffs, Corinne Balemans, Anneke van 
der WoudeBech, Yvonne de Waal, Lies Vingerhoets, AnneEls van de Logt, Meint 
Volbeda, Karin Haring, Hilde Peters, Jacobien Verhave, Lisa Pipeleers, Eugenie 
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Nawoord 
 
Tijdens het bezoek aan het Amerikaanse Transplantatie Congres in Boston in juni 2012 
liep ik langs een wand waar nabestaanden herinneringen hadden opgeschreven aan 
familieleden die na hun dood hun organen voor donatie hadden afgestaan. De tekst van 
één van die gedenktekens heeft mij erg gegrepen en ik heb deze tekst op de volgende 
pagina overgenomen, uit respect voor alle orgaandonoren en hun nabestaanden. 
 
178 
Martijn van den Hoogen werd op 22 juli 1981 geboren te Apeldoorn. In 1999 behaalde hij 
zijn VWOdiploma aan de Koninklijke Scholengemeenschap te Apeldoorn. Dat zelfde jaar 
begon hij zijn studie geneeskunde aan de Katholieke Universiteit Nijmegen. Eind 2005 
behaalde hij zijn artsexamen. Na een korte voortzetting van zijn onderzoeksstage op de 
afdelingen hematologie en nefrologie (onderwerp: bloedingen na nierbiopsieën, 
begeleiders Dr. L.B. Hilbrands en Dr. I.R.O. Nováková) begon hij in maart 2006 aan zijn 
opleiding tot internist in het UMC St Radboud te Nijmegen (opleider Prof. dr. J.W.M. 
van der Meer, later gevolgd door Prof. dr. J. de Graaf). Kort nadien zette hij zijn 
opleiding voort in het Jeroen Bosch Ziekenhuis te Den Bosch (opleider Dr. P. Netten) 
Gestimuleerd door Dr. J. Beutler en aangemoedigd door de opleider zocht hij contact met 
de afdeling nefrologie in het UMC St Radboud om daar wetenschappelijk onderzoek te 
doen. In december 2007 keerde hij terug naar het UMC St Radboud om zijn opleiding tot 
internist te combineren met wetenschappelijk onderzoek naar de effecten van ATG en 
rituximab bij niertransplantatiepatiënten (supervisoren Prof. dr. A.J. Hoitsma en Prof. 
dr. L.B. Hilbrands). Deze onderzoeken hebben uiteindelijk geleid tot dit proefschrift. 
In september 2012 startte hij met zijn enkelvoudige differentiatie nefrologie (opleider 
Prof. dr. J.H.M. Berden, later gevolgd door Prof. dr. J.F.M. Wetzels). Per maart 2014 was 
hij internist en op 1 september 2014 voltooide hij zijn enkelvoudige differentiatie 
nefrologie. Hierna is hij twee maanden werkzaam geweest op de afdeling nefrologie van 
het Radboudumc. Per 1 november 2014 is hij werkzaam als internistnefroloog in het 
Erasmus MC te Rotterdam. 
Sinds november 2009 deelt hij zijn leven met Katarzyna Grygiel. 
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To remember me 
 
Give my sight to the man who has never seen a sunrise, a babyÊs face or love in the eye of 
a woman. 
Give my heart to a person whose own heart has caused nothing but endless days of pain. 
Give my blood to the teenager who was pulled from the wreckage of his car,                    
so that he might live to see his grandchildren play. 
Give my kidneys to the one who depends on a machine to exist from week to week. 
Take my bones, every muscle, every fiber and nerve in my body and find a way to make a 
crippled child walk. 
If you must bury something, let it be my faults, my weaknesses and all prejudice against 
my fellow man. 
Give my sins to the devil. 
Give my soul to God. 
If by chance, you wish to remember me, do it with a kind deed or word to someone who 
needs you. 
 
If you do all I have asked I will live forever. 
